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Patients with X-linked agammaglobulinaemia (XLA) have absent peripheral circulating B-
lymphocytes and agammaglobulinaemia caused by defects in BTK.  Treatment consists of 
life-long immunoglobulin replacement therapy.  This only contains the IgG isotype containing 
little or no IgA or IgM.  Patients may still, therefore, experience recurrent infections and 
complications.  Novel therapies are potentially available, most notably gene therapy and 
newborn screening. 
I aimed to examine the clinical health outcomes and quality of life for patients with XLA in 
England and Wales to evaluate current practices and the potential role for novel therapies. 
Methods 
This is a retrospective, longitudinal observational study of patients with a definite diagnosis of 
XLA (BTK mutation or absent BTK expression), in England and Wales.   
Retrospective clinical data were collected from patients’ records, including conversion of lung 
function results to Z-scores.  Patients and/or their families were invited to complete 
questionnaires on their health-related quality of life (HRQoL) and psychological health.  
Results were compared against UK norms and UK patients with cystic fibrosis. 
Results 
Fifty-four patients were enrolled in the study (21 children, 33 adults).  Median age at 
diagnosis was 2.59 years with no statistically significant improvement seen since 1990. 
Twenty-two patients (44%) had evidence of bronchiectasis on high-resolution computerised 
tomography.  Patients with bronchiectasis were diagnosed with XLA significantly later than 
patients without bronchiectasis.  Neither infection incidence nor IgG trough levels were 
associated with an increased risk of bronchiectasis.  
In the absence of bronchiectasis, XLA patients had normal HRQoL results.  HRQoL was 
strongly correlated with respiratory symptoms and lung function.  
Conclusions 
Recurrent respiratory tract infections and bronchiectasis remain a major burden for this cohort 
despite modern therapy.  In the absence of bronchiectasis, patients have a normal HRQoL.  
ii 
 
Curative therapy, such as gene therapy or bone marrow transplantation, may provide the only 
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Chapter 1 Introduction 
1.1 Definition 
XLA is an X-linked inherited primary immunodeficiency caused by defects in the BTK gene 
(1,2).  These defects result in the dysfunctional or absent expression of Bruton’s Tyrosine 
Kinase (BTK) (1,2).  This results in a catastrophic failure of B-lymphocyte development in 
the bone marrow, causing a near-complete or complete absence of circulating B-lymphocytes 
and a resulting agammaglobulinaemia (3).  The Pan-American Group for 
Immunodeficiency (PAGID) and European Society for Immunodeficiencies (ESID) 
diagnostic criteria for XLA are (4): 
1) Definitive 
A male patient with less than 2% CD19+ B cells and at least one of the following: 
a) Mutation in BTK 
b) Absent BTK mRNA on northern blot analysis of neutrophils or monocytes 
c) Absent BTK protein in monocytes or platelets 
d) Maternal cousins, uncles or nephews with less than 2% CD19+ B cells 
2) Probable 
A male patient with less than 2% CD19+ B cells in whom all of the following are 
positive: 
a) Onset of recurrent bacterial infections in the first five years of life 
b) Serum IgG, IgM and IgA more than 2SD below normal for age 
c) Absent isohemagglutinins and/or poor response to vaccines 
d) Other causes of hypogammaglobulinaemia have been excluded 
3) Possible 
A male patient with less than 2% CD19+ B cells in whom other causes of 
hypogammaglobulinaemia have been excluded and at least one of the following is 
positive: 
a) Onset of recurrent bacterial infections in the first five years of life 
b) Serum IgG, IgM and IgA more than 2 SD below normal for age 
c) Absent isohemagglutinins 
Congenital agammaglobulinaemia is estimated to affect 2-3 patients per million population in 
the United Kingdom (5).  Eighty-five per cent of patients have XLA with mutations in BTK.  




In the 1930s and 1940s, it became possible to measure serum immunoglobulin levels (6,7).  
Shortly after this, in 1952, Colonel Ogden Bruton identified a young boy suffering from 
repeated severe and low-grade infections (3).  He presented with a history of osteomyelitis, 
gastrointestinal (GI) infections, parotitis, otitis media, pneumonia and sepsis (3).  At eight 
years old,  suffering his 3rd episode of parotitis, Colonel Bruton found this young boy to be 
agammaglobulinaemic and went onto to treat him successfully with subcutaneous (SC) 
replacement immunoglobulin therapy (3,8).  This was the first reported case of XLA and is 
widely seen as the birth of clinical immunology. 
Shortly thereafter, in the 1970s, it was discovered that patients with XLA had a significant 
reduction in the number of circulating CD19+ B cells in the peripheral circulation (9–12).  
However, B cell precursors were identified in the bone marrow of these patients (13).  
Together, these findings suggested haematopoietic stem cells in patients with XLA could 
enter the B cell lineage, but that there was a block somewhere along the normal B cell 
differentiation pathway. 
1.2.1 BTK gene 
Kwan et al., reported in 1986 that the gene responsible for XLA was located on the long arm 
of the X chromosome at Xq21.3 to Xq22 (14).  In 1993 two groups simultaneously discovered 
the gene responsible (BTK) and this, along with its subsequent kinase, is named after Colonel 
Bruton, BTK (Bruton’s Tyrosine Kinase) (1,2).  The BTK gene is 19 exons spanning 37 kb 
(15–18).  X-linked females can, albeit very rarely, be affected due to skewed lyonisation (19).    
There are over 800 different BTK mutations implicated in being responsible for XLA, 
although no single defect accounts for more than 3% of patients (20,21). 
Some patients, despite a complete absence of BTK, have unusual phenotypes with higher than 
expected immunoglobulin and B-lymphocyte levels or reporting fewer, milder infections (22–
24).  However, attempts to establish a genetic/phenotype correlation have been difficult.  
There are no agreed definitions of what is mild, moderate or severe disease.  Furthermore, 
many other factors can determine clinical outcome, e.g. age at diagnosis, infection rates, IgG 
trough levels, which need examining in large cohorts to try to establish any genetic/phenotype 
correlation.  Such a correlation would be beneficial to clinicians to aid prognosis for patients 
and to help identify patients in whom radical treatments may be beneficial. 
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1.2.2 Autosomal recessive agammaglobulinaemia  
As well as XLA, there are autosomal recessive (ARA) congenital agammaglobulinaemias. 
Approximately 15% of all congenital agammaglobulinaemias are autosomal recessive with 
known genetic defects (Table 1-1) (25). 
Table 1-1 Gene mutations associated with ARA (26) 
Gene Defect Cytogenetic Location 
IGHM (Immunoglobulin Heavy Constant Mu) 14q32.33 
CD79A (B-Cell Antigen Receptor Complex-Associated 
Protein Alpha Chain) 
19q13.2 
CD79B (B-Cell Antigen Receptor Complex-Associated 
Protein Beta Chain) 
17q23 
IGLL1 (Immunoglobulin Lambda Like Polypeptide) 22q11,23 
BLNK (B-Cell Linker) 10q23.2-q23.33 
LRRC8A (Leucine-Rich Repeat Containing 8 Family 
member A) 
9q34.11 
PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit) 5q13.1 
TCF3 (Transcription factor 3) 19p13.3 
 
The incidence of ARA is extremely low affecting approximately 1:2,000,000 births 
(Orphanet, ORPHA33110).  30% of ARA cases are caused by mutations in the µ heavy 
constant region gene, IGHM (i.e. 5% of all congenital agammaglobulinaemia) (27).  Current 
known B cell defects are summarised in Table 1-2. 
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Table 1-2 Known B cell defects adapted from Hendriks et al., (28) 
Disease Category Defects Unknown (%) 
(29) 
Genes involved Proportion (%) 













Other BCR signalling 
defects 




B-lymphocytes are a vital part of the immune system.  They are defined as “a population of 
cells that express clonally diverse cell surface immunoglobulin receptors recognising specific 
antigen epitopes” (30).  They can be traced back more than 500 million years in the evolution 
of the adaptive immune system in jawed vertebrates (31).  Rather than the B-lymphocytes 
themselves being discovered first, it was, in fact, the discovery of immunoglobulin that first 
prompted ideas of specific immune cells producing antibodies within the immune system 
(32,33).  The final discovery and classification of B-lymphocytes occurred towards the end of 
the 1960s.  By the beginning of the 1970s, using animal models and examining patients with 
PID, the link between these marrow-derived cells and antibody production was confirmed 
(34–37). 
The development of B-lymphocytes begins in primary lymphoid tissue with further 
maturation occurring in a range of secondary lymphoid tissue.  One of the primary functions 
of B-lymphocytes is the production of immunoglobulins by a complex process described in 
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further detail in section 1.5.  This process first produces the isotypes IgM and then IgD.  Later 
on in development, through antigen stimulation, variable domains of the immunoglobulin 
may be associated with other isotypes: IgA, IgG and IgE. 
1.3.1 IgM 
IgM is expressed in the early stages of B-lymphocyte development, with little somatic 
mutation in response to antigen stimulation.  As such, this allows IgM to respond to a broader 
variety of antigens and is used in response to acute pathogen exposure as a first line of 
defence in the human immune system (38).  Similar to IgG, IgM can activate complement 
through the binding of C1q (39).  IgM is present in humans as polymeric structures (pIgM) 
(40).  Like IgA, IgM is transported to the mucosal surfaces (e.g. respiratory tract and GI tract), 
via the polymeric immunoglobulin receptor (pIgR) (41).  Epithelial cells express pIgR, which 
can bind to pIgM  (42,43).  The pIgM is then cleaved, leaving behind secretory IgM (sIgM) 
(42,43).     
As will be discussed further in section 1.10.3, current immunoglobulin replacement therapy 
(IGRT) contains little or no IgM. 
The half-life for IgM is short, at approximately 5-6 days (44,45).   
IgM accounts for approximately 10% of the circulating serum immunoglobulin in humans 
(38).   
1.3.2 IgD 
Levels of circulating IgD in human serum are very low, and the function of both the free form 
and the membrane-bound form is poorly understood.  Class-switched IgD secreting B-
lymphocytes are present in the upper respiratory tract and are highly sensitive to respiratory 
pathogens (46).  In addition, IgD class-switched B-lymphocytes are involved in the activation 
of innate immune cells, most notably basophils (46). 
1.3.3 IgG 
IgG is the principal circulating antibody in humans, with the longest half-life of all the 
isotypes (38).  There are four different subclasses IgG1, IgG2, IgG3 and IgG4.  IgG plays a 
significant role in various immune pathways, including activation of the complement 
pathway, secondary antibody response, and direct neutralisation of toxins and viruses (38). 
6 
 
Like IgM, IgG can activate complement through C1q binding (39).  This ability varies 
amongst the IgG subclasses due to differences in their C1q binding (47,48).  IgG3 has the 
highest ability, followed by IgG1 and IgG2 (47,48).  IgG4 is unable to bind to C1q (47,48). 
The half-life of IgG is the longest of the immunoglobulins, with approximately 3-4 weeks for 
IgG1, IgG2 and IgG4 and two weeks for IgG3 (44,49). 
IgG accounts for approximately 75% of the circulating immunoglobulins in humans (38). 
1.3.4 IgA 
There are two classes of IgA; IgA1 and IgA2 (50).  The predominant circulating form is IgA1.  
IgA1 and IgA2 are both found at mucosal surfaces (50).  Circulating levels of IgA are much 
lower than IgG levels  (51).  However, this is reversed at mucosal surfaces and in secretions 
(51).  Here, IgA plays a critical role in protecting these surfaces against pathogens by either 
direct neutralisation or by preventing the antigen binding to the mucosal surface (52,53).  IgA 
exists in two forms, with circulating IgA being predominately monomeric and mucosal IgA 
(secretory IgA, sIgA) being dimeric (dIgA) (54).  Like IgM, as discussed above, IgA is 
transported to the mucosal surfaces where dIgA can bind to the pIgR on the epithelial surfaces 
(41).  Once again, similar to pIgM, the dIgA is cleaved, leaving behind the sIgA (42,43).  It 
should be noted, as will be discussed further in section 1.10.3, that current immunoglobulin 
replacement therapy contains very little (if any) monomeric serum IgA and no sIgA. 
Like IgM, the half-life of IgA is short, at around 5-6 days (44,45).  
IgA accounts for approximately 15% of human circulating immunoglobulin levels (38). 
1.3.5 IgE 
Although found in extremely low levels, the effects of IgE are well known for its role in its 
reaction to allergens triggering mast cells and basophils to release histamine.  IgE has an 
additional role in protection against parasitic worm infection (55).  
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1.3.6 Other functions of the B-lymphocyte 
Figure 1-1 B-lymphocyte function 
 
Aside from immunoglobulin production, B-lymphocytes have other integral roles within the 
human immune system (Figure 1-1).  B-lymphocytes act as antigen-presenting cells (APCs), 
activating T-lymphocyte immune responses (56).  They are also involved in the regulation of 
T-lymphocytes and dendritic cells through an array of immunomodulatory cytokines (IFN-γ. 
IL-6, IL-10) (30).  It is therefore likely that an underlying B alymphocytosis would have 
subsequent detrimental effects on T lymphocyte-mediated immunity.  Meyers et al., have 
added to these concerns by demonstrating a reduced frequency of regulatory T-lymphocytes 
in patients with XLA (57). B-lymphocytes also have an antibody-independent contribution to 
T-lymphocyte response to fungal pathogens (58). 
As a consequence of agammaglobulinaemia, the subsequent decreased antibody/antigen 
interaction can have further effects on the immune system to those described above, most 
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notably impaired chemotaxis, decreased complement activation and reduction in the 
phagocytosis on pathogenic organisms (59). 
It is now well understood that thymic B cells play a vital role in negative T cell selection and 
therefore, in their absence, there is an increased risk of autoimmune disease in congenital 
agammaglobulinaemia (60). 
1.4 Bruton’s Tyrosine Kinase 
BTK is a 659 amino acid cytoplasmic tyrosine kinase with a molecular weight of 77 kDa.  It 
is expressed at all stages of B-lymphocyte development except in plasma cells (1,2,61,62).  It 
is also expressed in myeloid cells but not T-lymphocytes (63).  It is a member of the Tec 
family of kinases (TFKs) which is the second largest family of mammalian cytoplasmic 
tyrosine kinases (Table 1-3).  This family of non-receptor tyrosine kinases is strongly 
conserved and contributes to signal transduction pathways involving growth or differentiation 
factors (64,65). 
Table 1-3 The Tec family of kinases 
Kinase Predominant expression 
Bruton’s Tyrosine Kinase (BTK) Haematopoietic cells 
Tyrosine kinase expressed in hepatocellular 
carcinoma (TEC) 
Haematopoietic cells 
Inducible T cell kinase (ITK) Haematopoietic cells 
Resting Lymphocyte kinase (RLK, also 
known as TXK) 
Haematopoietic cells 
Bone marrow tyrosine kinase on 
chromosome X (BMX) 
Endothelial cells 
 
These kinases all consist of a similar structure to the SRC family of kinases, i.e. with each 
kinase containing a C-terminal kinase, an SRC homology (SH) 2 and SH3 domain.  However, 
they also contain a proline-rich region upstream of the SH3 domain, apart from BMX.  This 
proline-rich region plays a vital role in the autoregulatory intramolecular interactions which 
occur in the SH3 domains (66).  One other key difference between TFKs and SRCs is that 
they do not contain an N-terminal myristoylation signal or COOH-terminal negative 
regulatory tyrosine.  They instead contain an N-terminal pleckstrin homology (PH domain) 
except for RLK (28).  It has been demonstrated that more than one member of the TFK family 
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is expressed within the same cell suggesting an element of possible redundancy, potentially 
explaining the milder phenotype seen in BTK knockout mice where TEC can partially replace 
the lost BTK (67).  
BTK consists of five domains, a PH domain, SRC homology 2 (SH2) domain, SH3 domain, 
TEC homology domain (TH) and a kinase domain (Figure 1-2). As a cytoplasmic kinase, 
BTK is temporarily transported to the plasma membrane upon binding of the PH domain to 
phosphatidylinositol 3,4,5-triphosphate (PIP3).  PIP3 is generated by phosphoinositide 3-
kinase (PI3K) activity (65).  The TH domain contains a highly conserved zinc finger motif 
which is vital, mediating the binding and co-ordination of BTK to Zn2+  (65,68,69).  Reliable 
activity and stability of BTK are entirely reliant on Zn2+.  Mutations in this region 
understandably result in an extremely unstable protein  (70,71).  The SH2 domain is involved 
in protein to protein interactions that bind to phosphorylated tyrosine (65).  The exact role of 
the SH3 domain in BTK remains unknown, but it has been demonstrated to have 
autoregulatory intramolecular interactions with the TH domain in ITK (66).  Y223 and Y551 
are key tyrosine phosphorylation sites located in the SH3 and kinases domains (72) (Figure 
1-2).  Y551 is first phosphorylated by SYK or LYN during BCR signalling and promotes the 
catalytic activity of BTK and subsequent Y223 autophosphorylation.  BTK catalytic activity 
activates three key signalling pathways; phospholipase C, phosphatidylinositol-3-kinase/Akt 
and NF-κB.    
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Figure 1-2 The structure of Bruton's Tyrosine Kinase and some of its interactions, 
adapted from Mohamed et al., (21) ankyrin repeat domain-containing protein 54 
(ANKRD54), filamentous acting (F-actin), an inhibitor of Bruton’s tyrosine kinase (IBTK), 
phosphatidylinositol-4-phosphate-5-kinase (PIP5K), Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1 (PIN1), protein kinase C (PKC), phospholipase Cγ2 (PLCγ2,), SRC 
homology (SH), SH2 domain-containing leukocyte protein of 65 kDa (SLP65), spleen tyrosine 
kinase (SYK), TEC homology (TH), Wiskott-Aldrich syndrome protein (WASP) 
 
BTK is predominately expressed in B-lymphocytes (but not plasma cells).  However, it is also 
expressed in all haematopoietic lineages apart from T-lymphocytes (21,62).  Aside from B-
lymphocytes, BTK is an expressed in numerous myeloid cells, most notably neutrophils, 
natural killer cells and monocytes (73–75).  There is also some murine evidence for impaired 
osteoclast development in BTK-deficient mice (76,77).  However, the clinical significance of 
absent BTK expression in cells other than B-lymphocytes has yet to be firmly determined.   
Following downstream activation of the pre-B cell receptor (BCR), BTK plays a critical role 
in the mediation of proliferation and maturation of B-lymphocyte at the pre-B lymphocyte 
stage (20,78).  This is done mainly via the promotion of calcium influx and will be discussed 
further in the sections below (20,78). 
BTK is most recognised for its role in haematology where malignant B-lymphocytes depend 
heavily on BTK activity for survival.  As such, BTK is a crucial target for the development of 
small molecular inhibitors, e.g. Ibrutinib (79).  These inhibitors only target the kinase domain. 
1.5 B-Lymphocyte Development 
B-lymphocytes develop from haematopoietic stem cells (HSCs) through rearrangement of the 
immunoglobulin heavy and light chain gene segments.  After recombination of the IgµH V, D 
and J genes, the IgµH protein is expressed on the cell surface along with the surrogate light 
chain (SLC) protein, as the pre-BCR (80,81).  The SLC is substituting for the Ig L chains not 
11 
 
yet arranged.  It is a heterodimer consisting of two germline-encoded invariant proteins, λ5 
(similar to the constant region of the conventional λ) and VpreB (80,81).  The pre-BCR 
signalling marks a vital checkpoint to test the functionality of the IgµH protein (28,82).  The 
mechanisms initiating this pre-BCR signalling are not yet fully understood.  The primary 
functions of this pre-BCR signalling are to inhibit further IGµH V(D)J recombination, known 
as allelic exclusion, clonal expansion and the triggering for B cell differentiation (82).   
The rearrangement of the immunoglobulin loci is a vital part of functional B-lymphocyte 
development.   This rearrangement process involves a purposively error-prone combination 
and rearrangement of the V, D and J gene segment in the H chain locus and the V and J 
segment in the L chain loci (83).  This process ultimately results in an incredibly diverse 
functional repertoire of VDJH and VJ rearrangements encoding the B-cell receptor (BCR).  
The recombination activating genes 1 and 2 (RAG1, RAG2) play a vital role in instigating the 
initial DNA cleavage (84,85).  
The pre-BCR plays a pivotal role in the maturation from the pro-B-cell to the large pre-B-cell 
stage (78).  Pre-BCR signalling leads to a proliferation of pre-B cells and downregulation of 
SLC expression (82).   This stage is vital to allow pre-B cells to transition from large cycling 
cells into small resting pre-B cells in which IGL chain recombination occurs (82).  These pro–
B cells are the earliest group committed to the B-cell lineage. B-lymphocyte development and 
survival in the periphery are, therefore, wholly dependent on BCR expression (86). 
The exact arrest in XLA patients is at the transition from pro B (cµ-SLCbright) to large pre-B I 
cells (cµlowSLCbright) (87) (Figure 1-3).  XLA patients have large numbers of pro-B cells 
resulting in an increased ratio of pro to pre-B cells (87–90).  In healthy individuals, the pre-B 
I cells population contains large and small pre-B cells.  In XLA patients, however, the pre-B I 
cells are predominately small, suggesting that BTK is essential for the proliferation and 
survival of cµ+ pre-B cells (28). 
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Figure 1-3 B-lymphocyte development, adapted from Hendriks et al., (28) 
 
Initial studies, prior to the discovery of BTK, had identified that the underlying gene defect in 
XLA caused a fatal defect in the proliferation and survival of B-lymphocyte precursors 
(91,92). It was then further shown the earliest B-lymphocytes from carriers; CD34+. CD19+ 
pro-B-lymphocytes demonstrate normal, random X-chromosome inactivation (93).  In 
addition, bone marrow from XLA patients demonstrates normal levels of CD34+, CD19+, 
sIg- pro-B-lymphocytes, but a significant decline in the numbers of cells expected at the next 
stage of differentiation (CD34-, CD19+, sIg-) (88).  These findings suggested that BTK 
deficient haematopoietic stem cells, while being able to enter the initial B-lymphocyte 
lineage, are unable to proceed through normal differentiation (93).   
1.5.1 Role of BTK in pre-B cell and B cell Receptor Signalling 
The presence of BTK and its interaction with the pre-BCR is crucial for normal B-lymphocyte 
development with BTK considered a sine qua non for B-cell development and survival.    
Although less is known about signals mediated by the pre-BCR compared to the IgM-BCR 
signal, it is assumed that the pathways are similar.  This is supported by evidence 
demonstrating that pre-BCR signalling results in the formation of a raft-associated calcium 
signalling molecule composed of the same tyrosine-phosphorylated signalling molecules 
found in BCR stimulated B-lymphocytes (94). 
The activation of BTK upon BCR stimulation is dependent on two essential processes; 
membrane association and phosphorylation of the Y551 tyrosine (72,95–97).  The membrane 
association of BTK is dependent on the interaction between the PH domain and the product of 
PI3K (72,95–97).  Phosphorylation of the Y551 tyrosine by tyrosine kinases such as LYN 
results in BTK autophosphorylation at Y223 (72,95–97).  
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Figure 1-4 BTK activation downstream of the pre-BCR/BCR, adapted from Hendriks et 
al., (98) B cell receptor (BCR), Diacylglycerol (DAG), Bruton’s Tyrosine Kinase (BTK), 
inositol 1, 4, 5 – triphosphate (IP3(R)), nuclear factor of activated T-cell (NFAT), 
immunoreceptor tyrosine-based activation motifs (ITAM), phospholipase Cγ2 (PLCγ2), SH2 
domain-containing leukocyte protein of 65 kDa (SLP65), Wiskott-Aldrich syndrome protein 
WASP, nuclear factor-κB (NF-κB), forkhead box O (FOXO) transcription factors; BCL-2 
antagonist of cell death (BAD), B cell adaptor for PI3K (BCAP), calmodulin (CaM), caspase 
recruitment domain-containing protein 11(CARD11), CBL-interacting protein of 85 kDa 
(CIN85), glycogen synthase kinase (GSK), inhibitor of κB (IκB), inhibitor of NF-κB kinase 
(IKK), inositol trisphosphate (IP3), IP3 receptor (IP3R), mucosa-associated lymphoid tissue 
lymphoma translocation protein 1 (MALT1), 3-phosphoinositide-dependent protein kinase 1 
(PDK1), phosphatidylinositol-3,4,5,-trisphosphate (PIP3), protein kinase C (PKC), spleen 
tyrosine kinase (SYK), RAS guanyl-releasing protein 3 (RASGRP3)   
 
BCR activation results in phosphorylation of the Ig family member Igα and Igβ cytoplasmic 
immunoreceptor tyrosine-based activation motifs (ITAMs) and the formation of a lipid raft-
associated calcium-signalling module.  This complex consists of tyrosine-phosphorylated 
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LYN, SYK, BLNK (SLP65), PI3K, BTK, VAV, and PLCγ2.  This a crucial complex, 
stabilised by the C-terminal SH2 domain of PLCγ2 (65,99).  Activated BTK is responsible for 
PLCγ2 phosphorylation at Y753 and Y759, a critical step for lipase activity (100–102).  The 
activation of PLCγ2 results in the production of diacylglycerol (DAG) and, by cleavage of 
PIP2, inositol 1,4,5-triphosphate (IP3) (65).  IP3 binds to its receptor (IP3R) in the 
endoplasmic reticulum (ER), causing a release of intracellular Ca2+ stores (65).  This ER store 
of Ca2+ is replenished and maintained by stromal interaction molecules, STIM1/STIM2 and 
calcium release-activated calcium (CRAC) channels (103).  The intracellular Ca2+ activates 
nuclear factor of activated T-cell (NFAT) transcription factors and induces NFAT nuclear 
import (65).  Protein kinase Cβ (PKCβ), mediated by DAG, activates the NF-κB pathway.  In 
addition to NF- κB pathway activation, PKCβ activates mitogen-activated protein kinases 
(MAPK) (104,105).  These MAPKs are important promotors of cell survival and cell cycle 
entry (104,105).  PKCβ also acts as a vital feedback inhibitor of BTK activation by 
phosphorylation of the highly conserved S180 serine residue within the TH domain of BTK 
(65,106). 
The IgM B-Cell Receptor (BCR) is essential for the survival of peripheral B-cells (86).  
Without BTK, B-cells suffer from a high rate of apoptosis, in conjunction with reduced BCR-
mediated induction of the anti-apoptotic protein Bcl-xL (107,108).  BTK lacking B-cells fail 
to induce cyclin D2 expression and, as a result, do not enter the S phase of the cell cycle 
(109).  In addition to B-cell survival and proliferation, BCR controls integrin α4β1 (VLA-4)-
mediated adhesion of B-cells to vascular adhesion molecule-1 (VCAM-1) and fibronectin via 
BTK (110).   
In summary, upon IgM-BCR and pre-BCR stimulation, BTK plays a crucial role in the 
activation of PLCγ2, resulting in Ca2+ influx, activation of PKCβ and CaM.  These processes 
activate four key transcription factors essential for B-cell survival, proliferation and 
differentiation: ELK1, c-MYC, NFκB and NFAT. 
1.6 Role of BTK in myeloid cells 
Aside from its role in the pre-BCR and BCR receptor pathways, BTK is expressed in all 
haematopoietic cell lineages except T cells and is involved in numerous signalling pathways 




Table 1-4 Signalling pathways BTK plays a role in, adapted from Hendriks et al., (28) 
Signalling Pathway Cell types 
Pre-BCR (111,112) Pre-B cells 
BCR (112–114) B cells 
CXCR4 (115) Pre-B cells, B cells 
CD38 (116) Activated B cells 
Epo-R (117) Erythrocytes 
TRAIL-R1 (117) Erythrocytes 
FcεR (118) Mast cells, basophils 
FcγR (119,120) Myeloid cells 
GPVI (121) Platelets 
IL-5R (122,123) B cells, eosinophils, basophils 
IL-6R (124) Activated B cells, plasma cells 
TLR2/4 (125,126) Myeloid cells, B cells 
TLR 7/8/9 (127–131) Myeloid cells, B cells 
CDC303 (BDCA-2) (132) Plasmacytoid dendritic cells 
 
While the role of BTK in the adaptive immunity is well known and is the subsequent impact 
on immunity self-explanatory, the effects of innate immunity are less well recognised despite 
work demonstrating the key roles BTK can play in innate immunity (Figure 1-5).   
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Figure 1-5 The role of BTK in innate immunity, adapted from Weber et al., (133) 
 
1.6.1 Monocytes 
Aside from its integral role in the development of B-lymphocytes, recent work has suggested 
that BTK plays a vital role in establishing the immunity function of monocytes (134).  
Monocytes in human XLA patients have been shown to have decreased chemotaxis, and 
defective FcγR (Fc-gamma receptors), CR1 (Complement Receptor 1) and CR3 (Complement 
Receptor 3) mediated phagocytosis when compared to healthy subjects (135).  These data 
demonstrated that BTK deficiency causes increased susceptibility to apoptosis in monocytes 
(134).  However, other work shows that BTK deficiency does not affect the function of 
monocytes or polymorphonuclear cells in XLA patients, albeit in those patients who are on 
treatment with intravenous immunoglobulin (IVIG) therapy (136).  
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1.6.2 Role of BTK in the development and function of innate immune cells 
The prerequisite of BTK for B-lymphocyte maturation is well known.  A role in the 
development of myeloid cells could also make logical sense, given their dependence on 
signalling from a variety of cell surface receptors (137). 
In murine models, BTK deficiency was associated with reduced total numbers of monocytes 
and macrophages (138).  Further work demonstrates these same models had an increased 
number of granulocytes. However, these were often immature, had reduced efficacy and had 
impaired recruitment of neutrophils to sites of inflammation (138,139).  In human XLA 
patients, neutrophils have been shown to be arrested at the myelocyte/promyelocyte stage, 
which may go some way to explain to neutropenia often seen in XLA patients, as will be 
discussed in Chapter 2 (140–142).  In particular, there is increased TLR and TNF induced 
reactive oxygen species (ROS) in XLA neutrophils (at the expense of increased neutrophil 
apoptosis) (73).  However, like much work in this area, there are contradictory findings from 
other groups, although these included patients on established IGRT (136,143).  Dendritic cells 
(DCs) in BTK deficient mice have been shown to have defects in maturation in antigen 
presentation (144).  
Both recognition and response to a range of microbes (Listeria monocytogenes (145), 
Staphylococcal aureus (146), dengue virus (147), Aspergillus fumigatus (148)) have been 
shown to be dependent on BTK.  The exact mechanism behind this is not fully understood but 
the involvement of BTK in Toll-like receptors (TLRs) (most notably TLR2 (124,128), TLR3 
(147), TLR4 (125,128), TLR7/8 (128,149,150), TLR9 (145,150,151) demonstrated in human, 
and mouse macrophages and dendritic cells appears to be of clear significance.  However, 
when transferring these experimental results to human XLA patients, the results seem to 
contradict these previous studies (143).  While most BTK mutations appear to cause complete 
loss of function and a broadly similar phenotype across all patients, the impact of TLR 
signalling may have more input from genotype-phenotype correlation.   
Murine models have demonstrated BTK deficiency results in delayed microfilaria clearance 
and decreased levels of Interleukin-12A (IL-12A), Interleukin-1 (IL-1), Tumour Necrosis 
Factor (TNF) and Nitric Oxide (NO) (152).  Further work has demonstrated the importance of 




BTK is able to interact with TLR4, TLR6, TLR8 and TLR9 and some key proteins involved 
in the TLR signalling pathways; myeloid differentiation protein 88 (Myd88), Myd88 adapter-
like protein (Mal) and interleukin-1 receptor-associated kinase-1 (IRAK1) (124,127).  
Additional work has demonstrated that BTK-deficient lymphocytes can produce higher levels 
of pro-inflammatory cytokines but less of the inhibitory cytokine IL-10 (154).  These works 
on BTK-TLR interaction suggest that BTK-deficiency may have a significant impact upon 
immune regulation, inflammation and immune defects other than the classical antibody 
deficiency typically thought of in XLA.   
1.6.3 BTK and in the NLRP3 inflammasome 
Recently, the NLRP3 inflammasome has been shown to have a significant role in the 
activation of bioactive IL-1β (155,156).  Furthermore, the NLRP3 inflammasome has also 
been implicated in pathological processes not only underlying infection but also sterile 
inflammatory states including myocardial infarction, stroke, Alzheimer’s disease and diabetes 
(156).  Genetic mutations in NLRP3 causes dysregulated activity of NLRP3, resulting in 
cryopyrin-associated periodic syndrome (CAPS) (157).   The NLRP3 inflammasome consists 
of NLRP3, adapter ASC and caspase-1.  BTK has been demonstrated to be an integral 
regulator in the activation of the NLRP3 inflammasome (156,158).  BTK has also been shown 
to be essential for the NLRP3 inflammasome-dependant IL-1β release from macrophages in 
murine models (158).  It has been demonstrated in peripheral blood mononuclear cells 
(PBMC) from XLA patients that NLRP3 inflammasome activity was impaired (146), which 
may go some way to explain some of the inflammatory symptoms that some patients appear 
to suffer from in this cohort.  Impaired or dysfunctional NLRP3 inflammasome activity is 
likely to lead to immune dysregulation and has been shown to contribute to a number of 
human diseases including autoimmunity and malignancy (159).  
1.7 BTK and autoimmunity 
The few remaining B-lymphocytes XLA patients possess express immature, IgM-rich 
phenotypes and are enhanced for autoreactivity (160,161).  As will be discussed further in 
chapter 2, a significant proportion of XLA patients appear to suffer from inflammatory 
symptoms.  This could be as a result of overproduction of inflammatory cytokines in response 
to TLR signalling (151,162).  BTK-deficient marrow-derived dendritic cells (BMDCs) in 
mice demonstrate increased levels of CD86 in response to lipopolysaccharide (LPS) and 
become antigen-presenting MHC Class-IIhigh cells at a higher rate than controls.  These 
differences were associated with a decreased ability of these BMDCs to produce IL-10 (144).  
However, the impact of BTK deficiency on autoimmunity and inflammation is not clear-cut.  
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There is some demonstration that BTK deficiency can protect against autoreactivity, at least 
in murine models, which began with the first report of Xid mice being protected against 
collagen-induced arthritis (163).  It is even speculated that we may soon see the introduction 
of BTK-inhibitors in the management of autoimmunity (164).  For example, Fenebrutinib is a 
BTK inhibitor in phase 2 clinical trials to treat several autoimmune conditions such as 
rheumatoid arthritis, systemic lupus erythematosus and chronic spontaneous urticaria 
(ClinicalTrials.gov Identifiers: NCT02983227 and NCT03407482).  
1.8 Clinical Presentation 
The defects leading to XLA and ARA all block early B cell development, failing B 
lymphocyte maturation, absent or very low serum immunoglobulin levels and failure of 
specific antibody production (2).  CD19+ B-lymphocyte numbers are usually less than 2% 
compared to 5-20% in the healthy population (63).  Any B-lymphocytes that are present in the 
circulation demonstrate an immature phenotype with IgMhighIgDhigh but decreased HLA-DR, 
Bcl-2 and CD 21 (63).  Any B-lymphocytes that were present at diagnosis usually tend to 
decrease even further with age (63).    
The resulting agammaglobulinaemia forms the basis of the clinical phenotype.  Patients 
typically become symptomatic after placental transferred maternal antibodies begin to decline 
from  4 to 6 months of age (165).  Patients typically being to suffer from recurrent bacterial 
infections from 6 months of age once these immunoglobulin levels being to fall (166–168).  
Before diagnosis and instigation of treatment, patients will present with recurrent otitis, 
purulent rhinorrhoea, conjunctivitis, pneumonitis, diarrhoea and skin infections (166–168).  
They are particularly prone to encapsulated bacteria, especially S. pneumoniae and H. 
Influnezae¸ as well as Giardia lamblia (63,165,169).  They are also susceptible to 
mycoplasma and ureaplasma, both of which are reported to have the potential to cause chronic 
pneumonia, arthritis, cystitis and cellulitis in this cohort as well as urethral stenosis in males 
(170,171).   
Patients are thought to be able to combat fungi and viruses competently with the notable 
exception of enteroviruses (165).  They are particularly susceptible to chronic enteroviral 
infections, which may prove fatal. (172–176).  The two most common subtypes reported are 
Echovirus type 11 and Coxsackievirus B5 (177).  Historically, the most feared complication 
of enterovirus infection was chronic meningoencephalitis in agammaglobulinaemia (CEMA) 
which is often fatal  (177).  It has been suggested recently that the lost role of BTK in TLR 
signalling may explain this particular susceptibility to enterovirus (178).  Enterovirus 
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infection in XLA has always been a well-recognised complication historically with rates 
between to 15-20% in the pre IVIG era (168,179).  In this era, before the introduction of IVIG 
enteroviral infection would often lead to chronic meningoencephalitis and often be fatal 
(168,176,180).  The switch to IVIG/SCIG from intramuscular preparations has made a 
dramatic impact, but enterovirus has not disappeared in the modern era, and deaths still occur 
in this cohort due to enteroviral infection (142,177,181).  Modern therapy will still have 
limitations in its treatment of enteroviral infections; infection may have started before the 
commencement of immunoglobulin therapy and enterovirus antibody titres in modern 
immunoglobulin preparations show considerable variation (182,183). 
In addition to enterovirus, XLA patients may be susceptible to infections from other viruses 
and, in particular, have great difficulty in clearing these infections resulting in prolonged or 
permanent infection.  XLA patients appear particularly susceptible to rhinovirus infections of 
the respiratory tract and often have positive respiratory samples for a prolonged period of 
time, up to 5 months in one case series (184).  In addition, Norovirus infection of the GI tract 
may also play a burden for XLA patietns with one case report demonstrating a patients 
inability to clear a Norovirus infection (185). 
Patients are usually diagnosed in early childhood, although there are case reports of patients 
being diagnosed well into adulthood and seemingly well despite no immunoglobulin 
replacement highlighting the potentially wide variation in phenotype (22). 
Approximately half of all patients will have suffered a severe infection before their second 
birthday (63,186,187) and 10% of patients present with sepsis leading to their XLA diagnosis 
(167). 
Neutropenia is seen in 10-25% of patients with XLA, usually at the time of their diagnosis 
(141,167,188,189).  Interestingly, neutropenia is only very rarely seen in patients who are on 
immunoglobulin therapy (63).  The neutropenia can be associated with Pseudomonas or 
Staphylococcal sepsis (141).  Pseudomonas infections are well documented in XLA and one 
patient presented to medical services as a result of a pseudomonas liver abscess (190).  
There exists a risk of vaccine-associated paralytic poliomyelitis in this cohort, although this 
risk has been reduced with many programs switching to the inactivated polio vaccine 




1.9 Murine Models 
There are two commonly used murine models for XLA.  The first is Xid.  These mice have a 
spontaneous mutation at a CpG site in the BTK gene resulting in a change from arginine to a 
cysteine at residue site 28 (R28C) (194).  In humans, this identical mutation leads to a 
complete absence of B-lymphocytes and immunoglobulins (195).  However, the affected Xid 
mice retain about half the normal number of splenic B-lymphocytes.  The second model, 
using genetically BTK knock out mice, has a similar phenotype to the Xid model (126,196). 
1.10 Immunoglobulin Therapy 
1.10.1 History 
In the initial report by Bruton, the child was treated with a subcutaneous injection of Cohn 
Fraction II immunoglobulin, first reported in 1944 (3,197).  This process described the 
introduction of a novel ammonium sulphate and cold-ethanol fractional processes using large 
pools of human donor serum, therefore meaning immunoglobulin (Ig) products contained 
antibodies against a wide range of pathogens such as polio, measles and pertussis (197).  This 
process became mainstream in the 1950s, and intramuscular injections of immunoglobulin 
became the standard of care for patients with antibody defects.  However, these were painful, 
resulting in suboptimal dosages, and many severe adverse reactions were reported, such as 
nerve injuries.  Attempts at this time to administer Cohn fraction II intravenously lead to 
severe anaphylactic reactions in 90% of patients due to IgG aggregates formed during the 
manufacturing process (198).  Advances in the fractionation, purification and formulation 
process overcame these hurdles in the coming years using caprylate treatment and ion-
exchange chromatography (199). 
Further reaggregation of IgG is prevented by lowering the pH and addition of stabilisers (e.g. 
sucrose, maltose, fructose, proline, glycine).  The significant reduction in adverse events 
through methods such as preventing aggregation meant intravenous immunoglobulin (IVIG) 
was able to be offered as the mainstay of treatment of patients who required IGRT.  This 
switch from IM to IV preparations was made available in the 1980s with the UK switching 
over in 1982 (168,200).  IV preparations are less painful, allowing more substantial volumes 
to be administered, leading to higher trough IgG levels compared to IM preparations 
(201,202).  These higher trough levels dramatically reduced invasive infection rates and 
improved survival outcomes (201,202).  This period coincided with the emergence of HIV, 
and in addition to Hepatitis C, contaminated products placed a significant burden on this 
cohort due to their dependency on donor blood products (203).  The safety profile of donor 
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immunoglobulin products has dramatically improved with screening of donors and through 
improvements in the production process with exposure to low pH, pasteurisation, detergents 
and viral filtration (204).  With improved production protocols, the previous risks of 
contamination with blood born viruses have dramatically fallen, although a small risk still 
exists, particularly of prion-borne disease  (205,206).   
An alternative route of administration is via subcutaneous injections (SCIG).  This route may 
prove less of a burden to patients as it is often easier to self-administer at home compared to 
IVIG (207).  It may also produce more stable IgG trough levels which would, in turn, 
theoretically improve clinical outcomes (207).  SCIG has been available for some time, with 
the first case report of XLA by Bruton using the subcutaneous route as the method of 
administration (3).   However, initial techniques were hampered by slow infusion rates which 
ultimately limited the total dose of available IgG.  In conjunction with the fact that IgG is 
better absorbed from muscle than fat, initial IGRT was almost always given via the IM route 
(167,208).  Recent improvements have meant that the limitation of slow infusion has been 
overcome and, as such, SCIG is now a mainstay of treatment alongside IVIG with often the 
only deciding factor of one over the other being patient preference (209).  SCIG is often more 
feasible as home treatment compared to IVIG, which has been demonstrated to be cheaper, 
more convenient and leads to a reduction in days taken off school or work (210).  Both 
modalities are associated with a number of side effects.  IVIG may be associated with more 
systemic side effects, e.g. headache and hot flushes whereas SCIG may be associated with 
more local reactions such as redness or swelling around the injection site.      
Modern IGRT is available either through the intravenous route (usually on a 3-4 weekly 
basis) or the subcutaneous route (usually on a weekly basis).  Recently, the technique of pre-
infusion of SCIg with recombinant human hyaluronidase (facilitated SCIG, fSCIg) may also 
offer the infusion of SCIG to be extended to 2 to 4 weeks, similar to IVIg (211). 
1.10.2 General Management 
Historical guidelines recommended aiming for a trough IgG level of at least 5g/l, although 
more recent studies advocate a higher target of 8g/l to prevent infections and improve 
respiratory health (212–214).  Furthermore, it is now recommended that target trough IgG 
levels should be individualised, aiming for a level that adequately prevents infection and 
minimises lung function decline on an individual basis (181,215).    
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1.10.3 Potential Limitations 
Despite advances in immunoglobulin therapy, there remain obstacles.  Commercial products 
contain virtually no IgA or IgM.    There are limited data suggesting benefit using IgM and 
IgA rich immunoglobulin products for a carefully selected subset of patients (216,217).  
However, most immunoglobulin products continue to be IgA and IgM deplete due to concerns 
regarding safety data from historical cohorts and their efficacy.    IgM is routinely removed as 
it can rapidly form complexes leading to serious adverse events.  The majority of products are 
IgA deplete as patients can develop anti-IgA antibodies which precipitate severe anaphylactic 
reactions (218). Also, donor serum IgA is mostly monomeric, compared to locally produced 
pulmonary IgA, which is polymeric and better suited to protecting mucosal surfaces (51,219).  
While donor IgG has had a dramatic, effect in reducing life-threatening invasive infections, 
IgA and IgM play a significant role in protecting the mucosal surfaces. Therefore, despite 
IGRT, XLA patients will remain IgA and IgG deficient throughout their lives.  Without 
adequate replacement of these isotypes, patients are likely to continue to experience frequent 
mucosal infections, increasing the risk of serious complications such as bronchiectasis (220–
222).  Furthermore, IGRT does not attempt to compensate for other lost functions of BTK as 
described in this chapter.  Although the exact clinical implications of the loss of these other 
functions are yet to be firmly established, it would be logical to conclude they must have 
some clinical impact. 
1.10.4 Adverse Events 
Coinciding with the introduction of intravenous preparation of immunoglobulin therapy came 
the emergence of Human Immunodeficiency Virus (HIV), and in addition to Hepatitis C, 
contaminated products placed a significant burden on cohorts dependent on donor blood 
products (203).  While there are no confirmed reports of immunoglobulin transmitted HIV, 
contracting hepatitis C through contaminated immunoglobulin has been confirmed (223). 
The contamination of blood products with blood-borne viruses and the subsequent scandals 
has resulted in multiple international inquiries and millions of pounds either set aside or 
awarded as compensation (224).  Through intensive efforts to improve the immunoglobulin 
production processes, serious adverse effects of IGRT have become rare in modern times.  
These improved processes include an improved screening of donors,  exposure of the product 
to low pH, pasteurisation, detergents and viral filtration (204).  Contamination with Hepatitis 
C, HIV and other blood-borne viruses is now unheard of, although a small theoretical risk still 
exists, principally of prion-borne disease (205,206).   The risk of prion-borne disease, in 
particular, most notably vCJD, has resulted in the decision that no immunoglobulin is 
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procured from UK donor pools.  As of 2019, no UK patient with primary immunodeficiency 
on IGRT has shown clinical evidence of vCJD or shown to have abnormal prion protein in 
tested tissues (225).  
Furthermore, there are still risks associated with IgG therapy, such as skin necrosis (226).  In 
addition, specifically in the XLA cohort, there are reports of IVIG triggered tubulointerstitial 
nephritis, which can be fatal (227–230). 
1.11 Haematopoietic Stem Cell Transplantation 
Although Haematopoietic Stem Cell Transplantation (HSCT) is the primary treatment for 
many PIDs, there are limited data available examining its role in XLA.  Howard et al. 
reported a case series in which 6 XLA patients underwent HLA matched sibling donor HSCT 
without a preconditioning regime (231). 
In all patients, there was no donor engraftment.  While these transplants resulted in no harm; 
there was no benefit (231).  A recent case report describes successful HSCT for a patient with 
both XLA and Acute Myeloid Leukaemia (AML) (232).  This patient underwent 
myeloablative conditioning, and two years, post-transplant demonstrates normal CD19, IgG, 
IgM and IgA levels off immunoglobulin replacement therapy (232).  Colleagues in Japan 
have used this experience to successfully transplant an XLA patient using a reduced intensity 
conditioning regimen (233).  This patient demonstrated normal IgG, IgM, IgA and CD19 
levels 500 days post HSCT and discontinued immunoglobulin replacement therapy.  
This limited literature provides some evidence that HSCT may play a role in XLA treatment 
in carefully selected cases, especially so in healthcare settings where lifelong immunoglobulin 
therapy would be prohibitively expensive and sustained follow up unfeasible.  In most 
developed countries, the associated risks of GvHD, chemotherapy and the associated 
mortality, means HSCT is not routinely offered to patients with XLA in favour of 
immunoglobulin replacement therapy (234). 
1.12 Newborn screening 
T cell receptor excision circles (TRECs) are produced during normal T-lymphocyte receptor 
gene splicing and rearrangement.  They are found only in naïve T-lymphocytes and, therefore, 
defects causing low or absent T-lymphocytes (most notably severe combined 
immunodeficiency, SCID), will concurrently have near absent or absent levels of TRECs.  
These can be quantified on dried blood spots taken on the Guthrie card used in newborn 
screening programmes (235,236). 
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The B-lymphocyte counterparts to TRECs are kappa-deleting recombination excision circles 
(KRECs),  which are episcopal DNA fragment by-products that occur as a result of 
immunoglobulin kappa gene arrangement throughout B-lymphocyte maturation (237,238).  
KRECs do not replicate during mitosis and therefore, will exhibit a dilution pattern that 
allows a quantifiable estimation of B-lymphocyte replication (238).  Regardless of the 
underlying genetic or molecular aetiology of their disease, patients with B-lymphocyte defects 
leading to absent B-lymphocytes will have low levels of or absent KRECs. This measurement 
can also be performed from dried blood spots on the new-born Guthrie card (238).     
The potential impact of evidence thus far of national newborn screening programs for XLA is 
discussed in Chapter 2. 
1.13 Gene Therapy 
While HSCT remains the mainstay of treatment for many PIDs where a cure is the aim of 
treatment, gene therapy is fast evolving to become a promising alternative for certain diseases. 
Patient’s own hematopoietic stem cells are transduced using either lentiviral or 
gammaretroviral vectors containing a correct version of the affected gene.  These corrected 
HSCs are transfused back into the patient, often with a small amount of conditioning.  This 
modality offers the significant advantage of using the patient’s own stem cells, negating the 
risk of GvHD and significantly reducing the amount of conditioning often used in HSCT 
therapy potentially offering significant safety advantages over HSCT. 
The road to current clinical gene therapy has been long, and concerns remain surrounding 
efficacy and safety.  Initial studies using gammaretroviral vectors for the treatment of X-
Linked SCID resulted in high rates of malignancy caused by viral integrations within 
oncogenic loci (239,240).  Interestingly, the similar vector designs in ADA-SCID has not 
shown the same adverse events to date (241).  
Gene therapy for ADA-SCID using gammaretroviral vectors has shown great success and was 
recently approved by NICE for inclusion in the treatment of ADA-SCID in the UK (242), 
despite being one of the most expensive therapies ever developed (242).  Despite no cases of 
malignancy caused by the gene therapy, research is underway developing lentiviral vectors for 
ADA-SCID gene therapy (242).   
Significant efforts were undertaken to redesigning the gammaretroviral vector, and current 
gene therapy is often based on lentiviral vectors offering a potentially improved safety profile.  
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Although lentiviral vectors are now being implemented into clinical trials and do not 
demonstrate increased rates of malignancy, concerns remain regarding long-term safety and 
efficacy.  Compared to viral vectors, methods that employ gene editing may offer greater 
efficacy and improved safety profile.  One method of gene editing, which garners much 
public and press attention is CRISPR-Cas9.  There are still concerns using CRISPR-Cas9, 
most notably that of ‘off-site’ cleavages, which may have mutagenic effects (243).  However, 
while still in its infancy, recent work to repair stem cells from patients with chronic 
granulomatous disease (CGD) and JAK3 mutations using CRISPR-Cas9 demonstrate the 
potential promise this technique could have in the future (244,245).  
The progress made thus far in developing gene therapy models in XLA is discussed in 
Chapter 2. 
1.14 Outline of thesis 
Chapter 2 will review the literature for current outcomes and novel treatment strategies for 
XLA and ARA. 
Chapter 3 will detail the methodology for the study 
Chapter 4 will detail the aims and hypotheses of the study 
Chapter 5 will present the clinical outcomes for the study cohort 
Chapter 6 will present in further detail the respiratory health outcomes for the study cohort 
Chapter 7 will present the psychological health data for the study cohort 
Chapter 8 will present the quality of life data for the study cohort 
Chapter 9 will discuss the findings from this research project 
Chapter 10 will present the conclusion from this research project 
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Chapter 2 Literature Review of Clinical Outcomes 
This chapter will review the current and historical literature detailing clinical outcomes and 
health-related quality of life (HRQoL) in congenital agammaglobulinaemia and other primary 
antibody deficiencies (PAD).  There will also be a review of the effectiveness of 
immunoglobulin replacement therapy in these patients.  In addition, the final part of this 
chapter will review the current research into novel treatment and diagnostic strategies. 
A literature search of MEDLINE and EMBASE was performed with the keywords “XLA”, 
“Primary antibody deficiency”, “Agammaglobulinaemia”, “X-linked agammaglobulinaemia” 
and “BTK deficiency”.  Both UK and US spellings were used.  The abstracts of these results 
were screened to include only relevant articles such as those focusing on clinical outcomes or 
novel therapies such as gene therapy.  In addition, articles were chosen from the references 
from select seminal studies such as Plebani et al., and Hermaszewski and Webster (168,186). 
2.1 Previous UK Cohort Studies 
There have been only two previous studies examining outcomes in XLA in the United 
Kingdom.  In 1971, there was a Medical Research Council (MRC) report into primary 
hypogammaglobulinaemia (246).  However, further work has identified the diagnostic 
accuracy in this study to be weak with some patients in that cohort most likely suffering from 
some forms of severe combined immunodeficiency (SCID) (168,246).  Furthermore, all 
patients were on (intramuscular immunoglobulin) IMIg therapy, which was the only 
immunoglobulin preparation available at the time, leading to suboptimal IgG trough levels 
and a high mortality rate (246). 
In 1993, Hermaszewski and Webster carried out the second and most recent survey of XLA 
patients in the UK (168).  Forty out of forty-four  XLA patients presented with sino-
pulmonary infections, and it is interesting to note that the authors noted a plateau in 
improvement in diagnostic delay already at this early stage in modern immunology (168).  
Improvement in reducing diagnostic delay and an apparent plateau in this improvement are 
discussed further below in this chapter.  The overall 30-year survival for this cohort was 62%, 
although when excluding those patients born before 1971, the 20-year survival was 100% 
(Figure 2-1) (168). 
On treatment, 36/44 patients suffered from recurrent lower respiratory infections and 36/44 
experienced from chronic otitis media or sinusitis (168).  The authors noted that the rate of 
these infections had started to decrease since the introduction of intravenous immunoglobulin 
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(IVIg) therapy, consistent with their overall improvements in survival (168).  The results of 
this cohort are now however considered out of date, suffering from a legacy of historical, 
inadequate IMIg therapy and diagnostic inaccuracies due to the lack of genetic testing and 
inability to test for BTK protein expression (168).  However, this seminal study set out a vital 
baseline for UK XLA outcomes and, along with others, helped lay the groundwork for 
establishing the UK primary immunodeficiency (UKPID) registry (5).  
 
Figure 2-1 UK XLA survival 1956 – 1991 (168) 
 
 
2.2 Prevalence and Incidence 
With more accurately defined diagnostic criteria, and improved access to diagnostic testing, 















has altered over time due to increased awareness and diagnosis.  Boys, historically, who died 
early in infancy due to infection, may have had undiagnosed XLA.  Improved awareness of 
XLA has now allowed these boys to be diagnosed earlier, starting IGRT earlier and not 
succumbing to overwhelming infection early in infancy.  Furthermore, ascertaining an 
accurate number of cases has proven difficult until the recent introduction of national and 
international registries as well as important large-scale studies. 
The US study of 201 XLA patients by Winkelstein et al. in 2006 estimated the US incidence 
of XLA to be 1:190,000 male births or 1:379,000 live births (142).  The latest data from the 
UKPID estimates the minimum UK prevalence of XLA to be 2.41 cases per 1 million 
population (247).  This registry estimates the minimum UK incidence to be one case per 
200,000 live births (247).  However, both these figures are much lower than the reported 
incidence of proven XLA in Argentina of 1:60,000 live births (248).  Even when including 
only genetic proven cases, this figure is still higher than the US and UK figures at 1:115,000 
births (248). 
The impact of XLA and ARA in developing counties is increasingly being recognised (248–
251).  Cases are reported in a wide range of developing countries, with many beginning to 
establish national registries and publish cohort studies.  Outcomes in these cohorts are 
invariably worse than developed nations due to difficulties in accessing health care, delays in 
diagnosis and unreliable access to immunoglobulin therapy.  For example, in India, the mean 
age of diagnosis is 5.9 years, with a mean survival of 137 months (250).  Nevertheless, the 
number of identified cases worldwide is likely to increase, as access to diagnostics and 
therapies increase.  These nations, and methods to improve outcomes for their patients, must 
be born in mind when considering future research into congenital agammaglobulinaemia. 
Since the beginning of the 1980s awareness of primary immunodeficiency (PID) has 
dramatically increased with the establishment of specialised centres and charities.  Also, the 
availability of intravenous immunoglobulin replacement products, as will be discussed in 
section 2.6, led to a major step-change in outcomes for patients dependent on these products.  
Therefore, for the purposes of this literature review, ‘modern’ is defined as any cohort after 




2.3.1 Age at Diagnosis and Diagnostic Delay 
In large, modern cohort studies from Europe and the USA, the median age at diagnosis (and 
therefore instigation of therapy) ranges from 2.2 to 5.27 years (142,167,186,187).  Both 
Plebani et al. and Winkelstein et al. demonstrated an improvement in the age of diagnosis 
over time (Winkelstein et al. r = -0.43, p<0.0001) (142,186).  However, both authors 
demonstrate that this improvement has reached a plateau, with no real improvement over the 
last 15-20 years (142,186).  There has been much effort to reduce diagnostic delay in all PIDs.  
As diagnostics and therapies improve and more primary immunodeficiencies (PIDs) are 
discovered, clinicians will be more aware and more likely to think of PID in their differentials 
earlier in the patient's diagnostic workup.  In addition, efforts such as those by the Jeffrey 
Modell Foundation and their ‘10 warning signs of primary immunodeficiency’ project, have 
helped to raise the awareness of PID  to all healthcare professionals, aiming to reduce 
diagnostic delay (252,253).   However, there will always be limits in reducing the diagnostic 
delay due to the considerably wide range of what is considered a ‘normal’ number of 
infections in the healthy child and the difficulties in identifying the child with a rare a PID 
against a backdrop of the healthy population. We may have, therefore, now reached the limits 
in reducing diagnostic delay in congenital agammaglobulinaemia (254,255).  It is unclear 
what factors in the pre-diagnosis period increase the risk of later complications, but as 
discussed below, older age of diagnosis is associated with an increased risk of bronchiectasis.  
It is also unclear whether our current improvement in the diagnostic delay is sufficient to 
prevent these complications.     
The age at diagnosis in developing countries or countries with less well-established 
immunology centres tends to be higher, ranging from 3.88 years to 7.6 years in China, 
Argentina and Iran suggesting a more considerable diagnostic delay than their western 
counterparts (191,248,251,256,257).  This diagnostic delay, and therefore a delay in 
instigation in IGRT, could potentially lead to more complications. 
There is a reported family history in XLA cases of between 15-55% (186,187,256,258).  
Despite these figures, patients with a family history of XLA are still rarely screened at birth or 
early infancy with only a third of potential patients in the 2006 USA XLA study being 
appropriately screened based on their family history (142).  Lederman and Winkelstein both 
demonstrated that a family history of PID is associated with a younger age of diagnosis 
(median 3.5 versus 2.5 years and 5.4 versus 2.6 years respectively) (142,167).  An important 
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area of research would be to examine those patients who were diagnosed at birth because of 
their family history, but such data do not yet exist. 
Patients will typically become symptomatic as maternally transferred IgG level begins to 
wane by approximately 4-6 months of age (187).  Accurate data pertaining to the clinical 
picture before the diagnosis of agammaglobulinaemia are lacking.  Such data are difficult to 
validate, are subject to significant recall bias and result in uncertainties in differentiating 
typical childhood infections from infections that this cohort would experience.  The available 
literature suggests 40-50% of patients presented to a medical practitioner with infections 
within the first 12 months of life (168,251).  The diagnostic delay from the first presentation 
to diagnosis (and instigation of immunoglobulin therapy) is reported to be between 33 and 60 
months, with developed countries having a shorter diagnostic delay (186,191,251,256).  Due 
to the limitations in examining the pre-diagnosis period, the use of diagnostic delay is limited, 
and age at diagnosis is our best marker of improvements in speed to diagnosis.  Future, 
prospective studies of newly diagnosed patients, may prove useful to help improve the 
accuracy of data leading up to diagnosis, but the rarity of these disorders would likely make 
such studies unfeasible unless a large-scale multi-national approach is taken. 
2.3.2 Infections 
As discussed in the introduction, the defects in these patients make them particularly 
susceptible to encapsulated bacteria, G. lamblia and enteroviruses.  This is well presented 
within the published literature, which clearly shows that, before diagnosis, the sinopulmonary 
tract infections represent the most significant burden for these patients (Table 2-1).  Delays in 
diagnosis and instigation of immunoglobulin replacement therapy may, therefore, mean that 
these repeated sinopulmonary tract infections are resulting in significant lung damage before 
the diagnosis of XLA.  In the recent large cohort from Italy, 15/71 (38.5%) XLA patients had 
already developed chronic lung disease (CLD) before their XLA diagnosis (63% of all 
patients with CLD)(186).  While IGRT may aid in reducing the progression of their CLD, it is 
unlikely to reverse it.  Therefore, patients who have developed CLD before the diagnosis of 
their XLA are likely to have CLD for the rest of their lives  
In addition, prior to treatment, patients are susceptible to severe and invasive diseases as 
noted by Table 2-1 reporting CNS disease and sepsis. 
Neutropenia is often seen prior to or at the presentation of XLA, affecting between 11% and 
22% of patients (142,248,250).  Interestingly, this neutropenia is not seen in patients who are 
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on immunoglobulin replacement therapy (63).  It has been proposed that XLA-associated 
neutropenia may in part be due to the limited bone marrow reserve of neutrophils seen in 
infants, exacerbated by the near-complete lack of B-lymphocytes (189).  These episodes of 
neutropenia, in association with the B-lymphocyte defect, make them particularly susceptible 
to Pseudomonas infections.  Many manuscript introductions and textbooks give this little 
attention but instead focus on the susceptibility to encapsulated bacteria and enterovirus 
infections.  However, a summary of the literature clearly shows this organism to represent a 
significant burden to patients before their diagnosis.  In addition, this organism often causes 
invasive disease (167), and a recent case report describes an XLA patient presenting with a 
pseudomonas liver abscess (190).  
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Table 2-1 Summary of reported presenting symptoms and organisms in congenital 
agammaglobulinaemia (references in brackets) 







Streptococcus pneumoniae, Haemophilus 
influenzae, Pseudomonas species, 
Staphylococcal aureus, Mycoplasma 
pneumonia (187,248,260) 
ENT 22-75% (167,191,251)  
Sinuses 27-45% (142,186,251)  
Gastrointestinal 13-67% (142,186,251,261) Giardia lamblia, Rotavirus (248) 
Central 
Nervous System 
16-21% (167,250,251) Haemophilus influenzae, Streptococcus 
pneumoniae, Enterovirus 
(167,168,179,248) 
Skin 21-27% (186,251)  
Arthritis 10-15% (186,251)  
Sepsis 10% (167) Pseudomonas species, Haemophilus 




Historically, in the 1950s and 1960s, the majority of XLA patients would die in early 
childhood due to acute or chronic infections (63).  Improvements in recognition and diagnosis 
meant that in the 1970s, most patients were often able to survive through early childhood.  
However, it was unusual to reach adulthood due to chronic enteroviral infections or 
progressive pulmonary disease (167).  The most significant difference in survival rates 
occurred when therapy was switched to intravenous and subcutaneous therapy in the 1980s.  
These modalities allowed more substantial and more frequent administrations of replacement 
immunoglobulin therapy resulting in higher IgG trough levels.  It is generally accepted that, 
with modern therapy, patients should expect to survive into adulthood, likely with a near-
normal life expectancy although there is no long-term follow up data of recent cohorts to 
confirm this fully (142,168,186,258,262). 
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The mortality rate of recent cohorts is now approximately 1-1.5% with many of those deaths 
still due to chronic enteroviral infections or hepatitis as a result of contaminated 
immunoglobulin products (142,186).  These deaths most likely represent a legacy from 
patients treated with historically suboptimal therapies and from the contaminated blood 
products scandal in the 1980s, in which the use of contaminated blood products before 1986 
lead to 4800 patients being infected with hepatitis C, of which 1200 were also infected with 
HIV (224).  It is reported that nearly every patient with haemophilia (who are often dependant 
on donor blood products) treated before 1986 was infected with a blood-borne virus as a result 
of contaminated blood supplies (224).  This scandal has led to multiple international inquiries 
and billions of pounds set aside or awarded for compensation (224)  The remaining deaths are 
mainly due to chronic lung disease, and it is likely this will become the predominant cause of 
death in the future for the reasons discussed throughout this thesis. 
In countries where clinical immunology services are still being established or where there are 
difficulties with access to health care, survival rates are more akin to those seen in the 1950-
1980s in Europe and America.  Recent data from India and Iran report 5-year survival in their 
XLA cohorts as 80% and 78% respectively (191,250).  The most common causes of death 
seen in these and other developing countries are respiratory disease (both acute and chronic 
lung disease), sepsis and infections of the central nervous system (191,250,256,257) 
2.4.2 Infections 
The main aim in the management of congenital agammaglobulinaemia is to reduce infection 
rates, thereby reducing the subsequent risk of developing severe complications, reducing the 
burden of disease and maintaining a quality of life comparable to that of the background 
healthy population. 
The recent, significant improvements in survival in western cohorts most likely reflect a 
dramatic reduction in invasive, life-threatening infections as a result of more timely 
diagnoses, the switch from intramuscular to intravenous and subcutaneous immunoglobulin 
therapy, improved supportive care and antibiotic prophylaxis (202).  In particular, since the 
advent of modern management, rates of invasive disease and sepsis have plummeted 
(142,186).  In historical cohorts, enterovirus infections affected between 15% and 20% of 
XLA patients, often associated with inferior outcomes (168,179).  Recent interrogation of the 
US PID registry of 390 XLA patients demonstrates 26 of those patients have suffered from 
meningoencephalitis, of which, 12 (3%) had confirmed enteroviral infection (177).  However, 
all but one of these patients suffered their infection before 1995 confirming the evidence from 
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other cohorts that enteroviral infection on modern therapy is increasingly rare, contributing to 
the improvements in overall survival (177).    
Although there are limited data showing incidence rates, recent studies from Italy and the 
USA consistently demonstrate that patients continue to experience recurrent respiratory tract 
infections despite adequate immunoglobulin therapy (142,186,258).  In the Italian cohort of 
73 XLA patients, Plebani et al. reported 37 episodes of pneumonia requiring hospital 
admission over a median follow-up of 7 years (186).  Howard et al. report 17% of adult 
patients experienced at least 1 episode of otitis media in the preceding year, 80% had sinusitis, 
17% had pneumonia, 39% had bronchitis, and 90% reported a recurrent cough (258). 
Rates of chronic sinusitis in XLA patients remain high with reported rates of 48% - 59% 
despite treatment (142,186).  Plebani et al. found that only the duration of follow-up was 
associated with an increased risk of sinusitis, and there was no correlation with IgG trough 
levels (186).  Despite its high frequency in XLA, there are no data examining the impact of 
sinus infections on patients’ lives, nor is there a consensus on the management of sinusitis for 
patients with XLA.  This is especially disappointing given the potential acute complications 
associated with sinusitis, including intracranial abscesses (263).  Earlier work has 
demonstrated that chronic sinusitis is often refractory to treatment and may require surgical 
intervention (264).  Causative organisms isolated in sinusitis are likely to be those that XLA 
patents are particularly susceptible, such as S. pneumoniae and H. influenzae.  There are likely 
to be limitations in the effectiveness of IGRT in treating sinusitis which may progress to 
chronic infection and cause long term complications (265).  Most notably, there is a clear 
relationship between the development of sinusitis and subsequent bronchiectasis, with the 
sinuses acting as a clear gateway to the lung parenchyma (266).  Rusconi et al. demonstrated 
in their antibody deficiency cohort that sinus disease could be well controlled with a medical 
regimen of antibiotics, steroids (intranasal/oral) and saline nasal washes, as used in the 
immunocompetent population (267).  This recent work suggests, that active, combined 
therapy can be effective in the XLA cohort, and could reduce the burden sinusitis can place on 
patients’ lives (267).    
Interestingly, recurrent conjunctivitis is also commonly reported in XLA patients on 
treatment, affecting up to 8% of patients in previous cohorts, although this finding has yet to 
be repeated in modern cohorts (187). 
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While it is recognised that sinopulmonary tract infections are the most common infections in 
XLA, accurate annual infection rates are not known in large cohorts.  In a recent pilot study, 
examining fifteen patients with congenital agammaglobulinaemia in northern England, the 
infection rates in adults and children post-diagnosis were quantified as 2.12 and 0.74 
infections/patient/year respectively (268).  The reason for this difference in infection rates in 
unclear but could represent a lingering effect of previous suboptimal care in the adult cohort 
(i.e. under-recognition of infections in their childhood).  It should be noted these retrospective 
data are likely to be an underestimate and prospective data for CVID patietns has 
demonstrated an infection incidence much higher at 4.32 per year (269). 
2.4.3 Pulmonary Health 
The development of bronchiectasis is one of the clinician’s and patient's greatest fears and is a 
leading cause of mortality and morbidity for XLA patients, diminishing their quality of life 
(186,270–272).  Bronchiectasis is often progressive, refractory to treatment and may 
necessitate radical surgery or lung transplantation (268,273).  Lung transplant is rare, but 
reported in XLA.  However, outcomes appear poor.  The addition of immunosuppression in 
patients with immunodeficiency will increase the risk of infection and, without correcting the 
underlying defect, the patient and their new lungs will still be at risk of developing 
bronchiectasis.  A case series of 6 patietns demonstrated that 4 developed recurrent 
pulmonary sepsis and/or development of chronic lung disease (274).  Bronchiectasis is 
defined as a permanent and abnormal dilatation of the bronchial airways (275).  This leads to 
further increased susceptibility to infections with additional damage and inflammation, 
leading to a spiral of damage (Figure 2-2) (275).  In non-cystic fibrosis (CF) bronchiectasis, 
the 5-8 year mortality rate is reported as 10% and 13-year mortality as 30% (276–278), 
although the specific mortality for patients with XLA is unknown.  Factors found to be 
independently associated with mortality in non-CF bronchiectasis are age, St. George’s 
Respiratory Questionnaire (SGRQ) activity score (279), Pseudomonas aeruginosa infection 
and lung function (280).    
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Figure 2-2 The vicious circle of bronchiectasis, adapted from (281) 
 
 
The problem of chronic lung disease in PID, especially primary antibody deficiency is well 
known.  As soon as IV/SC immunoglobulin therapy became available, drastically reducing 
the frequency of severe acute infections and improving life expectancy, the potential problems 
of chronic lung disease in this cohort have been noted (167,168).  Furthermore, it is well 
recognised that many patients may still develop significant lung damage despite the best 
current treatment (221,272,282–284).  This is primarily because current IGRT products lack 
replacement of IgA and IgM, replacing only IgG.  With IgA and IgM being important 
protectors of mucosal surfaces, it is perhaps logical to presume patient will still experience 
recurrent respiratory tract infections, even when on IGRT.  IgG from IGRT is likely to reach 
small and large airways alike but may have a shorter half-life than serum IgG (285).  Most 
published reports concentrate on the more common disease, common variable 
immunodeficiency (CVID), which has a distinctly different phenotype and genotype to XLA.  
Overall, rates of bronchiectasis in recent XLA cohorts range from 24% to 44% with median 
ages in those cohorts ranging from 9.4 years to 33 years (186,248,251,258,286). 
It is logical to presume that delay in diagnosis and therefore, instigation of treatment would 
increase the risk of developing bronchiectasis, supported by primary antibody deficiency 
cohort studies (271,287).  The large Italian XLA cohort found that an increasing age at 
diagnosis increased the risk of developing bronchiectasis before their XLA diagnosis, but did 
not increase the risk of developing bronchiectasis after the diagnosis of XLA (186).  This may 
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suggest that the onset of bronchiectasis occurs due to infection pre-burden pre-diagnosis, 
emphasising the need for prompt diagnosis. 
In this seminal study by Plebani et al. chronic lung disease was recorded in 24/73 XLA (33%) 
patients, and the authors calculated a 25-year post-diagnosis risk as high as 92% in their 
cohort from 2002 (median age 14 years, range 2-33) (186) (Figure 2-3). 
Figure 2-3 Cumulative risk of developing chronic lung disease in relation to follow-up in 
Italian XLA patients (186) 
 
For those patients who developed chronic lung disease after diagnosis, the only risk factor 
was a longer duration of follow-up. IgG trough levels, previous IM therapy or the age at 
diagnosis did not predict the development of chronic lung disease, once again hinting at 
limitations of current management (186).  Indeed, the follow up in the healthy group was very 
short compared to the patients with bronchiectasis (5 years versus 15 years, p<0.001) and it 
would be interesting to see how the status of these healthy patients has progressed over time 
(186). 
Interestingly, 70% of respiratory tract infections that required hospitalisation were from the 
nine patients who developed chronic lung disease after their diagnosis (186).  Fifteen patients 
(21%) had developed chronic lung disease by the time of diagnosis of XLA.  Compared to the 
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other 24 patients who also reported respiratory tract infections pre-diagnosis, these patients 
had a higher mean age of diagnosis (8.8 years versus 4.8 years, p=0.06).  The authors chose 
only to analyse those patients with a presenting history of respiratory tract infections.  As 
discussed earlier in this chapter, there are difficulties with validating presenting complaints 
and dealing with recall bias.  These differences between patients with bronchiectasis and 
those without may have been different when including all 73 patients.  However, the data 
strongly suggest that an earlier age of diagnosis and instigation of immunoglobulin therapy 
reduces the risk of bronchiectasis but that progression may still occur despite current therapy 
(186). 
Howard et al. found that 13/41 US adults with XLA had chronic lung disease (mean age 30, 
range 21-57), mirroring the findings of Plebani et al. (258).  Chronic lung disease in XLA is 
entirely made up of bronchiectasis.  In contrast, patients with CVID can develop 
granulomatous-lymphocytic interstitial lung disease (GLILD), as they can develop 
lymphoproliferation as part of their underlying defect, which is not seen in XLA.  The authors 
found age at diagnosis was not significantly different in those with chronic lung disease 
compared to those without, but this analysis excluded those patients who had an unusually 
late diagnosis of XLA in adulthood (258).  Those with chronic lung disease reported more 
episodes of sinusitis and complained of more frequent shortness of breath (258).  Seventy-one 
per cent of those with chronic lung disease reported at least one episode of sinusitis in the 
preceding 12 months and 61% reported a chronic cough (258).  There are no data available in 
this cohort examining the relationship between IgG trough levels or infection incidence and 
the subsequent risk of developing bronchiectasis (258).   
Fifteen of forty-three Argentinian XLA patients had chronic lung disease (using both chest 
radiography as well as computerised tomography for diagnosis), 14 of whom reported 
recurrent pneumonia or bronchitis (248).  Recurrent lower respiratory tract infections (LRTI) 
and LRTI requiring hospitalisation pre-diagnosis were strongly associated with developing 
chronic lung disease before diagnosis (p <0.0001 and p <0.0008, respectively) (248).  In this 
cohort, patients with chronic lung disease were diagnosed later than healthy XLA patients (6.5 
versus 3.5 years, p=0.00001) (248).  However, in this cohort, as well as further LRTI, 
inadequate therapy may have been a factor in the development of chronic lung disease (low 
IgG trough levels <400mg/dL, and the use of IMIg) (248). 
A recent UK survey of 139 patients with agammaglobulinaemia (including 109 with a proven 
BTK genetic defect) reported that 56% developed bronchiectasis (median age 27 years, range 
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18-40) (286).  The risk of bronchiectasis in this cohort was associated with previous 
pneumonia (RR 4.6, CI 1.8-11.8) and otitis media (RR 4.2, CI1.6-11.0) but not sinusitis (286).  
However, this was just a single reported previous episode of these infections and not the total 
burden of infections, nor the rates.  It is therefore not possible to ascertain how the rate of 
infection correlates with the risk of bronchiectasis.  Unsurprisingly, patients with 
bronchiectasis had a lower predicted FEV1 (74% versus 92%) (286). 
There are no Z-scores for these results, so it is difficult to quantify the measure of the 
difference.  Also, there are no data on changes in FEV1 over time.  Using percentage 
predicted lung function scores rather than Z-scores has many limitations which will be 
discussed in further detail within the methodology section.  In summary, predicted lung 
function scores do not take into account the normal distribution of values within a population.  
Therefore they cannot provide an accurate normal range of values and cannot be accurately be 
compared across time (288). 
Forty-five per cent of patients in the UK agammaglobulinaemia survey were on subcutaneous 
immunoglobulin, and more patients currently on IVIg developed bronchiectasis than SCIg 
after adjusting for current age (RR 3.5, CI 1.2-10.1) (286).  However, this analysis does not 
consider previous immunoglobulin routes.  Bronchiectasis patients, on average, started 
therapy at an older age, but on multivariable analysis, only age higher than 18 years, history 
of previous pneumonia and intravenous therapy were significantly associated with 
bronchiectasis (286). 
These data highlight the burden of bronchiectasis in this cohort and mirror those findings of 
the US and Italy (142,186).  This cross-sectional data lacks detailed information on potential 
contributing factors to developing bronchiectasis, and it is, therefore, difficult to accurately 
define the risk factors for developing bronchiectasis.  Furthermore, there are no data on 
previous IgG trough levels and how this relates to therapy, infection rates and may 
subsequently alter the risk of bronchiectasis,  
Bacterial pathogens are repeatedly isolated from airway secretions from primary antibody 
deficiency patients, despite treatment. Some of these isolates are taken during asymptomatic 
periods (289–291) and are particularly concerning. Data from CVID patients demonstrate a 
‘silent progression’ of lung disease, even in the absence of overt respiratory tract infections 
(292).  Although largely thought to be able competently to tackle viruses, recent work has 
demonstrated patients with primary antibody deficiency do indeed suffer from recurrent and 
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persistent respiratory viral tract infections, and it is, therefore, possible that these viral 
respiratory exacerbations may be contributing to the development of chronic lung disease 
(184). 
High-resolution computerised tomography (HRCT) is the gold standard for diagnosing 
bronchiectasis and is often used to monitor disease although there are no agreed guidelines to 
dictate how frequently this should occur.  There needs to be a careful balance with the need to 
monitor lung disease and the concerns of repeated exposure to ionising radiation (293).  There 
is increasing evidence to suggest magnetic resonance imaging (MRI) could be a viable 
alternative imaging modality, although there remain obstacles such as scan resolution and 
availability of resources (294).  Both MRI and HRCT still provide some barriers to 
monitoring disease in infants and young children due to the need for general anaesthesia 
(295,296).  Although limited in its ability to detect early lung disease, lung function 
investigations play a vital role in monitoring progression and are usually performed on an 
annual basis in patients with respiratory symptoms or proven lung disease (297).  However, 
lung function can be unreliable in children less than six years of age (298).   
There is currently no agreement on the frequency of HRCT employed to diagnose or monitor 
lung disease (299).  A recent European survey showed that many clinicians agreed that adults 
should have a baseline HRCT scan, but there was no consensus for paediatric patients (299).  
There was no consensus on further imaging for follow up, but previous work would suggest 
HRCT every 2-4 year for patients with proven disease and less frequently for those with no 
disease (221,222,300,301). The need to monitor disease and not miss bronchiectasis must be 
balanced with radiation risk (302).  This risk is particularly pertinent to children, but HRCT 
still plays an essential role in monitoring disease (303).  Overall, children tend to be imaged 
less than adults, most likely due to these reasons above (299).  There is a lack of local, 
national and European guidelines for screening and treating lung disease not just in primary 
antibody deficiency but PID as a whole (299). 
Furthermore, there are no standardised protocols for the use of biomarkers (e.g. sputum 
neutrophil elastase, catalase activity, lipid peroxidation) to predict disease course, 
complications nor to record the presence or progression of lung disease (283,304,305).  Quinti 
et al., have developed and validated a QoL questionnaire for CVID patients which does 
capture some of the impacts on QoL made by respiratory health and shows strong correlation 
with the SGRQ (306).  However, work attempting to use this questionnaire in other PADs, 
including XLA, demonstrate that this tool may not capture all aspects of QoL in PAD patients 
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and further evaluations are needed to assess its perforamnce in PAD (307).  The SGRQ could 
be a useful tool in this cohort (270,308)  as would the bronchiectasis severity index (309).  
However, further work is needed to validate these tools in patients with PID or XLA.  These 
barriers and lack of agreed guidelines have resulted in considerable variation in the 
monitoring and screening of bronchiectasis in primary antibody deficiency (299). 
There are scant data assessing the severity or progression of bronchiectasis once it has 
developed in patients with XLA, despite the worsening of chronic lung disease being of 
paramount concern to patients as shown in cohorts of CVID (310).  There are data in primary 
antibody deficiency to suggest that airway and systemic inflammation (as measured by CRP, 
IL-6 and IL-8), play a significant role in FEV1 decline and QoL in this cohort. It may be 
appropriate to develop strategies to reduce airway inflammation in these patients (270).  It 
should be noted that the primary antibody deficiency cohort was heterogeneous, mainly 
examining CIVD patients and therefore, caution must be taken when extrapolating these 
results to patients with XLA (270).  One further study with a small number of XLA patients 
found rates of decline in FEV1 in those with bronchiectasis to be more rapid than for smokers 
and patients with CVID (65 vs 30 and 36mL/year respectively) (215). 
The Northern England pilot study showed 8/15 patients with CT-proven bronchiectasis 
(median age 26 years, range 5-46). Six of these patients demonstrated evidence of 
deterioration on either HRCT or lung function testing.   This was despite adequate IgG trough 
levels, with two patients requiring pneumonectomies and one patient in the cohort progressing 
to end-stage lung failure and undergoing lung transplantation (268). 
Currently, the only method to prevent bronchiectasis or reduced lung function decline is to 
reduce the frequency of sinopulmonary tract infections through optimisation of 
immunoglobulin therapy.  A lower IgG trough level is associated with worsening lung 
disease, but there are no data to suggest an optimal level to preserve lung function (292).  
Previous work suggests that while increasing IgG trough levels exerts no protective effect, 
increasing doses of IVIg can play a protective role in reducing the decline in FEV1 (311), but 
this needs to be confirmed on a larger scale.  
Once bronchiectasis is established, there is the potential use of inhaled corticosteroids, β 
agonists, prophylactic antibiotics, higher IgG trough levels, physiotherapy but minimal data 
support these modalities, especially in the primary antibody deficiency cohort (281,312–314).  
Mucous clearance is an essential part of bronchiectasis management and physiotherapy is a 
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standard adjunct to therapy in bronchiectasis (315,316).  Mucolytics are also widely used, 
although the evidence base supporting their efficacy is limited.  A Cochrane review in 2014 
demonstrated that, while there may be some linted data supporting the use of some mucolytics 
such as bromhexine and erdosteine, other mucolytics should not be recommended in non-CF 
bronchiectasis, such as recombinant human DNase due to no evidence of benefit and potential 
harmful effects (317) .  There are very scant data examining the use of mucolytics in children, 
and further work is needed to evaluate the use of mucolytics in non-CF bronchiectasis.  
Although a wide range of manoeuvres exists, there is a lack of published literature examining 
the best method and therefore no international or nationally agreed guidelines as to the best 
physiotherapy approach in bronchiectasis (318). 
Prophylactic antibiotics may play a role in preventing infection, although practices regarding 
prophylactic antibiotic use in XLA vary significantly (297).  A recent UK survey 
demonstrated that 54% of patients with agammaglobulinaemia took regular prophylactic 
antibiotics, even in the absence of lung disease (286).  This proportion rose to 64% in those 
with lung disease (286).  This variation in practice is confirmed in a recent European survey 
examining the practice of monitoring lung disease in PID (299).  While many centres 
administer prophylactic antibiotics for patients who have developed bronchiectasis; there are 
few data to prove its effectiveness specifically in primary antibody deficiency or XLA (311).  
However, recently Milito et al., have published an RCT examining the use of prophylactic 
antibiotics in PAD (319).  They enrolled 89 patients with PAD, assigning 44 to the treatment 
arm and 45 to the placebo arm (319).  Treatment consisted of Azithromycin 250mg 3 times a 
week for 2 years (319).  These data showed a clear benefit for the use of prophylactic 
azithromycin with the hazard risk for having an acute exacerbation in the azithromycin group 
of 0.5 (95% CI, 0.3-0.9; p = 0.03), and the hazard risk for hospitalization was 0.5 (95% CI, 
0.2-1.1; p = 0.04) (319).  The authors did note that whilst Haemophilus influenzae and 
Streptococcus pneumoniae were the commonest organisms isolated, as expected, there was 
resistance to macrolides in 25% of patients of both arms (319).  The safety profile of 
azithromycin and placebo was comparable (319).   For non-CF bronchiectasis, the most 
studied and effective prophylactic antibiotic is Azithromycin (250mg daily or 500mg three 
times a week for adults) (320).  A few studies suggest clarithromycin or erythromycin as 
alternatives (320).   However, caution must be taken when interpreting data from this 
heterogeneous non-CF cohort transferring these findings to the XLA cohort.  Recent work 
demonstrates that primary antibody deficiency patients with bronchiectasis appear to have 
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greater airway inflammation compared to their immunocompetent counterparts despite similar 
severity of appearance on HRCT (270). 
There are increasing data to suggest that despite more aggressive IgG therapy and the use of 
prophylactic antibiotics, some patients still develop bronchiectasis and that the bronchiectasis 
can progress further in its severity (258,321,322).  However, there are scant data specifically 
examining XLA patients in large numbers or using more accurate measures of monitoring 
lung disease progression such as FEV-1 Z-Scores.  
2.4.4 Autoimmunity and Inflammation 
Many primary immunodeficiencies (PIDs) have an associated risk of autoimmunity and 
inflammatory disease (323).  Inflammatory disease in XLA is conventionally thought to be 
infection-related, and so, with adequate immunoglobulin therapy, it has been accepted that 
patients with XLA are spared these complications (167,324).  However, as this chapter has 
discussed, patients may still be experiencing recurrent infections despite modern therapy.  In 
addition, with the potential loss of inflammatory regulation caused by the lack of B-
lymphocytes, there is a possibility that this cohort may be at risk of these complications.  Data 
from the USA demonstrates that 69% of XLA patients report at least one inflammatory 
symptom, 53% report multiple inflammatory symptoms and 28% of patients have been 
formally diagnosed with an inflammatory disorder (324). 
Data from the United States Immune Deficiency Network (USIDNet) registry demonstrated 
12% of XLA patients reporting arthralgia or joint swelling, with 16% having a diagnosis of 
arthritis (324).  However, some of these may have an underlying infectious cause rather than a 
solely autoimmune process (e.g. Mycoplasma and Ureaplasma species) (325).     
Gastrointestinal manifestations represent a significant, and perhaps under-recognized burden 
on this population.  Further analysis of the USIDNet registry reported that 35% of XLA 
patients experienced gastrointestinal complications ranging from recurrent infections to 
inflammatory bowel disease (IBD) (326).  Up to 10% of patients within this registry are 
formally diagnosed with IBD or enteritis (326).  The most commonly reported symptoms 
were abdominal pain, diarrhoea, weight loss, nausea, and vomiting (326).  For some patients, 
GI disease and/or IBD like symptoms may be the main presenting symptoms of XLA (326).  
Commonly isolated pathogens within stool samples in this registry are typical of the immune 
defects in XLA; G. lamblia, Salmonella, Campylobacter, Cryptosporidium, mycoplasma and 
enterovirus (326).  How much of the GI disease in XLA is secondary to infection and how 
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much is due to genuine inflammatory or autoimmune processes remain unknown.  IVIg has 
been identified as of potential benefit for the treatment of Crohn’s disease and modification to 
standard therapy may be of some benefit in XLA patients (327,328).  The microbiome is 
postulated to play a major role in the phenotype of IBD patients, with increasing research 
examining the role of potential management strategies to alter the microbiome such as 
probiotics, prebiotics, antibiotics and faecal microbiota transplantation (329).  There are no 
data on the GI microbiome in XLA patients, and this would be a useful target for future 
research.  Overall, there is scant literature examining the benefit of potential management 
strategies for GI disease in this cohort.   
2.4.5 Malignancy 
Rates of malignancy in XLA have been reported to be between 1.5 and 6%, with patients 
most likely to develop lymphoproliferative disorders (e.g. AML, B-precursor ALL), gastric 
cancer and colorectal cancer  (232,330–333).  This risk may be related to chronic infections, 
although this needs to be further studied in a large cohort with modern management and 
longer life expectancy (334).   It is possible that, as we enter an age with increasing longer-
term survival, the risk of malignancy in XLA will become more apparent.  
A review of GI carcinoma in XLA reveals a young-onset (median 30 years (range 7-40)) 
(335).  This compares to the mean age of onset of GI carcinoma in the background US 
population of 69 years (335).  There are limited data on the exact clinical background of these 
patients but over half had persistent IgG trough levels <7g/L which would likely to be 
considered suboptimal (335).  In addition, one third had proven chronic GI infection with the 
majority suffering from chronic atrophic gastritis (335).  It should be noted that while the low 
IgG trough levels could represent inadequate therapy, they could also be as a result of 
increased GI losses or increased IgG catabolism from chronic inflammation and infection.  
The authors of this study and subsequent reviews have questioned whether there is a role for 
GI malignancy screening in this cohort (335).  It may also be useful to examine baseline and 
serial values of faecal calprotectin in this group, for which no current data exist, as a marker 
of GI inflammation and risk of developing GI disease. 
2.4.6 Other Clinical Complications 
Approximately 3-5% of patients with XLA have large deletions at the 3’ end of BTK and the 
closely linked TIMM8A gene (also known as DDP) (336,337).  This contiguous gene deletion 
results in the individual having XLA Mohr-Tranebjaerg syndrome (336).  The diagnosis of 
XLA typically precedes any deafness, and the deafness may be wrongly thought to be 
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secondary to recurrent otitis media.  Deafness in XLA is common and most are secondary to 
central nervous system infections before diagnosis.  Although data on recent cohorts are 
lacking, Lederman at al. reported 32% of the US cohort experienced hearing loss as a result of 
CNS infection (167).  
In addition to IBD like disease seen in XLA, there is also a case report of chronic Norovirus 
infection in a patient with XLA (185).  In addition to this case, this PhD study also revealed 
another XLA patient with chronic Norovirus infection.  Chronic Norovirus infection is well 
documented in CVID (338), but not previously thought to be a problem for XLA patients due 
to prevailing opinion that these patients are competent to fight viral infections (with the 
exception of enterovirus).  The potential impact of chronic Norovirus will be discussed further 
within the result and discussion sections of this thesis as a relatively novel finding and 
opinion. 
Despite these well documented GI complications, data on their nutritional impact are lacking 
in the literature.   However, recent work examining the overall nutritional status of the 
agammaglobulinaemia cohort found that obesity was a more pressing concern rather than 
faltering growth in keeping with the general population (339).  Dellepiane et al. examined the 
Italian agammaglobulinaemia cohort and found 38% of patients were overweight or obese and 
5% were underweight (339).  In the US cohort, 18% of patients are obese, 32% overweight 
and one patient was underweight (258). 
2.4.7 Quality of Life 
Quality of life (QoL) is an increasingly important measure and research tool in the assessment 
of disease and treatment burden on patient’s lives, particularly in the context of chronic 
disease (340).  Previous research assessing QoL in primary immunodeficiencies and their 
treatments have played vital roles in developing optimum treatment strategies (340).  The first 
publication of QoL in primary antibody deficiency was in 1993 with numerous studies 
published since (341,342).  However, primary antibody deficiency covers a wide range of 
clinical phenotypes, and there may be significant differences in QoL amongst individual 
diseases.  Even after grouping several disorders, the resulting sample sizes are small.  
Furthermore, a great deal of the published literature is mainly focused on the impact of 
varying immunoglobulin therapy strategies on QoL.   
There are ongoing and significant efforts to improve QoL research in primary antibody 
deficiency and PID.  For example, specific QoL surveys for PID, primary antibody deficiency 
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and CVID have very recently been published and have begun to be validated (306,343,344). 
However, these surveys are designed for heterogeneous cohorts and/or focused on CVID, 
which represents the biggest burden by the number of patients within primary antibody 
deficiencies.  Furthermore, these specific tools lack the ability (currently) to compare patients 
with the healthy population or other disease cohorts.  However, they are an important step 
forward in monitoring QoL in PID and could form an essential role in the ongoing clinical 
review of patients by measuring QoL longitudinally.   
Generally, all QoL surveys in primary antibody deficiency agree that overall QoL is lower 
than age-matched healthy controls and even some other chronic diseases, including cancer 
(345).  In addition, QoL appears to decline over time and the risk of developing psychological 
distress increases (346).  However, these studies are small, often focus on CVID, and their 
findings, therefore, may not be entirely transferable for XLA. 
Forty-one per cent of US XLA patients have not been hospitalised since their diagnosis, and 
83% described their health as good or excellent, highlighting the progress that has been made 
in the management of this disease and PID in general (258).  86% reported missing fewer than 
ten days of work or school in the preceding 12 months, with 44% reporting missing none 
(258).  Forty out of forty-one patients had adequate insurance, but nineteen of these had 
difficulty obtaining it (258).  However, 20% of patients reported missing appointments or not 
keeping up with immunoglobulin therapy because of difficulties with their health care 
insurance (258).  This highlights some of the difficulties in transferring findings from US 
cohorts to the UK with its nationalised health service and improved access to health care and 
lack of (relative) financial barriers. 
American adults with XLA have lower QoL scores on the 12-item short-form version 2 
(SF12v2) compared to the background healthy US population, although not statistically 
significant.  Half of USA patients stated they have or would, in the future, undertake a 
prenatal diagnosis.  Interestingly, in a separate questionnaire, patients reported that it was the 
treatment, rather than the disease that placed the highest-burden on their quality of life and 
daily living (258).  A third of patients reported that having XLA affected their social 
activities, sleep or normal physical exertion (258).  In addition, over half the US cohort in this 
study by Howard et al. reported that XLA affected their ability to travel and choose their 
career (258).  However, the impact on employment was mainly driven by the ability and need 
to get adequate health insurance (258).  Different findings may, therefore, be seen in the UK 
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population with access to universal healthcare.  The second reason was the impact of the 
treatment (rather than being unwell) (258).  
There appear to be more significant reductions of QoL in the paediatric population.  Titman et 
al. showed that UK paediatric patients with primary antibody deficiencies have worse QoL 
scores compared to the healthy population and patients with diabetes mellitus (347).  In 
particular, children scored disproportionately worse on psychological and emotional aspects, 
suggesting that mental and emotional health is more severely affected than physical health 
(347).  However, when only analysing the XLA patients in this cohort, the results suggest the 
children scored similar scores to healthy norms, but the parents consistently reported lower 
scores.  There were only 5 XLA patients in this study, so it is difficult to come to firm 
conclusions, nor is it possible to carry out statistical analyses (347).  Due to the small sample 
sizes, the authors were unable to correlate QoL with aspects of disease and treatment burden.  
Soresina et al. in their larger sample size of 25 Italian paediatric XLA patients found more 
statistically significant differences (348).  In all domains of the PedsQL 4.0, aside from 
physical health, children and parents reported worse scores than healthy norms (348).  Their 
physical health was reported as slightly lower but not statistically significant (348).  
Importantly, they scored consistently higher on the physical health domain than children with 
rheumatic arthritis (348).  There was no association with QoL score and socioeconomic status 
or disease severity (according to clinician self-reporting) (348).  These findings seem logical 
given children diagnosed in recent years benefit from earlier diagnoses and more aggressive 
immunoglobulin therapy (214), but still have to deal with the impact of treatment and from 
feeling ‘abnormal’ which is a well-recognised phenomenon for parents and children with PID 
(340).   
A recent paper examining 60 children with primary antibody deficiency on SCIg (albeit with 
one XLA patient) also tried to quantify these differences in PedsQL 4.0 QoL scores (349).  
They did this by using Cohen’s d effect, a commonly used method in psychology research 
(350).  The authors found that children had medium-sized lower QoL scores than healthy 
norms and children with diabetes and these scores were similar to those children with cancer 
(349).  They found that the school, social and physical subsections were affected most and the 
emotional subscale affected the least (349).  The QoL scores in this cohort were similar to that 
found in other PID QoL studies helping validate the results (349).  Also, the authors found 
that children and parents both had a low perception of the effectiveness and convenience of 
their treatment compared to patients with cystic fibrosis (349).  The authors have grouped 
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both proxy and self-reports, so it is not possible to analyse any differences between children 
and parents (349). 
The northern England pilot study showed QoL scores for eight adults with XLA, using the 
SF-36v2, were not statistically significantly different compared to that of the UK population, 
except for the subsection ‘General Health’ which was significantly lower compared to that of 
the UK population (59.5 vs 78.37, p <0.05)  (268),  although the small sample size means 
these results should be interpreted with care. 
Given the impact of respiratory disease in this cohort, it would be logical to presume this 
would contribute greatly to QoL scores, yet surprisingly this is an area rarely covered in the 
published literature.  In 7 XLA patients, Hurst et al. have shown that SGRQ scores and SF36-
v2 scores are highly correlated (r=-0.79, p <0.001), suggesting that QoL is strongly influenced 
by the impact of respiratory disease and symptoms (270). The northern England pilot study 
showed total SGRQ scores significantly higher (i.e. worse) than the background healthy 
population (17.21 vs 2.72, p = 0.005) (268).  Interestingly, the SGRQ symptom subscore for 
those seven patients without proven respiratory disease was still significantly higher than the 
background healthy population (25.08 vs 4.24, p=0.028) (268).  In addition, the impact sub-
score was also significantly higher (2.74 vs 0.00, p = 0.043).  Although the total SGRQ score 
for patients without proven lung disease tended to be worse than the healthy population, this 
did not reach significance (8.38 vs 2.72, p=0.116) (268).  This may indicate that patients 
without proven lung disease still have a significant QoL impact from respiratory symptoms 
because of their disease. 
Although an increasingly important measure of outcome, published data on QoL in XLA is 
still scarce.  Most current knowledge is extrapolated from small cohorts or other PIDs.  
Further work is needed to examine QoL in XLA, including the impact of respiratory disease.   
2.4.8 Psychological Health 
Congenital agammaglobulinaemia is chronic, incurable and is associated with a high risk of 
complications (186).  Chronic disease not only affects physical health but can impact upon 
future emotional and social well-being (351).  When patients are able to maintain a healthy 
emotional balance, have healthy social interactions and feel they are contributing to society, 
they can adjust to living with a chronic disease (352).  Living with a chronic physical disorder 
has been shown to increase the risk of depression, anxiety, obsessive-compulsive disorder and 
attention deficit disorder (353,354).   
50 
 
In the Titman et al. study of 19 UK children with primary antibody deficiency (including 5 
with XLA) parents reported significantly higher proxy rates of psychological difficulties 
compared to healthy children (347).  The children themselves reported higher rates of 
psychological difficulties compared to their peers, but these differences did not reach 
significance (347). 
In the USA, 25 adults with XLA showed good adjustment with fifteen in long-term 
relationships, twenty patients have graduated from college, and 20 were employed or self-
employed (262).  However, there is a lack of precise data on the clinical outcomes, and so it is 
not possible to correlate health status with psychological health or social adjustment.  Within 
the 2006 cohort by Howard et al., patients with chronic lung disease scored significantly 
worse on the mental health component (258). 
2.4.9 Autosomal recessive agammaglobulinaemia 
XLA accounts for 85% of all congenital agammaglobulinaemia cases.  Approximately 2/3rd of 
the remaining 15% are female, offering clues to early researchers that autosomal recessive 
disorders of B-lymphocyte development may also occur (25,176,355). 
30% of autosomal recessive agammaglobulinaemia (ARA) cases are caused by mutations in 
the µ heavy constant region gene, IGHM, first described by Yel et al. in 1996 (27,356).  Other 
genes in which defects in can lead to congenital agammaglobulinaemia are B-cell linker-
adaptor protein (BLNK) (357), immunoglobulin λ-like polypeptide (IGLL1) (358), leucine-
rich repeat contained 8 (LRRC8A) (359), B-Cell Antigen Receptor Complex Protein Alpha 
Chain (CD79A) (360–362), B-Cell Antigen Receptor Complex Protein Beta Chain (CD79B) 
(363,364)  and in the Phosphoinositide-3-Kinase Regulatory Subunit (PIK3R1) (365).  Due to 
the rarity of these individual causes of ARA, there are no sizeable detailed cohort studies.  
However, it is well recognised that patients with ARA tend to suffer from a more severe 
phenotype of agammaglobulinemia than their X-linked counterparts, often with a younger age 
of onset (27,366).  Patients with ARA are treated similarly to XLA. 
2.5 Genotype/Phenotype Correlation 
There is a wide range in the clinical phenotype of XLA, even within the same family whose 
members share the same mutation.  For example, some patients continue to be diagnosed late 
in adulthood, or even only after a grandson or nephew has been diagnosed with XLA (after 
leading a relatively healthy life) (20,22,367).   
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There is a wide range of BTK mutations causing XLA with over 500 different mutations now 
reported, and with no single mutation accounting for more than 3% of patients (368).  A 
genotype/phenotype correlation has long been sought after to help offer a more accurate 
diagnosis or offer more aggressive therapy to those who might require it. Evidence for some 
geno/phenotype correlation is supported by the well-recognised feature that some patients 
with XLA can have residual circulating IgG/IgM and even a small number of circulating B-
lymphocytes due to the leaky nature of their B-lymphocyte differentiation defect (369). 
Efforts so far to establish an accurate and predictive clinical correlation with BTK mutation 
have been disappointing.  A contributing factor to this is difficulty in defining severe or mild 
mutations in BTK.  The majority of mutations in BTK result in the absence of BTK protein 
expression in platelets and monocytes (370–372).  However, some amino acid substitutions 
do allow either small amounts of normal BTK protein to be produced, and some splice defects 
allow the BTK protein to be produced but with reduced function (373–375).   
Conley and colleagues have produced most of the reliable published data examining genetic 
defects in XLA.  Based on their expertise and experience, their definition of severe and mild 
mutations are shown in Table 2-2 (187).  These definitions are widely used in modern studies 
examining genetic defects in XLA. 
Table 2-2 Definitions of mild and severe mutations by Conley et al., (187) 
Mild mutation Severe mutation 
Amino acid substitution at non-conserved 
sites 
Amino acid substitution at conserved sites 
in other members of the Btk family (Itk, 
Tec) 
Splice-site defects at conserved base pairs 
but not invariant 
Frameshift mutations 
 Splice site alteration at invariant sites 
within the first two and last two base pairs 
of an intron 
 Premature stop codon 




From 110 US patients, 36.4% had an amino acid substation, 25.4% splice defects, 10% frame 
shifts and 15.5% premature stop codons (368).  Using these severity definitions, Broides et al. 
demonstrated that the percentage of patients diagnosed with mild mutations increased with 
age (p=0.04) (368).  In patients diagnosed in the first year of life, 29.4% had a mild mutation, 
whereas those diagnosed after five years, 56.2% had a mild mutation (368).  The authors 
found a correlation between the mutation severity and plasma IgM levels (368).  Patients with 
mild mutations were diagnosed later, had a higher percentage of circulating B-Lymphocytes 
and higher plasma IgM levels (368).  However, there are no data correlating current clinical 
outcome (e.g. infection rates, complications) with mutation, and the authors concede that 
correlation is not strong enough to predict prognosis based on the mutation type (368). 
Studies from Spain mirror these associations between mutation type and age at diagnosis, 
plasma IgM levels, and circulating B-lymphocytes (376).  They found a trend for fewer 
hospital admission pre-diagnosis amongst patients with mild mutations (p = 0.04) (376).  The 
authors note that in their 54 patients, there was a range of clinical phenotypes among patients 
with the same mutation, including within the same family (376).   
In summary, while there is not a strong genotype/phenotype correlation in XLA, there is 
evidence of a correlation with age at diagnosis, which may be a marker of disease severity 
(377–381). 
2.6 Immunoglobulin Therapy 
2.6.1 Effectiveness 
The effectiveness of modern IVIg and SCIg perpetrations and therapies in the management of 
patients with antibody deficiencies is well established.  A meta-analysis from 2010 examined 
the relationship between trough IgG levels and the incidence of pneumonia in 676 patients 
with antibody deficiency, including 253 patients with XLA, but only those patients on IVIG, 
excluding those on SCIG (382).  This study found a fivefold protection against pneumonia 
with trough levels >10g/dL compared to 5g/dL (382), supporting contemporary guidelines 
which advocate the use of higher trough levels (Figure 2-4) (382).   
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Figure 2-4 Adapted from a meta-analysis from Orange et al. showing the effect of IgG 
levels (mg/dL) on pneumonia incidence per patient-year (382).  Each data point 
corresponds to a single study.  Data points are labelled by the referencing in the original 
article by Orange et al.  Solid line shows multilevel model predictions and dashed lines 
indicate the 95% CI of metaregression.  Abbreviations: CI, 95% confidence interval; IRR, 
incidence rate ration per 100mg/dL increase in trough IgG level. 
 
In contrast, a study examining 100 patients with CVID and 101 patients with XLA (not 
included in the above meta-analysis) found no significant difference in IgG trough levels 
between those who developed pneumonia and those that did not (222).  There was an 
increased incidence of pneumonia with IgG trough levels below 4g/dL, a target which is not 
relevant to modern management of XLA (222).  The major risk factors for pneumonia in this 
study were low IgA and IgG at diagnosis, current IgA levels <7mg/dL and those who have 
bronchiectasis (222).  The downward spiral patients enter once they develop bronchiectasis 
emphasises the importance of preventing pneumonia as early as possible. 
Many of these studies include only small numbers of patients with XLA or ARA. 
Furthermore, they concentrate solely on the number of infections that require hospital 
admission, which will tend to be more severe infections compared to outpatient infections.   
The effectiveness of IgG therapy on infections that require hospital admissions is well known.  
Indeed, this has been specially researched in XLA with infections requiring hospitalised 
falling from 0.09 per month to 0.01 month after the instigation of IVIg (p<0.001) (251). Data 
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on infections treated as an outpatient are lacking in this cohort, which may still be frequent 
and leading to significant morbidity for these patients.  
Chan et al. found those XLA patients with IgG trough levels >700mg/dL tended to have fewer 
overall complications, fewer rates of bronchiectasis and better lung function (p=0.041) (256).  
No patients with IgG trough levels >700mg/dL had bronchiectasis or impaired lung function 
although it is unclear if these IgG data are cross-sectional or retrospective (256). 
There is no evidence or guideline available to dictate Ig therapy once bronchiectasis has 
developed, although most clinicians will generally target a higher trough IgG level to prevent 
further sinopulmonary infections (383).  In addition, patients with bronchiectasis often need 
higher IgG doses than those without bronchiectasis, to achieve similar IgG trough levels 
(181,384).  Gouilleux-Gruart et al. suggest that the presence of bronchiectasis affects IgG 
recycling though FcRn expression and local catabolism (385) and Litzman suggests this effect 
could be directly proportional to the severity of bronchiectasis (386).  It has also been shown 
that these effects in pharmacokinetics are more prominent in those patients on intravenous 
compared to subcutaneous therapy, highlighting a possible increased efficiency of SCIG 
versus IVIG (384,385). 
It is possible to administer immunoglobulin with recombinant human hyaluronidase 
(facilitated SCIg (fSCIg)).  This combination allows much larger volumes to be given at a 
single site (>600ml) at singe meaning fewer needles, infusions and an adverse event profile 
similar to SCIg with improved bioavailability (211,387).   
Recent work from a French cohort, showed there were no differences in QoL when comparing 
PID patients on home, hospital SCIg or IVIg (388).  However, they found that QoL was 
impaired across all subgroups compared to healthy norms (388).  Although this group 
included five patients with XLA (of 116 patients), these findings highlight the importance that 
route and place of immunoglobulin therapy are unique to each patient (388).  Some patients 
may prefer hospital-based therapy, as in this cohort.  Thirteen per cent of patients changed 
either the route or the site of their therapy in the preceding 12 months, although there are no 
data to determine if this was for personal or clinical reasons (388).  The overall rate of serious 
infections was 0.19/patient year (95% CI 0.08-0.46), which is somewhat higher than the 
expected rate for solely XLA patients, highlighting the heterogeneous nature of this cohort 




As discussed in Chapter 1, current IGRT lacks replacement of IgA and IgM, consisting only 
of IgG.  With IgA and IgM both playing vital roles in protecting mucosal surfaces, it would 
be logical to presume patients will still experience recurrent infections on these sites.  The 
most pertinent risk would be that of recurrent respiratory tract infections and the subsequent 
risk of bronchiectasis.  Recent work from Hodkinson et al. demonstrating primary antibody 
deficiency patients with a low IgA and IgM are at increased risk of bronchiectasis, supports 
this proposed risk (389).   
Patients with Hyper IgM syndrome (e.g. CD40L deficiency) have a statistically significant 
lower rate of non-typeable Haemophilus influenzae carriage compared to patients with XLA 
(relative risk 0.39, 95% CI 0.21-0.63) (390).  Those patients with hyper IgM were able to 
generate antibodies against non-typeable Haemophilus influenzae in their saliva and blood 
(390).  These findings were clinically significant, with hyper IgM patients suffering from 
fewer acute sino-pulmonary tract infections (relative risk 0.38, 95% CI 0.22-0.68) (390).   
Further work demonstrates that patients with isolated IgA deficiencies who, despite normal 
IgG and IgM levels, experience four times as many respiratory, gastrointestinal and skin 
infections compared to matched healthy controls, increasing their risk of serious long-term 
complications (391).   
Recent advances in the optimisation of immunoglobulin therapy have had a positive impact 
upon patient’s lives, but treatment is limited in efficacy to reduce infection rates given the 
lack of IgA and IgM in current products.  These isotypes play a major role in protecting the 
mucosal surfaces, most notably the sinopulmonary tract (219,390).  Without their 
replacement, it would be logical to presume patients will continue to experience recurrent 
sinopulmonary infections as suggested by the evidence above (186).  
2.7 Newborn Screening 
Plebani et al., demonstrated that while the age at diagnosis has reduced dramatically over the 
preceding 20 years, this improvement is now reaching a plateau at between 2 and 3.5 years 
(13,14).  Newborn screening, via a dried blood spot on day 5 of life, is a well-established 
practice, screening for life-long and potentially life-threatening conditions where early 
diagnosis and/or intervention has significantly improved outcome (392).  Newborn screening 
would allow diagnosis of XLA and instigation of treatment at a pre-symptomatic phase.   
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Newborn screening for SCID, using TREC analysis is established or soon to start in 7 
countries worldwide, including the USA, enabling diagnosis and curative treatment before 
serious infections develop, significantly improving outcomes (393,394).  It is currently being 
considered for inclusion in the UK newborn screening programme (393).    
A further 25 countries are carrying out pilot programmes and/or applying for newborn 
screening using TREC analysis to be included within the national program (394).  Twelve of 
these counties are planning or are using a combined TREC/KREC screening program (394). 
Barbaro et al. recently published the most extensive combined TREC/KREC screening study 
examining 58,834 newborns (395).  From these, 64 were recalled with three being diagnosed 
with PID (395).  The vast majority of these recalls were due to the abnormal KREC levels 
(49/64) (395).  In the majority of recall cases on retesting, the low TREC/KREC levels 
normalised or were attributed to transient causes such as maternal immunosuppression or 
prematurity (395).  The authors note that a correct cut-off level of KREC levels for children 
with congenital agammaglobulinaemia is not known and, with further studies, the cut-off 
KREC level could be further optimised reducing the recall rate further (395).  
The authors have also have estimated that adding KREC measurement onto an existing TREC 
screening programme would involve minimal additional costs due to multiplex PCR reactions 
(<€0.10 per new-born) (395).  As well as allowing the screening of XLA, a combined 
TREC/KREC screening programme would also allow the identification of PIDs which may 
otherwise be missed by a TREC analysis alone (such as late-onset ADA and Nijmegen 
breakage disorder) (396–398).  It may also help distinguish those SCID patients with and 
without B-lymphocyte production, further helping the diagnostic process for these patients. 
Introducing a new test into any newborn screening programme would necessitate the meeting 
of strict criteria, often using an amended version of the Wilson-Jungner criteria (Table 




Table 2-3 UK Public Health England criteria for appraising the viability, effectiveness 
and appropriateness of a screening programme (400) 
The condition The condition should be judged a significant health problem 
All cost-effective primary prevention interventions have been 
implemented 
The natural history and implications of carriers should be understood 
The test There should be a simple, safe, precise and validated screening test. 
The distribution of test values in the target population should be known. 
The test should be acceptable to the target population. 
There should be an agreed policy on further diagnostic investigation  
Methods for the selection of genetic variants will be kept under review  
The intervention There should be an effective intervention for patients identified 
There should be agreed evidence-based policies covering which 
individuals should be offered interventions and the appropriate 
intervention to be offered. 
The screening 
programme 
There should be high-quality evidence that screening programme is 
effective 
There should be evidence that the complete screening programme is 
acceptable to health professionals and the public 
The benefits of the screening programme should outweigh any harms 




Clinical management should be optimised in all health care providers 
prior to participation in a screening programme. 
Other options for managing the condition should have been considered 
There is a plan for managing and monitoring the screening program. 
Adequate resources should be available prior to commencement 
Evidence-based information should be made available to potential 
participants 




2.8 Gene Therapy 
There are several studies demonstrating a proof of concept for the utility of gene therapy in 
XLA in BTK-deficient mice (401–404).  However, it should be noted that BTK deficient mice 
tend to have a milder phenotype than their human counterparts (369).  Initial retroviral vectors 
have demonstrated considerable and sustained B-lymphocyte function, immunoglobulin 
production and T-independent type II immune responses (405).  Due to the concerns 
regarding safety and retroviral vectors, recent work has concentrated on lentiviral vectors, 
again showing good response and proof of concept in murine models (404,406).  Despite gene 
therapy research in XLA beginning over a decade ago, there are currently no studies in place 
or planned, examining the use of gene therapy in human XLA patients. 
2.9 Summary 
The rarity of XLA and ARA make it extremely difficult to set up and coordinate studies with 
large numbers of patients.  Conclusions regarding outcomes and treatment are primarily 
derived from heterogeneous primary antibody deficiency cohorts.  While these sample sizes 
are often large; they regularly contain small numbers of XLA patients.  These cohort studies 
are often made up of patients with CVID and findings from CVID; patients cannot be 
automatically and easily extrapolated to the management of XLA.   While also an antibody 
deficiency, the phenotype of CVID is different from XLA and therefore subsequent outcomes 
are likely to be too.  The age of onset is often different, and there are often other 
complications in CVID such as autoimmunity and or granulomatous-lymphocytic interstitial 
lung disease seen much less frequently in XLA or even not all (407).   
The rarity of the disease often means immunology centres will only care for a minimal 
number, often a handful of patients.  This results in difficulties in both coordinating national 
studies and in collecting detailed clinical information.   
The XLA cohort studies that exist are mainly out of date, often confounded by many patents 
having received previous and inadequate IMIg therapy.  The two recent and large XLA 
cohorts from the USA and Italy while large, are now over 15 years old.  The data collection 
for these two studies was primarily surveys sent out to clinicians.  The level of detail on these 
surveys is often limited, to aid input and cooperation from clinicians.  For example, these two 
studies did not record data on previous IgG trough levels, only the most recently recorded 




As developing countries begin to establish their clinical immunology programmes, the burden 
of XLA and ARA worldwide is becoming ever more apparent.  These countries are producing 
reliable cohort studies of their patients most notably from China, Iran and Argentina.  
However, clinical immunology is still in its infancy in these countries and treatment is not yet 
optimal, illustrated by their much higher mortality rates compared to Western Europe and 
America.  Research into outcomes in XLA is vital for these countries.  Access to health care 
and regular immunoglobulin therapy can be challenging.  In some countries, it may be more 
effective and cheaper to offer HSCT to these patients.  Although HSCT is associated with 
significant mortality and morbidity, newer protocols with reduced conditioning, better HLA 
matching, more flexible HLA matching with alternative stem cell sources (e.g. cords) has 
improved outcomes.  However, there are many patients for whom HLA matches are 
unavailable. 
Furthermore, it is still the prevailing opinion that the risk-benefit ratio does not swing in 
favour of HSCT for the management of XLA.  Gene therapy may offer a promising 
alternative curative therapy in combination with newborn screening.  This is likely to require 
significant research and financial investment with a subsequent high treatment cost.  Due to 
rarity of the disorders, the business argument can be difficult to make, but the recent success 
of NICE approval for gene therapy in ADA-SCID offers promise these hurdles can be 
overcome (243).  
Overall, the published literature suggests some consistent points.  They tend to agree that age 
at diagnosis is reducing, but work from Plebani et al., (186) suggests this may be reaching a 
plateau.  In keeping with the much broader literature on IGRT, the introduction of intravenous 
and subcutaneous preparations of IGRT has made life-threatening infections exceptionally 
rare.  This improvement is also extended generally to milder infections requiring 
hospitalisation for the XLA cohort.  However, patients still suffer from recurrent respiratory 
tract infections and, as such, bronchiectasis is likely to be a significant burden for this cohort.  
Age at diagnosis and instigation of IGRT appear to have variable effects on this outcome.  
Subsequent effects on QoL appear variable with adults more significantly affected than 
children.  This may represent improved care in recent years or that many of the complications 
in XLA develop in late childhood and adulthood. 
While there are some overarching points arising from the literature there remain some 
significant gaps and lack of up to date data which may have stalled further research into novel 
areas.  There are no recent outcome data for UK patients.  Accurate information on all 
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infections (in and outpatient), as well as lifetime IgG trough levels is lacking.  With this 
further detailed information, it may be possible to fully assess the effect of age at diagnosis on 
the development of bronchiectasis.  While rates of bronchiectasis in XLA are noted in the 
literature; there are no data examining the timing of onset, its severity and natural history in 
XLA.  Examining other complications, notably GI disease and inflammatory symptoms, is 
also needed within a more extensive cohort study. 
Furthermore, QoL and psychological health data are needed in a larger sample size, 
particularly with a focus on the impact of respiratory symptoms.  Finally, attempts at 
genotype/phenotype correlation have so far proved fruitless.  Part of this may be due to a lack 




Chapter 3 Study Aims 
3.1 Study Objectives 
The objectives of the study were 
1. To ascertain the current prevalence of complications in congenital 
agammaglobulinaemia, most notably that of bronchiectasis 
2. To ascertain factors which increase the risk of complications in congenital 
agammaglobulinaemia 
3. To document the progress of bronchiectasis in congenital agammaglobulinaemia 
4. To quantify infection incidence in congenital agammaglobulinaemia while on 
treatment 
5. To evaluate the QoL in patients with congenital agammaglobulinaemia 
6. To evaluate the psychological health in patients with congenital 
agammaglobulinaemia 
3.2 Hypotheses 
The main hypotheses of the study were 
1. Rates of bronchiectasis remain high in congenital agammaglobulinaemia despite 
modern diagnosis and treatment regimes 
2. That early diagnosis significantly improves outcomes and reduces the risk of later 
complications 
3. That development of bronchiectasis is not related to IgG replacement dosages or 
trough levels 
4. That, once developed, bronchiectasis continues to progress in patients with no 
relation to IgG replacement dosages or trough levels 
5. That patients QoL and psychological health is worse than the background healthy 
population and comparable to CF 




Chapter 4 Methodology 
4.1 Design 
This research project is comprised of two components: 
• A single researcher review of patient medical records forming both a cross-sectional 
and retrospective analysis of clinical health outcomes 
• A cross-sectional analysis of HRQoL and psychological health using self-report 
questionnaires. 
This was a multi-centre site study across England and Wales. 
4.2 Recruitment 
4.2.1 Inclusion Criteria 
All patients in England and Wales, with a definitive diagnosis of XLA and other genetically 
confirmed autosomal recessive agammaglobulinaemia defined as per the PAGID and ESID 
guidelines (4); 
• Less than 2% CD19+ B cells and, at least, one of the following: 
▪ Mutation in BTK 
▪ Molecular or genetic diagnosis of autosomal recessive agammaglobulinaemia 
(deficiencies of µ heavy chain, µ5, Igα, Igβ, BLNK, TCF3, λ5) 
▪ Absent or diminished BTK protein expression 
▪ Maternal cousins, uncles or nephews with less than 2% CD19+ B cells 
There were occasional cases where a diagnosis of XLA was made, but the criteria above not 
met.  For example, patients with a known BTK mutation and agammaglobulinaemia but 
CD19+ cells > 2%, or patients with absent BTK expression but with a normal level of one or 
more immunoglobulin isotypes.  These so-called ‘leaky’, atypical XLAs are increasingly 
being recognised (367).  Such cases were reviewed on a case-by-case basis for inclusion in 
this study.  Their exact clinical characteristics and reasons for inclusion are detailed in the 
results section. 
4.2.2 Exclusion Criteria 
Patients who lacked capacity were not recruited for this PhD research study.  However, 
patients who lacked capacity may have been included in the United Kingdom Primary 
Immunodeficiency (UKPID) registry.  Approval was gained to access the UKPID registry, 
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where there was access to limited information on the clinical status, but no data were 
collected on HRQoL or psychological health for these patients. 
4.2.3 Ethical and HRA approvals 
Written consent was obtained from patients before enrolment into the study.  For patients 
under 16, consent was obtained from their parents or guardian and assent obtained from the 
young person where appropriate (Appendix A). 
Ethical approval was granted by the Tyne and Wear South Research Ethics Committee (REC) 
on the 22nd September 2016 (REC reference 16/NE/0268).  Health research authority (HRA) 
approval was granted on the 28th of November 2016 for sites residing in England.  For sites 
outside England, R&D approval was sought locally at each site.  
4.2.4 Identification 
The United Kingdom primary immunodeficiency network (UKPIN) granted access to their 
national registry for data pertaining to patients with congenital agammaglobulinaemia 
(https://www.ukpin.org.uk/registry/registry-intro).  This registry aims to collect clinical health 
outcome data for all patients with a PID living in the UK and was set up in 2008 (247).  There 
are currently 35 centres which actively participate in recruiting patients and enter clinical 
information into this database (247).  As of 2017, there were 4310 patients entered into the 
database (247).  The UKPID registry currently has 159 alive patients with XLA entered into 
the database, cared for by 25 centres.  Of these, 126 are cared for within England and Wales 
by 19 centres.  Information was accessed on the initial diagnosis and latest clinical state from 
these data.       
This information was used to approach local consultants at these nineteen centres enrolled in 
the UKPID registry to identify any patients who were not on this database and those with 
autosomal recessive agammaglobulinaemia, to consent them for more detailed clinical data 
recording and administration of HRQoL questionnaires.  Patients and carers were given 
patient information sheets at routine appointments or by post.  Patients were followed up at a 
further clinic appointment for counselling and consent for the study.  All patients eligible for 
this study were receiving replacement immunoglobulin therapy and therefore, under the care 
of a specialist immunologist working for one of the above centres.  It is, therefore, doubtful 
there were any further sources of patients eligible for inclusion in this study.   
Following invitations, there were nine centres across England and Wales actively recruiting 
into the study.  Upon their participation, it was confirmed that there would be 93 eligible 
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potential patients for this study. The corresponding UKPID data for these sites listed 77 
eligible patients.  However, the UKPID registry also included patients with probable and 
possible diagnoses of XLA, whereas this study only included those with a proven BTK 
mutation or proven absence of BTK expression. 
4.3 UKPID Registry Data 
While the registry attempts to encompass all patients within the UK, the depth of information 
is relatively shallow.  Nevertheless, there were data available on the age of diagnosis, family 
history and current therapy.  Patients identified with XLA within this registry may have also 
included those with a probable or possible diagnosis with XLA in addition to those with a 
definite diagnosis.  It was not possible to differentiate between these within the registry data.   
4.4 Data Collection 
The following areas of research interest were chosen after discussion with patients and carers, 
specialists, literature review and a pilot study of congenital agammaglobulinaemia patients in 
the northeast of England (268).   
Data collection included a combination of examining medical records and self-reporting 
questionnaires.  
4.5 Clinical Data 
Clinical data were collected from hospital notes by a single researcher and recorded via a 
standard proforma including infection history, IgG trough levels, IgG doses, HRCT results 
and pulmonary function testing (PFT) results.  A copy of the standard proforma is supplied in 
the appendices (Appendix B).  
4.5.1 Diagnosis 
Age at diagnosis was defined as the age of clinical diagnosis of XLA and/or instigation of 
IGRT, whichever occurred earliest.  Where available, the immediate full blood count (FBC), 
immunoglobulin levels and lymphocyte subsets before instigation of IGRT were recorded.  
Identification of the genetic mutation was taken from medical notes.  Analysis of the BTK 
mutation was undertaken at centres according to local arrangements.  BTK expression on 
monocytes was recorded from medical notes.  BTK expression was undertaken at centres 




4.5.2 Current laboratory values 
The patient’s latest FBC, immunoglobulin levels and lymphocytes subsets were recorded. 
4.5.3 Infections 
Data regarding the number of infections were gathered from clinic letters.  Infections were 
classified into the site of infection (e.g. respiratory tract, ENT) and whether the patient 
required inpatient or outpatient treatment (as a proxy marker of infection severity).  These 
data were used to calculate the overall annual infection incidence per patient and infection 
incidence per patient by the site of infection.  Patients with congenital agammaglobulinaemia 
undergo regular reviews from a specialist immunologist, usually on a 3 to 6 monthly interval.  
It is best practice at these reviews to document any infections the patient has experienced 
since the last clinic appointment as part of evaluating the effectiveness of their current IGRT.  
Based on the experience from a previous pilot study, documentation of infections in clinic 
letters was found to be of a very high standard (268).  Only infections that required a course 
of antibiotics were recorded.  If the infection was thought to be viral in origin, this was not 
recorded.  The site of infection was documented as per the clinic letter.  If this was not 
recorded, the anatomical site was recorded as ‘not documented’.  Also, infections caused by 
enterovirus and Giardia lamblia, to which this population is susceptible, were explicitly 
recorded.   
Data pertaining to infections pre-diagnosis of agammaglobulinaemia were less frequently 
recorded, and it was not possible to accurately ascertain the infection incidence pre-diagnosis 
for the majority of patients.  However, it was possible to record infections that required 
hospital or intensive care admission accurately.  The pattern of the presentation was often 
recorded, e.g. recurrent chest or ear infections, and this was recorded for analysis where 
available and unknown if not available. 
4.5.4 Nutritional status 
Height and weight data were collected where available and body mass index calculated 
(BMI).  For adults, BMI category was classified as per World Health Organisation (WHO) 
guidelines (408).  For children, BMI scores were converted to Z-Scores and categories 
assigned as per the Royal College of Paediatrics and Child Health (RCPCH) growth charts 
using the UK90 data set(409,410).  This was done using the zanthro and zbmiuk 
functions in STATA (411). 
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Table 4-1 Adult World Health Organisation BMI categories (408) 
BMI Classification 
<18.5 Underweight 
18.5 – 24.9 Normal weight 
25.0 – 29.9 Overweight 
>30.0 Obese 
4.5.5 Immunoglobulin replacement therapy 
Doses, route, brand and frequency of IGRT were recorded as well as the geographical 
location of therapy (home/hospital).  These were recorded from hospital records or patient’s 
records if self-administered.  Where concurrent weight was available, doses were recorded as 
mg/Kg/month.  
4.5.6 Treatment compliance 
Treatment compliance was categorised according to the following (Table 4-2).  There are no 
currently agreed methods for assessing treatment compliance in PID.  The following were 
chosen after discussion with PID specialists, following experience with the pilot study (268) 
and based on how much data could reliability be collected from the cohort.  As well as noting 
deviation from prescribed IGRT, it was also important to note the deviation from respiratory 
health monitoring, this being the major complication for this group 
Table 4-2 Categorisation of treatment compliance 
Category Features 
Fully compliant – All 
of the following 
Has not missed a clinic appointment in the preceding two years 
to data collection 
Has received all IGRT on schedule in the preceding five years to 
data collection 
Has attended all investigations for IgG trough levels, HRCT and 
PFTs in the preceding two years to data collection 
Mild issues Has missed two or more clinic appointments in the previous two 
years, but receives all IGRT on time and attends for 
investigations including trough level measurement, HRCT and 
PFTs 
Moderate issues– at 
least one of the 
following 
Has missed three or more clinic appointments in the preceding 




Has not attended for at least one requested investigation in the 
preceding two years to data collection including trough level 
measurements, HRCT and PFTs  
Has stretched out IGRT interval, but to no more than one week 
in the preceding five years to data collection 
Severe issues – at least 
one of the following 
Has stretched out IGRT interval more than one week in the 
preceding five years to data collection 
Has missed IGRT infusion, resulting in periods without IGRT 
therapy 
4.5.7 IgG trough levels 
IgG trough levels were recorded from medical records and laboratory values.  Only those 
values related to trough levels were recorded, i.e. with ‘trough level’ in the investigation 
request or documented in clinic letters and nursing records. 
When recording and calculating the IgG trough levels for later analysis the following steps 
were taken 
• Annual median IgG trough levels were calculated for each patient.  Rather than analysing 
individual data points, this method would limit some of the bias from occasional outliers 
(these outliers are addressed in the next point).  As other outcome data were calculated on 
an annual basis, for example, annual infection incidence, this also allowed a more 
straightforward analysis of these outcomes. 
• To assess for variance in an individual’s IgG trough levels the standard deviation (SD) 
was calculated across their lifetime.  For each patient, the mean IgG trough level was 
calculated for each year, and the SD of the mean of these values was then used.  This 
method allowed the analysis of any effect that occasional outliers might have on clinical 
outcomes (e.g. brief but potentially significant short periods where IgG trough levels were 
suboptimal).  Due to the differences in the pharmacokinetics, absorption and frequency of 
administration between IVIG and SCIG, the trough IgG may not be completely 
comparable and there may be impacts upon the SD.  In particular, trough IgG levels may 
show less deviation in SCIG due to the frequency of administration (weekly), potential for 
more recording of trough IgG levels (up to weekly) and absorption of IgG from the 
subcutaneous tissues allowing for a steadier release of IgG and serum IgG level.  
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However, trough IgG levels in both modalities are the currently the best measure of 
assessing deliverable IgG dose. 
• Lifetime medians of all IgG trough levels were also calculated. 
• For patients with lung disease, this was further analysed for the period before and after the 
diagnosis of bronchiectasis. 
4.5.8 GI Disease and nutrition 
Weight and height were recorded where possible, and body mass index (BMI) calculated.  
Data were collected on GI symptoms and whether the patient had undergone endoscopic 
investigations and their results. 
4.5.9 High-Resolution Computerised Tomography 
Sequential HRCT images were analysed for reported evidence of lung disease and subsequent 
progression or resolution.  Interpretation of the HRCT was based on the local hospital 
radiologist report.  It is standard practice in the reporting of HRCT scans for the reporting 
radiologist to compare the images to any previous scans and comment upon any progression 
of disease state.  There were no new HRCT scans performed as part of this study. 
HRCT remains the gold standard for diagnosing bronchiectasis.  However, it would be safe to 
assume that patients may have established bronchiectasis before any official diagnosis due to 
the interval time periods between scans.  This is especially pertinent if bronchiectasis was 
shown on the first scan after the diagnosis of agammaglobulinaemia.  These patients will 
likely have never had an HRCT scan performed before, and it, therefore, makes it likely the 
patient’s bronchiectasis pre-dates their diagnosis of agammaglobulinaemia and instigation of 
immunoglobulin therapy.  To enable consistency and integrity of data regarding the onset of 
bronchiectasis, any patient receiving a diagnosis of bronchiectasis within 12 months of 
starting immunoglobulin therapy was defined as having bronchiectasis at the time of their 
agammaglobulinaemia diagnosis.  To further assess the impact of the lag from true 
bronchiectasis onset to diagnosis in some analyses, the date of diagnosis of bronchiectasis was 
adjusted to minus one year, minus three years and minus five years.   
Where possible, it was recorded whether the HRCT was performed for routine monitoring or 




4.5.10 Pulmonary Function Testing 
Sequential historical lung function test results were analysed for changes in FEV1 (forced 
expiratory volume in 1 second), FVC (forced vital capacity) and FEV1/FVC ratio.  These 
values are adjusted for height.  It is standard clinical practice for lung function tests to report 
the values as a ‘percentage of predicted’ (e.g. an FEV1 of 1.5 compared to a predicted median 
population value of 2 would equal 75% predicted).  It has been a standard part of clinical 
practice to define the lower limit of normal (LLN) in pulmonary function as 80% of the 
predicted value.  This practice arises from a paper by Bates and Christie (412): “a useful 
general rule is that a deviation of 20% from the predicted normal value probably is 
significant”.  This recommendation, with little clinical evidence, was seemingly adopted 
without question across medical practice.  However, this rule is only valid if the scatter 
around the predicted value is proportional to that value which, in PFTs, it has shown not to be 
(288).  The reality is that over a broad age range, the LLN is well below this 80% predicted 
value line (288) (Figure 4-1).   
Figure 4-1 The lower limit of normal (LLN) for FEV1 and FVC expressed as a 
percentage of the GLI-2012 predicted values in the 3-95 year age range.  Taken from 
(288) 
 
In 2012, the Global Lung Initiative (GLI) published extensive data on the normal distribution 
of lung function values in healthy individuals across a range of ages and races.  These values 
are adjusted for height, sex and race.   The LLN in respiratory medicine is the 5th percentile 
(i.e. 90% of the healthy population), equal to a Z-Score of -1.64.  The Z-score is defined as 
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the measure of the standard deviation from the population mean or predicted score and is 
calculated from the following formula: 
𝑍 =
𝑥 −  𝜇
𝜎
 
Where Ζ = the Z-Score, x = the observed value, μ = the mean of the sample or population and 
σ = the standard deviation of the sample or population. 
To further emphasise the flaws in accepting 80% predicted as the LLN, the LLN using a Z-
Score of -1.64 in a 3, 20 and 80-year-old white female is 74%, 80% and 66% of the predicted 
value respectively.  The predicted values and Z-Scores from this GLI dataset have been well 
validated (413,414).  For the present study, raw lung function data were recorded and inputted 
into supplied licensed software from GLI, calculating the Z-Score and whether lung function 
was normal/abnormal according to these figures (415).   
4.5.11 Bronchiectasis Severity 
The two most widely used tools to assess the severity of bronchiectasis are the bronchiectasis 
severity index (BSI) (309) and the FACED (416) score.  Both scores were developed 
simultaneously as areas of research into predicting long-term outcomes in bronchiectasis 
(309,416,417).  The BSI, comprising of HRCT score, FEV1, MRC dyspnoea score (418), 
bacterial colonisation, prior hospital admission and exacerbations is a sensitive tool for 
predicting future hospital admissions and mortality (Table 4-3, Table 4-4, Table 4-5) (309).  
The FACED score, comprising of FEV1, age, P. aeruginosa colonisation, radiological 
extension and dyspnoea accurately predicts mortality (Table 4-6, Table 4-7) (416).  Recent 
work has demonstrated that prediction of mortality over a more extended time period (15 
years) is more accurate in the FACED scoring system, which has the added benefit of being a 
simpler scoring system (417).  However, it does not make any prediction for hospital 
admissions.  Both tools still require validation in independent cohorts, but current consensus 
suggests that the two should play complementary roles in research and clinical practice (417).  




Table 4-3 Bronchiectasis Severity Index (BSI) (309) 
Severity criteria 0 points 1 point 2 points 3 points 4 points 5 points 6 points 





BMI kg/m2 >18.5   <18.5 
    
FEV1 % predicted >80% 50-80% 30-49% <30% 
   
Hospital admissions in 
the past 2 years 
No         Yes   
Exacerbation 
frequency in last 12 
months 
0-2   3 or more         
MRC dyspnoea score 
(Table 4-4) 
1-3   4 5       




  P. aeruginosa  colonisation       
Radiological severity <3 lobes 
involved 
3 or more lobes or 
cystic changes 
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Table 4-4 MRC Dyspnoea scale (418) 
Grade Degree of Breathlessness 
1 I am not troubled by breathless except on strenuous exercise 
2 I get short of breath when hurrying on a level or when walking up a slight hill 
3 I walk slower than most people on the level.  I have to stop after a mile or so or stop after 15 minutes walking at my own 
pace 
4 I have to stop for breath after walking 100 yards or after a few minutes on level ground 
5 I am too breathless to leave the house, or I get breathless when dressing/undressing 
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Table 4-5 Calculation of final BSI Score (309) 
BSI Score  Outcome Predicted incidence 
0-4 points 1 year Mortality 0-2.8%  
Hospitalisation Rate 0-3.4% 
4 year Mortality 0-5.3%  
Hospitalisation Rate 0-9.2% 
5-8 points 1 year Mortality 0.9-4.8%  
Hospitalisation Rate 1-7.2% 
4 year Mortality 4-11.3%  
Hospitalisation Rate 9.9-19.4% 
9+ points 1 year Mortality 7.6-10.5%  
Hospitalisation Rate 16.7-52.6% 
4 year Mortality 9.9-29.2% 
Hospitalisation Rate 41.2-80.4%  
Table 4-6 FACED score (416) 
Component  Score 
(F)EV1 >50% = 0 points 
≤50% = 2 points 
(A)ge ≤ 70 years = 0 points 
>70 years = 2 points 
(C)hronic colonisation No pseudomonas = 0 points 
Pseudomonas = 2 points 
(E)xtension <2 lobes affected = 0 points 
≥2 lobes affect = 1 points 
(D)yspneoa No dyspnoea = 0 points 
MRC Score ≥2 = 2 points 
Table 4-7 FACED scoring and bronchiectasis severity (416) 
Score Severity 
0-2 points Mild bronchiectasis 
3-4 points Moderate bronchiectasis 
5-7 points Severe bronchiectasis 
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4.5.12 Sputum microbiological data 
Microbiological data from the most recent sputum sample was recorded, including organism 
and antimicrobial sensitivities and resistance. 
4.6 Genetic Data 
Genetic mutation data were gathered from clinical information received from the patient’s 
local NHS genetic testing laboratory.  There are no established guidelines for analysing a 
genotype/phenotype correlation in XLA, and so several methods were used: 
• First, patients were grouped per type of mutation: missense, splice site, frameshift/in-
frame deletions/insertions and others (including mutations in the promotor or start codon). 
• Secondly, patients were grouped per domain site of mutation (i.e. PH, TH, SH3, SH2 or 
kinase domain). 
• Thirdly, patients were grouped as severe or mild as per categories first proposed by 
Conley et al. (Table 4-8) (368). 
Table 4-8 Mutation severity classification in XLA from Broides et al. (368) 
Mild mutation Severe mutation 
• Amino acid substitution at non – 
conserved sites 
• Splice-site defects at conserved base 
pairs but not invariant 
• Amino acid substitution at 
conserved sites in other members of 
the BTK family (ITK, TEC) 
• Frameshift mutations 
• Splice site alteration at invariant 
sites within the first two and last two 
base pairs of an intron 
• Premature stop codon 
• Inframe deletions 
 
• Fourthly, mutations were scored for predicted severity using a variety of genetic mutation 
prediction software packages as described in further detail below.  
• To assess predicted mutation severity, all mutations were inputted through VarSome 
(https://varsome.com), which processes mutations through a number of packages 
simultaneously.  Mutations were analysed against the hg19/CRCh37 human reference 
genome (419) and the NM_000061.2 BTK gene transcript (420).   The chosen packages 
were SIFT (421), Polyphen2 (422), PROVEAN (423), MutationTaster (424) and 
FATHMM (425).   Splice site mutations are also scored using Database Splicing 
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Consensus Single Nucleotide Variant (dbscSNV) (426).  These were chosen as some of 
the most widely used tools in the scientific literature with high sensitivity and specificity 
and were able to calculate converted rank scores (427).  Mutations were then analysed as 
per their converted rank score for each tool and as per their predicted pathogenicity 
category from each mutation prediction tool (definitely disease-causing, probably disease-
causing, probably not disease-causing and definitely not disease-causing).  These 
definitions are taken from and are in agreement with the joint consensus recommendation 
from American College of Medical Genetics and Genomics (ACMG) (428) .  
•  The mutations were also analysed using DANN, a pathogenicity scoring methodology 
based on deep neural networks, with scores ranging from 0 – 1 with 1 being the most 
damaging (429). 
4.6.1 Disease severity 
There are no agreed disease severity classification scales for XLA or other primary antibody 
deficiencies.  After discussion with immunology specialists, the following categories were 
devised for this study. 
Table 4-9 XLA severity classification 
Disease severity Clinical characteristic 
None No end-organ damage and 
No recurrent infections 
Mild  Recurrent infections but no end-organ 
damage 
Moderate End organ damage such as bronchiectasis or 
Recurrent hospital admissions for infections 
Severe Surgical intervention for end organ damage 
or 
Severe bronchiectasis defined as 
• BSI Score >8 
• FACED Score >4 
• FEV1 <50% predicted 
Or undergone HSCT 
4.7 Health-Related Quality of Life 
HRQoL is a multidimensional concept measuring physical, psychological and social 
wellbeing to assess the impact of a patient’s illness and its treatment on their QoL (430).  
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While QoL and HRQoL are often used interchangeably in the literature, they are two different 
concepts.  HRQoL focuses on the impact of the patient’s illness and its treatment on their 
QoL.  QoL is a much broader concept, assessing non-health related factors on a patient’s 
overall QoL.  This study only assessed health-related quality of life.  HRQoL should be 
measured by the patient’s/family’s perspective and not biased or influenced by opinions of the 
health care team.  Tools measuring HRQoL must adhere to this definition. 
HRQoL was recorded with a variety of self-reporting questionnaires either by the patient or 
by their carer/parent.  These self-reporting questionnaires and were handed to patients and/or 
their carers during clinic appointments.  Patients were also offered the opportunity to 
complete these at home and post back with provided stamped self-addressed envelopes.  The 
questionnaires were not completed on the day of immunoglobulin infusions to limit bias from 
any adverse reactions to the treatment.  The data collected were compared against published 
population norms and other disease cohorts as described below. 
4.7.1 Comparator groups 
All HRQoL data and psychological health data were compared against UK norms and against 
patients with cystic fibrosis where data was available (431–440). 
CF was chosen as a comparator, being a chronic, incurable condition complicated by recurrent 
infections and for which respiratory symptoms and bronchiectasis place a major burden.  It 
also has some comparisons in that the age of onset of bronchiectasis is young, as has also 
been shown in the existing literature for patients with XLA. 
4.7.2 Short Form 36 Version 2  
The short form 36 version 2 (SF36v2) is a well-recognised tool for measuring the quality of 
life in adolescents and adults and has been used extensively when researching patients with 
immunodeficiency and a range of other diseases groups (258).  The SF36v2 was used for 
patients over 16 years of age.  It comprises of 36 questions, of which the results are inputted 
through the provided licensed software to calculate scores for 8 subdomains and 2 overall 
scores (441).  There are 4 subdomains related to physical health: physical functioning (PF), 
physical role (PR), bodily pain (BP), general health (GH), all combining to calculate the physical 
component score (PCS) (441).  These are scored out of 100, with a higher score indicating a 
higher HRQoL.  These data were compared against normative UK data (431) and for UK 
patients with CF (432).   
A copy of the SF36v2 can be found in the appendices (Appendix C).   
77 
 
4.7.3 PedsQL 4.0 
The PedsQL 4.0 generic core scale questionnaire is a well-recognised self-reporting tool for 
measuring HRQoL (348,442).  It has been well validated, shown to be reliable and able to 
differentiate between healthy children and those with chronic diseases (442). It has been used 
previously to study the quality of life in patients with primary antibody deficiency (PAD) 
(347).  It comprises of 23 questions within four subdomains: physical, emotional, social and 
school functioning.  These combine to give an overall score, a physical health summary score 
and a psychosocial health summary score (433).  The higher the value in each these domains 
and overall score indicate a higher HRQoL.  There are altered versions of the questionnaire 
for children and young people, depending on their age and a separate one for parents.  The 
questionnaire was given to children aged 5 to 16 and parents of children aged 2-16.  The data 
were compared against UK population norms (433) and patients with CF (434). 
A copy of the PedsQL 4.0 can be found in the appendices (Appendix C)  
4.7.4 St. George’s Respiratory Questionnaire 
SGRQ is a widely used tool for recording HRQoL in regards to respiratory health in adults 
(435).  It comprises of 50 questions within 3 domains; symptoms, activity and impacts 
(psychosocial), contributing to an overall total score.  It was initially designed for chronic 
obstructive pulmonary disease (COPD) and asthma but has since been well validated in 
bronchiectasis (443) including a direct correlation with mortality (444).  It correlates strongly 
with other markers of disease activity such as FEV1, cough, breathlessness, 6-minute walk 
test as well as other measures of HRQoL such as the SF36v2 (279).  It has also been shown to 
be reliable studying patients with primary antibody deficiency (270).  The patient's answers 
are inputted into the supplied excel spreadsheet, calculating the scores for the subdomains and 
overall total score (435).  These data were compared against UK healthy norms data (435) and 
patients with CF (436).  
A copy of the SGRQ can be found in the appendices (Appendix C).  
4.8 Psychological Impact 
4.8.1 Strengths and Difficulties Questionnaire 
The strength and difficulties questionnaire (SDQ) was used for children aged 4-16 years old.  
The SDQ is a well-recognised measure of social, emotional and behavioural difficulties in 
children and is a widely used tool for screening for psychological difficulties in childhood 
(445).  It is validated in a range of chronic diseases such as arthritis (446) and cancer (447).  It 
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has also been used in studies of patients with immunodeficiency (347).  It is designed so 
carers of children aged 4-16 years old and children over the age of 11 can complete the 
questionnaire.  There are altered versions of the questionnaire for children and young people, 
depending on their age and a separate one for parents.   The tool consists of 4 areas; conduct, 
emotion, hyperactivity and peer relationships, which can then be combined to give a total 
difficulty score (445).  The scores were also used as a screening tool for detection of 
emotional, conduct, hyperactivity and any psychiatric disorder as either unlikely, possible or 
probable.  These total scores are generated using a pre-prepared STATA do file provided by 
the authors of the SDQ (448) (Appendix C).  These were compared against published 
normative UK data (449).     
A copy of the SDQ can be found in the appendices. (Appendix C).  
4.8.2 Short Form 36 v2 
As well as a physical component the SF-36 also contains a mental component with four 
domains; emotional role (RE), mental health (MH), vitality (VT) and social functioning (SF), 
combing to calculate the mental component score (MCS).  As discussed previously, the SF-
36v2 is a well-validated tool for examining physical and mental health and has been used 
extensively in research involving patients with immunodeficiency (258).  The results for the 
adult patients were compared against published normative data and patients with CF 
(431,432).   
A copy of the SF36v2 can be found in the appendices (Appendix C). 
4.8.3 Hospital and Anxiety Depression Scale 
The hospital anxiety and depression scale (HADS) is a frequently used scoring system 
designed specifically to avoid including symptoms associated with medical conditions and is 
validated in both adolescents and adults (12 years and over) (450).  It can be used to both 
screen for disease and to assess severity.  It comprises of 14 questions, 7 assessing for anxiety 
and 7 assessing for depression each answered on a 4-point scale (0-3).    The maximum score 
for each domain is 21, with a higher score indicating more severe disease.  It has been shown 
to be valid in individuals with or without psychological problems (450).  These scores can be 
assigned categories or compared against populations norms using the raw scores (437) (Table 
4-10).   
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Table 4-10 Categories for Depression and Anxiety domains of the HADS (451) 
Category  Score  
Normal  0-7  
Mild  8-10  
Moderate  11-14  
Severe  15-21  
 
Results were compared against UK male population norms (437), UK males with cystic 
fibrosis (438). 
A copy of the HADS can be found in the appendices (Appendix C).   
4.8.4 Rosenberg Self-Esteem Scale 
The Rosenberg Self-Esteem Scale (RSES) is a widely used tool in clinical research to 
ascertain self-esteem (452).  It was initially designed for adolescents but has been well 
validated in the adult population (453).  The RSES was used in participants aged 12 and 
upwards.  The RSES comprises of 10 statements with participants asked to rate their level of 
agreement with each one on a 4-point scale ranging from strongly agree to strongly disagree.  
The questionnaire combines to give a total score of 30, with less than 15 representing low 
self-esteem, 15-25 being normal and more than 25 signifying high self-esteem (453).  Raw 
scores were compared against UK male CF patients (440) and UK normative male data (439).   
A copy of the RSES can be found in the appendices (Appendix C). 
4.9 Cost and Impact of treatment 
Cost of IGRT was calculated using the latest values supplied by the 2017-2018 British 
national formulary (BNF) (454).  These are only the costs for the immunoglobulin product 
itself and do not account for the costs of other consumables or staff. 
Patients were asked to record the number of days they had taken off work or full-time 
education in the preceding 12 months as a direct consequence of their illness (e.g. hospital 
appointments, acute illness, infusions). 
Parents of affected children were also asked to record the number of days they had taken off 
work in the preceding 12 months to look after their child due to a direct consequence of their 




Statistical analysis was done using STATA v15.1 (www.stata.com).  A previous pilot study 
recruited 15 patients with congenital agammaglobulinaemia in the northern region of the UK 
(268).  The UKPIN registry currently has 159 alive patients in the UK with XLA.  Previous 
studies in PID have found a high participant rate from patients (455,456).   
Based on the previously published pilot data from Newcastle (268), the following sample size 
calculations were done 
• To detect a statistically significant difference in age at diagnosis of 4 years between 
those with and without bronchiectasis would require a total sample size of 58 
(significance level of 0.05 and 80% power)  
• To detect a statistically significant difference of 2 in the physical component score of 
the SF36v2 compared to a published healthy norm reference value would require a 
sample size of 46 (significant level 0.05 and 80% power).  2 is the current minimally 
clinically important difference (MCID) in the PCS calculated by the team who 
designed the SF36v2 (441). 
• To detect a statistically significant difference of 5.16 in the parent total score of the 
PedsQl 4.0, a sample size of 61 would be required.  5.16 is the MCID calculated by 
Hillard et al. examining young people with diabetes (457) 
Variables were assessed for normality using skewness and kurtosis assessment, and the null 
hypothesis that the data were normally distributed was rejected if the p-value was <0.05.  
Parametric data are displayed as mean and standard deviation (SD) and non-parametric data 
as the median and interquartile range (IQR).   
For the psychological health and quality of life data where data are compared against 
published norms, means were compared using a one-sample t-test.  For non-parametric data, 
the data were compared using the sign test.   A p-value <0.05 was considered statistically 
significant.  
For patients with bronchiectasis, a number of outcome variables (e.g. IgG trough levels, 
infection incidence), data and averages were subcategorised as either before or after the 
diagnosis of bronchiectasis.  This was assessed for a number of reasons.  Firstly, the presence 
of bronchiectasis confounds many of these variables.  For example, bronchiectasis itself 
predisposes to infections and clinicians are likely to target higher IgG trough levels in patients 
with bronchiectasis.  Separating the two time periods also allows a meaningful comparison of 
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these patients in their ‘healthy’ phase to patients who currently do not have lung disease.  
There are still some limitations to this method as will be discussed further in the discussion 
chapter, most notably the lag time from true bronchiectasis onset to the radiological diagnosis 
of bronchiectasis.  As discussed previously, the time of onset of bronchiectasis as adjusted to 
ascertain if this affected variables.  Despite the limitations, these steps were felt to the most 
reliable and accurate method available. 
Spearman’s correlation was used to analyse correlations between continuous variables and 
results are presented as Spearman’s rho correlation coefficient and p-values. 
Risk of developing bronchiectasis was modelled using a time to event analysis.  The time 
variable was taken from birth (age 0).  This was chosen as pathogenicity, and the risk factor 
leading to the development of bronchiectasis was the number of infections.  Patients were 
born with the predisposing risk factor (their XLA) to developing respiratory tract infections, 
and so they were deemed exposed to risk from birth.  Patients without bronchiectasis were 
censored at the time point that their clinical data was collected (right censored).  The final 
model was a cox regression and variables were analysed as follows 
• Categorical variables were analysed individually using the log-rank test of equality 
• Continuous variables were analysed using a univariate Cox proportional hazard regression  
Lung function results were analysed using repeated measures multilevel models (Stata’s 
xtmixed command) with observations over time (age at time lung function testing 
performed, level 1) nested within study participants (level 2).   This was done using growth-
curve models.  The model included a random effect for time and fixed effects for baseline 
covariates.  Again, similar for the above Cox regression, time is taken as from birth for the 
aforementioned reasons.  Covariates were inputted as unstructured.   
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Chapter 5 Clinical Results  
This chapter will detail the clinical outcomes for this XLA cohort.  Outcomes regarding 
respiratory health outcomes are introduced in this chapter but will be covered in more detail in 
Chapter 6. 
5.1 Recruitment  
One-hundred and thirty-two patients, cared for by ten centres in England and Wales, were 
identified using the UKPID registry data.  These registry data included patients with definite, 
probable and possible XLA according to the PAGID and ESID guidelines (4).  The UKPID 
registry data were used to identify and invite centres to participate in the study.  Ten centres 
replied and actively recruited into the study.  From these centres, 92 eligible patients were 
identified using the UKPID registry data, of which 79 were confirmed by local PIs as being 
definite XLA patients.  From these, 53 (67%) patients were successfully contacted and 






















92 patients identifed 
through the UKPIN 




Clinical data available on 
18 children
17 parents returned 
PedsQL
17 parents returned SDQ
13 children returned 
PedsQL
9 children returnded SDQ
5 children returnded RSES
5 children reutrned HADS
33 adults 
consented
Clinical data available on 
32 adults
30 adults returned SF36v2
30 adults returned SGRQ
30 adults returned RSES
26 adults returned HADS
79 confirmed eligble 




Patients were recruited from nine centres in England and one centre in Wales (Figure 5-2, 
Figure 5-3). 
Figure 5-2 Study recruitment sites 
 
 
Figure 5-3 Centre recruitment 
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5.2 UKPID Registry Data 
Before describing the XLA cohort data collected for this PhD research study, I will first report 
on the data made available from the UKPID registry.  The UKPID registry is limited in its 
depth of data but does aim to include all patients with a diagnosis of PID in the UK 
5.2.1 Incidence and Prevalence 
Data were extracted from the UKPID registry in July 2017. One hundred and sixty-four 
patients were recorded as having a diagnosis of XLA.  As of July 2017, 159 were alive; three 
have died since the inception of the registry (2008), and two were lost to follow up.  Based on 
the July 2017 Office of National Statistics (ONS) UK population estimate of 65.6 million 
(458), this equates to a minimum UK prevalence of 2.42 cases per million population.  Based 
on these registry data, the UK annual mortality rate of XLA is 0.24%.  The mean incidence 
from 1990-2010 was 0.50 cases per 100,000 UK live births.  This incidence has increased 
with time (Spearman ρ = 0.349, p = 0.010) (Figure 5-4). 
Figure 5-4 UK Incidence of XLA 1952-2013 (UKPID Registry Data) 
 
5.2.2 Diagnosis 
Age at diagnosis was defined as the age at which IGRT starts, or the clinical diagnosis of 
XLA was made, whichever was earlier.  Age at diagnosis was available for 140 patients.  The 
median age at diagnosis in the UKPID registry data is 2.12 years (IQR 0.60 – 4.80).  There 
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was a positive family history in 43 of 128 cases (33.4%) where data were available.  Those 
with a family history of XLA had a statistically significantly lower median age of diagnosis of 
1.47 years (IQR 0.31 -3.96) versus 2.99 years (IQR 1.68 – 5.51), p = 0.001.  However, the 
UKPID registry does not collect data on whether the patient was screened asymptomatically 
based on family history.   An approximate proxy was calculated by classifying those with a 
diagnosis of less than 12 months, and positive family history as being screened 
asymptomatically.  In addition, any child with a diagnosis of less than 6 months was deemed 
as being diagnosed asymptomatically.  Six months was chosen as a suitable cut off as this is 
the age that levels of maternally transferred immunoglobulin have a clinically significant 
decline and patients with congenital agammaglobulinaemia tend to become symptomatic 
(165).  Excluding those that were likely screened due to family history, the median age of 
diagnosis was 3.25 years (IQR 1.91 – 5.97) (Figure 5-5).   

























































Of the 48 patients, 15 patients were diagnosed at birth, and 33 patients were diagnosed as 
adults, with the oldest age of diagnosis being 39.77 years of age.  Age of XLA diagnosis (and 
therefore instigation of IGRT) has improved over time (Spearman’s ρ = -0.242, p = 0.004) 




ρ = -0.258, p = 0.037) and those who with a family history and likely asymptomatically 
screened (Spearman’s ρ = -0.270, p = 0.006).     
Figure 5-6 Age at diagnosis over time (UKPID registry data) 
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5.2.3 Immunoglobulin therapy 
There was a very slight preference for subcutaneous therapy, with 51.22% of XLA patients 
receiving their IGRT via this route (out of 164 available patients) (Figure 5-6).  There is a 
strong preference to receive IGRT at home with 78.40% of patients receiving their therapy at 
home (out of 162 available patients).  All patient’s receiving subcutaneous therapy did so at 
home, and fifty-five per cent of patients on IVIg did so at home. 
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Figure 5-7 Site and route of IGRT 
 
Privigen was the commonest IV product, accounting for 33.75% of all IV products prescribed 
(Table 5-1).  Hizentra and Subcuvia account for the commonest SC immunoglobulin products 
accounting for 30.95% and 29.86% of all SC products, respectively (Table 5-2) 
Table 5-1 IV immunoglobulin products 
Product Number (n) Percent (%) 
Privigen 27 33.75 
Flebogamma 12 28.75 
Kiovig 3 11.25 
Flebogamma 5% 8 10.00 
Vigam 5 6.25 
Gammaplex 3 3.75 
Octagam 3 3.75 
Intratect 1 1.25 
Pentaglobin 1 1.25 




























Table 5-2 SC Immunoglobulin products 
Product Number (n) Percent (%) 
Hizentra 26 30.95 
Subcuvia 25 29.76 
Subgam 25 29.76 
HyQvia 3 3.57 
Vivaglobin 3 3.57 
Gammanorm 2 2.38 
Total 84 100 
 
Table 5-3 Dosage and dosing interval period of IGRT (median (IQR)) 
 Dose (mg/Kg/month) 
Intravenous (n = 72) 568 (476 – 748) 
Subcutaneous (n = 67) 504 (436 - 668) 
All (n = 139) 544 (456 – 700) 
 Dosing interval (days) 
Intravenous (n = 66) 21 (21 – 21) 
Subcutaneous (n = 9) 14 (14 – 21) 
All (n = 75) 21 (21 – 21) 
 
As expected, patients on SCIG receive their therapy more frequently than those on IVIG 
(Table 5-3).  Patients on IVIG did have a significantly higher monthly equivalent dose than 
those on SCIG (p = 0.039). 
5.3 PhD XLA Data  
I will now describe the data collected exclusively for this PhD research project.  Fifty-four 
patients were recruited, of which clinical data were available for 50.  The ongoing results 
presented here and in Chapter 6, pertain to those 50 patients.  For analysis where data were 
not available for these 50 patients, this will be clearly stated in the denominator.  The 




5.4 Data coverage 
The total follow-up of study participants was 1015.57 patient-years (Table 5-4).  56% (571.18 
patient-years) of follow up data pertaining to infection rates, lung function data, HRCT and 
other data gathered from medical notes and clinic letters was collected.  This equated to a 
median data collection of 73% of follow up data collected per patient.  For paediatrics this 
was 100% and adults 54% (p = <0.001).  Fifty-three per cent of all potential IgG trough levels 
were available for data collection (542.34 patient-years).  This equated to a median IgG 
trough level collection of 76% per patient.  For paediatrics, this was 100% and adults 55% 
(p=0.000).  The better data collection in paediatrics representing better note keeping in recent 
years and the ease of collecting recent clinical notes versus historical notes (up to 60 years in 
some cases).  In addition, it is more likely that adults will have transferred care over their 
lifetime through numerous hospitals, increasing the difficulty in tracing and obtaining notes.    
Table 5-4 Total follow up and available data collected (patient-years) 
 
All Paediatric Adult 
Follow up (patient years) 1015.57 106.38 909.19 
Median follow up (patient years) 
(IQR) 
20.68 (8.63 – 
29.86) 
5.28 (1.76 – 
10.43) 
27.28 (20.85 – 
35.18) 
Available clinical information 
accessed (years) (percentage of all 
follow up) 
571.18 (56%) 90.75 (85%) 480.43 (53%) 
Median clinical information 
coverage per patient (%) (IQR) 
73% (45 – 100) 100% (100 - 
100) 
54% (31 – 77) 
Available IgG trough levels 
accessed (years) (percentage of all 
follow up) 
542.34 (53%) 98.37 (92%) 443.97 (49%) 
Median IgG trough levels 
coverage per patient (%) (IQR) 
76% (37 - 100) 100% (100 - 
100) 
55% (32 – 77) 
5.5 Demographics 
The median age of the cohort at the time of data collection and analysis (May 2018) was 
26.87 years (IQR 11.33 – 36.58) with a median follow up of 20.81 years (IQR 8.63 – 29.86).   
Thirty-six percent (n = 18) of patients were aged 18 or less.  With the Great North Children’s 
Hospital (GNCH) and Great Ormond Street Hospital (GOSH) being the tertiary centres for 
paediatric immunology in the UK, 72% of paediatric patients were recruited from these two 
centres.  The median age of the paediatric patients was 7.2 years (IQR 3.30 – 12.49) with a 
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median follow up of 5.28 years (IQR 1.53 – 9.53).  The median age of the adult patients was 
34.05 years (IQR 28.34 – 40.75) with a median follow up of 27.28 years (IQR 21.14 – 35.30).  
All but three patients of the cohort were Caucasian.  
Table 5-5 Baseline demographics of the study cohort 
Demographics  
Age (years) (median (IQR)) 26.87 (11.33 – 36.58) 
Paediatric 7.20 (3.30 – 12.49) 
Adult 34.05 (28.34 – 40.75) 
Follow Up (years) (median (IQR)) 20.60 (8.63 – 29.86) 
Paediatric 5.28 (1.53 – 9.53) 
Adult 27.28 (21.14 – 35.30) 
Age Group (N (%)) 
Paediatric 18 (36%) 
Adult 32 (64%) 
Family History (N (%)) 
Yes 24 (48%) 
No 26 (52%) 
 
5.6 Diagnosis 
I first present the data pertaining to factors and clinical phenotype pre-diagnosis and directly 
prompting the diagnosis of XLA.  Where available, I also present laboratory and 
immunological data in these patients before diagnosis and commencement of IGRT. 
5.6.1 Age 
The median age of diagnosis was 2.59 years (IQR 0.94 – 5.36) (Table 5-6).  This has 
significantly improved over time (Spearman’s ρ = - 0.367, p = 0.009) (Figure 5-8).  Excluding 
those who were screened at birth due to a family history of XLA (therefore relying on clinical 
findings for diagnosis, the median age at diagnosis was 2.97 (IQR 1.25 – 5.96).  This has 
tended to improve with time, but this correlation did not reach statistically significant 
(Spearman’s ρ = - 0.287, p = 0.069) (Figure 5-8). 
The median age of diagnosis for the paediatric patients is 1.19 years (IQR 0.71 – 3.27) and for 
adults 3.04 (IQR 1.10 – 7.89) (p= 0.036).  For patients who were screened because of a 
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previously known family history of XLA or suspected XLA, the age at diagnosis is 
significantly lower at 0.42 years (IQR 0.07 – 0.83 p = <0.001). 
Table 5-6 Variables and age at diagnosis (years, median (IQR)) 
Variable Age at diagnosis  p value 
Age at diagnosis for cohort 2.59 (0.94 – 5.36)  
Screened based on family history 
Yes (n = 9) 0.42 (0.07 – 0.83) <0.001 
No 2.97 (1.25 – 7.00) 
Current age group 
Paediatric 1.19 (0.71 – 3.27) 0.036 
Adult 3.04 (1.10 – 7.89) 
Figure 5-8 Age of diagnosis over time 
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5.6.2 Immunology at diagnosis 
Immunoglobulin levels at diagnosis and prior to commencement of IGRT were available for 
19 patients.  The median IgG level at diagnosis was 0.17 g/L (IQR 0 – 4.00).  Ten out of these 
nineteen patients had detectable IgG levels at diagnosis (median IgG level 3.7 g/L (IQR 2.42 
– 7.34).  The median IgA level at diagnosis was 0 g/L (IQR 0 – 0), with only four patients 
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having detectable IgA at diagnosis (median IgA level 0.22 g/L (IQR 0.06 – 1.23).  The 
median IgM level at diagnosis was 0 g/L (0 – 0.09) with seven patients having detectable IgM 
levels at diagnosis (median IgM level 0.17 g/L (IQR 0.08 – 0.38).     
The presence or absence of any of the immunoglobulin isotypes was not associated with 
significant differences in age of diagnosis.   There was no correlation with circulating 
immunoglobulin levels and age of diagnosis (Table 5-7).  It should be noted the lower limit of 
detection does differ between different assays between different centres and within centres 
with changing assays over time.  This will have affected the number of patients with 
detectable immunoglobulin.  In general, assays have improved over time and the lower limit 
of detection has decreased over time. 
Table 5-7 Immunoglobulin levels at diagnosis and age of diagnosis (years, median 
(IQR)) 
Detectable Immunoglobulin level or not Age at diagnosis  p-value 
Detectable IgA (n = 4) 6.87 (3.32 – 10.26) 0.110 
No detectable IgA (n = 15) 2.89 (1.07 – 3.30) 
Detectable IgM (n = 7) 3.30 (1.07 – 5.37) 0.866 
No detectable IgM (n = 12) 2.75 (1.19 – 6.68) 
Detectable IgG (n = 10) 4.47 (1.07 – 8.38) 0.286 
No detectable IgG (n = 8) 2.75 (1.87 – 3.13) 
Correlation of Immunoglobulin level with age at diagnosis/p-value 
IgG r = 0.027, p = 0.915 
IgM r = -0.047, p = 0.850 
IgA r = 0.418, p = 0.075 
 
The lymphocyte subsets at diagnosis were available for 15 patients and are shown in Table 
5-8. 
Four patients had a history of neutropenia prior to or at the time of diagnosis.  Three of these 
patients presented with pseudomonas skin infection.  No patient with normal neutrophil 
counts reported pseudomonas skin infection.  The median CD19/20 count was 0 cells/mcL 
(IQR 0.00 – 0.01) where data were available.  Four patients had detectable CD19/20 cells at 
diagnosis (median level 10 cells/mcL (IQR 10 – 20).  There was no statistically significant 
association between having detectable CD19/20 cells at diagnosis and detectable levels of 
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IgA, IgM or IgG (p = 0.111).  It should be noted that the lower limit of detection of CD19/20, 
neutrophils and serum immunoglobulins may differ between different centres within centres 
over time with changing and improving assays.  In general, as assays have improved over 
time the lower limit of detection have improved over time.  For example, at the Newcastle 
upon Tyne hospitals laboratories, the lower limit of neutrophil detection is 0.01 x 109/L and 




Table 5-8 Lymphocyte subsets of patients at diagnosis (prior to the instigation of IGRT) 
(cell/mcL, median (IQR)) 
 Cell count Percentage 
CD3 + T cells 3852 (2850 – 5650) 94 (93 – 95) 
CD4 + T cells 1090 (492 – 2637) 67 (55 – 70) 
CD8 + T cells 1418 (270 – 1650) 27 (24 – 38) 
CD16/56 + NK Cells 363 (212 – 480) 8 (5 – 50) 
CD 19/20 + B cells 0 (0 – 0.1) 0 (0 – 0.1) 
 
The presence or absence of detectable levels of CD19/20 lymphocytes at diagnosis was not 
significantly associated with a difference in age at diagnosis or correlation (Table 5-9). 
Table 5-9 Relationship of CD19/20 levels at diagnosis and age at diagnosis (years, 
median, IQR) 
CD19/20 Age at diagnosis p-value 
Present 2.02 (1.01 – 4.46) 0.396 
Absent 1.19 (0.08 – 2.68) 
Correlation of CD19/20 
(cells/µL) with age at diagnosis 
Spearman’s rho  = 0.189, p = 0.556 
5.6.3 Genetic mutations and BTK expression 
A genetic defect was found in 44 out of 50 (88%) patients, and BTK expression was absent in 
19, reduced in 2, normal in 6, and not tested in 23 (Figure 5-9).  In all patients with normal 
BTK expression, or where BTK expression was not tested, a BTK mutation was found.  The 
exact genetic defect was not available for eight out of the 44 patients recorded as having a 
proven genetic defect in BTK.  In two cases, this was due to missing/unavailable genetic 
results but there was a consistent recording of these cases having a proven genetic defect 
documented in the clinical records.  For the remaining cases, this was due to patients being 
diagnosed based on absent CD19/20 lymphocytes and a family member with a known BTK 
mutation.  In these cases, the patient was not retested, presuming they had the same mutation 




Figure 5-9 Genetic mutations (n, %) 
 
 
BTK expression data were available for 27 patients (54%).  It was absent in 19 (70%), 
reduced in two and normal in six.  In one of the patients with initial apparent normal BTK 
expression, further testing was undertaken, and it was found to be dysfunctional. 
There was no significant different difference in the age at diagnosis comparing the presence 
or absence of proven genetic mutation (p = 0.909), nor on the BTK expression status (p = 
0.332).  There may be potential differences between hospitals due to differing assays which 
may affect these results. 
Table 5-10 Relationship of BTK expression and genetic mutation on age at diagnosis 
(years, median (IQR)) 
 Age at diagnosis p-value 
Genetic Defect  
Yes (n = 44) 2.53 (0.88 – 5.79) 0.909 
No (n = 2) 3.04 (2.80 – 3.29) 
Unknown/Not tested (n = 4) 2.08 (1.07 – 3.98) 
BTK Expression 
Normal 5.64 (1.07 – 12.14) 0.332 
Absent 2.80 (1.55 – 5.36) 
Reduced 1.05 (1.00 – 1.11) 
Not tested 1.28 (0.51 – 4.05) 
n = 44, 88%
n = 2, 4%
n = 4, 8%




BTK mutations are described in more detail in section 5.14 within this chapter. 
5.6.4 Clinical Presentation 
There was detailed information on clinical presentation available for 43 patients (86% of the 
cohort).  There was a recorded family history of XLA in 24 (48%) patients.  Nine patients 
(21%) were screened due to a known or suspected family history of XLA.  They were all 
asymptomatic at the time of diagnosis.   
  All but one of the remaining patients presented with infection(s) (34 patients, 79%).  Two 
patients who could have been potentially screened due to positive family history were not, and 
were diagnosed once they became symptomatic with recurrent infections.    One patient was 
diagnosed with XLA during diagnosis and treatment of acute lymphoblastic leukaemia 
(ALL).   
Fifteen out of the 43 for whom data were available (35%) presented with repeated severe/life-
threatening infections, defined as either meningitis, osteomyelitis or infections requiring 
surgical intervention or ITU stay.  Five patients (10%) required at least one ITU stay prior to 
diagnosis. Fifty-one per cent of patients presented with a history of either recurrent upper 
respiratory tract infections (URTIs), lower respiratory tract infections (LRTIs) or otitis media 
(OM).  (Table 5-11). Three patients required surgical interventions for an infection prior to 
their XLA diagnosis.  One patient underwent a tonsillectomy; one patient required surgical 
intervention for pseudomonas skin infection, and a further patient required a below-knee 




Table 5-11 Presenting Symptoms.  (Totals add up to more than fifty and percentage to 
more than 100% as some patients presented with more than infection) 
Presenting Symptoms Number (Percentage) of patients 
presenting with (total available = 43) 
Recurrent lower respiratory tract infections 17 (40%) 
Screened on family history 9 (18%) 
Sepsis 7 (16%) 
Skin Infection 6 (14%) 
CNS Infection 4 (9%) 
Recurrent Otitis Media 3 (7%) 
Eye infections 3 (7%) 
Osteomyelitis 2 (5%) 
Infective Arthritis 2 (5%) 
Recurrent upper respiratory tract infections 2 (5%) 
GI Infection 2 (5%) 
Chickenpox 2 (5%) 
TB 1 (2%) 
Malignancy 1 (2%) 
 
Excluding those that were screened asymptomatically, for 18 patients (36% of the cohort) 
there was enough information available to calculate pre-diagnosis annual infection incidence.  
The median annual infection incidence pre-diagnosis was 1.11 infections per year (IQR 0.36 – 
3.90).  The median respiratory infection incidence pre-diagnosis was 0.24 per year (IQR 0 – 
1.63).  The median number of infections reported before XLA was diagnosed in those without 
a family history was 4.5 (IQR 2 - 7). 
For organisms cultured before the diagnosis of XLA (n = 21), Streptococcus pneumoniae was 
the most frequent organism isolated (33% of organisms) (Table 5-12).  Pseudomonas 
aeruginosa infections accounted for 60% of skin infections.  Where organism data were 




Table 5-12 Organisms cultured in pre-diagnosis infections 
Site of infection Cultured organism (n) 
Skin Staphylococcal aureus (n = 2), 
Pseudomonas aeruginosa (n = 3) 
Meningitis Streptococcus pneumoniae (n = 3) 
Sepsis/Bacteraemia Streptococcus pneumoniae (n =1), Neisseria 
meningitides (n = 1), Haemophilus 
influenzae (n = 2), Pseudomonas aeruginosa 
(n = 1), Staphylococcal Albus (n = 1) 
Osteomyelitis Streptococcus pneumoniae (n =1), 
Pseudomonas aeruginosa (n = 1) 
Lower respiratory tract Streptococcus pneumoniae (n =2) 
Gastrointestinal Rotavirus (1), Campylobacter (1) 
Arthritis Haemophilus influenzae (n = 1) 
5.7 Current Immunology 
I will now present data pertaining to the period after diagnosis of XLA and commencement of 
IGRT (Table 5-13).  It should be noted that the lower limit of detection may differ between 
laboratories due to differing assays.  I did not have access to the lower limit of detection of the 
differing assays but, for reference, the lower limit of detection of IgA, IgM and IgG is 0.05g/L 
at the Newcastle upon Tyne Hospitals laboratories. 
Thirty-nine out of forty-seven patients (83%) have current undetectable IgA levels and IgM 
levels (Table 5-13).  For those patients with detectable levels the median IgA level was 0.26 
g/L (IQR 0.055 – 0.675) and median IgM levels of 0.035 g/L (IQR 0.0 – 0.2).  Forty out of 
fifty (80%) patients have undetectable (<2%) circulating B-lymphocytes.  For those patients 
with detectable levels the median CD19/20 count was 12.5 cells/mcL (0%) (IQR 1 – 60).  
Patients who currently have some detectable CD19/20 cells were not statistically more likely 
to have circulating IgM levels (p = 0.051), or IgA (p=0.217).  Patients with detectable IgA 
were more likely to have circulating IgM levels (p = 0.02). 
There were no significant differences between adults and children and their current CD19/20 
count (p = 0.089), IgA levels (p = 0.181), or IgM levels (p = 0.515).   
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There were six (12% of the cohort) patients with normal BTK expression on monocytes (all 
on flow cytometry), their median CD19/20 count was 0 (IQR 0 – 1).  There were two (6%) 
patients with present, but reduced BTK expression; their median count CD19/20 was 86.5 
(IQR 0 - 173). There was no significant difference in patients current CD19/20 count based on 
their BTK expression status (p = 0.478).  
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Table 5-13 Current immunology and laboratory values  
Variable  
Immunoglobulins (g/L, median (IQR) 
IgA 0 (0 – 0.00) 
IgM 0 (0 – 0.00) 
IgG 9.7 (8.4 – 11.29) 
Adult Lymphocyte subsets Cells/mcL Percentage 
CD3 1801 (807 - 2454) 87 (80-91) 
CD4 1010 (661 – 1230) 58 (49 – 61) 
CD8 490 (350 – 972) 30 (26-35) 
CD19/20 0 (0 - 0) 0 (0 – 0) 
CD16/56 253 (183 - 315) 13 (7 – 19) 
Paediatric Lymphocyte subsets Cells/mcL Percentage 
CD3 3158 (2358 – 4986) 93 (91 – 95) 
CD4 1628 (1049 – 2533) 63 (51 – 69) 
CD8 670 (350 – 1418) 27 (24 – 37) 
CD19/20 0 (0 - 0) 0 (0 – 0) 
CD16/56 214 (164 – 341) 6 (5 – 8) 
Full Blood Count 
Haemoglobin (g/L) 141 (123 – 152) 
Platelets (x 109/L) 313 (254 – 359) 
White cell count (x 109/L) 8 (6.5 – 9.6) 
Neutrophils (x 109/L) 4.3 (4.0 – 5.8) 
Lymphocytes (x 109/L) 2.3 (1.6 – 2.9) 
BTK Expression 
Normal 6 (12%) 
Absent 20 (40%) 
Reduced 2 (4%) 
Not tested 22 (44%) 
Genetic defect 
Yes 44 (88%) 
No 2 (4%) 




5.8 Infections on IGRT 
Infections labelled as ‘respiratory tract’ are a combination of lower respiratory tract, otitis and 
sinus infections.    Infection of some sites is so rare that displaying incidence does not portray 
any useful information.  As such, some values for some infection sites are displayed as raw 
overall totals for illustration purposes.  For statistical analyses, the infection incidence is still 
being compared. 
The overall median annual infection incidence on IGRT was 1.11 infections/year (IQR 0.69 – 
1.87).  The median annual infection incidence in paediatric patients (1.38 (IQR 0.91 – 3.00)) 
tended to be higher than adult patients (0.91 (0.65 – 1.51)) but did not quite reach statistical 
difference, p = 0.053.  
The majority of these were infections of the respiratory tract with an annual infection 
incidence of 0.90 (0.53 – 1.88). Paediatric patients have a significantly higher respiratory tract 
infection incidence than adults (p = 0.034).  Due to increased awareness of PID in recent 
years and improvements in management, this difference could merely represent a decrease in 
the threshold for prescribing antibiotics in recent years.  To ascertain if this might be true, I 
examined the infection data for only the last 18 years for both current paediatric patent and 
current adults (i.e. 1999 onwards).   However, even when only analysing recent infection 
incidence (and therefore, potentially recent antibiotic prescribing practices), current paediatric 
patients still have a high respiratory tract infection incidence compared to adults over that 
same period (median 1.24 vs 0.72 infections per year, p = 0.034).  I then went on to further 
only analyse infections recorded in childhood to ascertain if it was paediatricians perhaps had 
a lower threshold to prescribe antibiotics than their adult colleagues did (as oppose to 
antibiotic prescribing practices changing over time).  I, therefore, compared the infection 
incidence under the age of 18 for current paediatric patients and for current adult patients, 
where data were available.  This showed that current paediatric patients have a higher 
respiratory tract infection incidence compared to the childhood of current adult patients 
(median 1.24 infections per year versus 0.48, p = 0.001).  These differences, therefore, most 
likely represent differences and changes in paediatric clinical practice, which will be 
discussed in further detail in the discussion chapter
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Table 5-14 Annual infection incidence (median (IQR)) 
 
All Patients (n=50) Paediatric Adult p value 
All infections 1.11 (0.69-1.87) 1.38 (0.91-3.00) 0.91 (0.65-1.51) 0.053 
Respiratory Tract infections 0.80 (0.53-1.87) 1.24 (0.70-1.96) 0.75 (0.41-1.25) 0.034 
Lower Respiratory infections 0.78 (0.52-1.65) 1.24 (0.70-1.96) 0.63 (0.27-1.25) 0.012 
Sinus infections 0.00 (0.00-0.03) 0.00 (0.00-0.00) 0.00 (0.00-0.08) 0.003 
Otitis infections 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.02) 0.355 
 Totals 
Skin infections 37 22 15 0.211 
Eye infections 25 7 18 0.698 
GI infections 17 2 15 0.357 
CNS infections 0 0 0 NA 
Bone and Joint infections 0 0 0 NA 
Sepsis 1 0 1 0.466 
GU infections 11 2 9 0.255 




The median number of total infections per patient was nine (IQR 4 – 15, minimum 0, 
maximum 54) for the overall cohort since diagnosis.  Respiratory tract infections accounted 
for the majority of these with a median value of seven infections per patient.  There were 603-
recorded infections for the cohort with respiratory tract infections accounting for 85% (n = 
511).  The number of sinus infections is surprisingly low and not reported in children.  This is 
most likely due to an underreporting of sinus infections or related symptoms due to their 
perceived benign nature.  Patients may also be self-treating these, and not reporting their 
symptoms to their immunologist. 
There were a small number of UTIs (2 in children, 9 in adults).  XLA and PAD patients are 
not usually thought of as being susceptible to UTI infections and these infections may simply 
reflect the normal background rate of UTIs although future work should seek to confirm this. 
The vast majority of these infections were treated as an outpatient, with inpatient treatment 
only accounting for 10 of all the infections recorded.  Four (18%) patients had an ITU/HDU 
admission on IGRT that was related to infection. 
There was no correlation with the lifetime median infection incidence and the lifetime median 
IgG trough level (rho = 0.174, p = 0.242). 
5.8.1 Infections pre versus post instigation of IGRT 
There were eighteen patients where data were available and who were not screened 
asymptomatically.  The median overall annual infection incidence before diagnosis (and 
instigation of IGRT) was 1.11 (0.36 – 3.90) compared to their annual infection incidence on 
IGRT of 1.12 (IQR 0.63 – 1.89), p = 0.557 (Table 5-15). 
There were significantly fewer central nervous system infections, invasive musculoskeletal 
infections and recorded sepsis on IGRT compared to without.  However, these events were 
still rare, both pre and post-diagnosis.
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Table 5-15 Annual infection incidence pre and post XLA diagnosis (median (IQR)) 
 
Pre diagnosis Post diagnosis p-value 
All infections 1.11 (0.36 – 3.90) 1.12 (0.63 – 1.89) 0.557 
Respiratory tract infections 0.90 (0.00 – 2.03) 0.86 (0.54 – 1.89) 0.723 
Lower respiratory tract infections 0.90 (0.00 – 2.03) 0.79 (0.54 – 1.89) 0.723 
Sinus infections 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.158 
Otitis infections 0.00 (0.00-0.56) 0.00 (0.00 – 0.00) 0.078 
 Totals 
Skin infections 8 7 0.200 
Eye infections 0 2 0.158 
GI infections 2 0 0.317 
CNS infections 4 0 0.046 
Bone and Joint infections 5 0 0.046 





For those patients whose pre-diagnosis data collection is considered to be 100%, increasing 
age of diagnosis was associated with a lower pre-diagnosis infection incidence (excluding 
those who were screened asymptomatically) (Spearman’s rho = -0.490, p = 0.039) (Figure 
5-10).  Translating this to clinical practice, this likely represents that those with more frequent 
infections (and potentially a more severe phenotype) are more likely to be investigated for 
PID earlier than those with fewer infections. 
Figure 5-10 Pre-diagnosis median annual infection incidence and age at diagnosis 
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5.8.2 Chronic sinusitis and conjunctivitis 
Eleven patients (22%) reported are diagnosed with recurrent sinusitis, and six patients (12%) 
are diagnosed with recurrent conjunctivitis.  There was a significant association between the 
two comorbidities (p = 0.017).   
At last follow-up, patients with sinusitis were significantly older than those without (36 years 
versus 20 years, p = 0.003).  There were no significant differences in current age for patients 
with or without chronic conjunctivitis (p = 0.355).  There were no significant differences for 
age at diagnosis or lifetime median IgG trough levels for patients with chronic sinusitis 
compared to those without.  The same was true when comparing those patients with and 
without chronic conjunctivitis. 
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Table 5-16 Demographics of patients with and without chronic sinusitis or chronic 
conjunctivitis (median (IQR)) 
 Chronic sinusitis None p-value 
Age (years) 36.22 (29.15 – 38.98) 20.07 (7.89 – 34.35) 0.025 
Age at diagnosis (years) 1.25 (0.83 – 7.00) 2.80 (0.94 – 5.36) 0.815 
Lifetime median IgG trough 
level (g/L) 
9.88 (9.37 – 10.48) 9.03 (7.90 – 10.60) 0.567 
Latest IgA level (g/L) 0.00 (0.00 – 0.04) (0.00 – 0.00) 0.341 




Age (years) 31.88 (19.88 – 40.34) 25.44 (9.22 – 36.41) 0.355 
Age at diagnosis (years) 1.55 (1.04 – 3.37) 2.70 (0.89 – 5.49) 0.754 
Lifetime median IgG trough 
level (d/dL) 
10.48 (8.10 – 11.51) 9.34 (7.90 – 10.50) 0.469 
Latest IgA level (g/L) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.292 




5.9 Comorbidities and Complications 
Past medical history and data pertaining to co-morbidities was available for 50 patients and is 
summarised in Table 5-17. 
Table 5-17 A summary of current comorbidities in this XLA Cohort 
Comorbidity Number of patients (%) 
Sinopulmonary disease 
Bronchiectasis 22 (44%) 
Abnormal HRCT (Not Bronchiectasis) 9 (18%) 
Chronic sinusitis 11 (22%) 
Gastrointestinal disease 
Chronic non infective diarrhoea 5 (10%) 
Chronic Infective diarrhoea 3 (6%) 
Inflammatory bowel disease 3 (6%), 1 of whom is Crohn’s 
Underwent endoscopy 10 (20%) 
Musculoskeletal 
Arthritis 4 (8%) 
Fatigue/arthralgia 3 (6%) 
Malignancy 1 (2%) 
Psychiatric/Neuro 
Memory disturbance 3 (6%) 
Anxiety 6 (12%) – 1 of whom have resolved 
Depression 7 (14%) - 2 of whom have resolved 
Epilepsy 2 (4%) 
Deafness 5 (10%) 
 
5.9.1 Respiratory Disease 
Twenty-two (44%) of patients had proven bronchiectasis on HRCT, and a further nine 
patients (18%) had abnormal HRCT scans (Table 5-17).  Sixty-three per cent of adults have a 
diagnosis of bronchiectasis and 11% of children have a diagnosis of bronchiectasis.  The 




The number of patients with a formal diagnosis of chronic sinusitis is surprisingly low given 
the background literature.  All of these patients were diagnosed with chronic sinusitis based 
on persistent clinical symptoms.  No patient had a CT or other imaging of their sinuses. 
The respiratory health of the cohort will be discussed further in Chapter 6. 
5.9.2 Gastrointestinal disease 
Ten (20%) patients report at least one GI symptom necessitating endoscopy, of which one has 
resolved (Table 5-18).  Two patients have confirmed infective (norovirus) diarrhoea with 
nutritional compromise.  One of these patients has undergone haematopoietic stem cell 
transplantation in a bid to clear the norovirus infection, and the second has undergone 
assessment for HSCT.  The second has undergone assessment for HSCT and is currently 
deciding whether to go ahead with the procedure.  He currently requires supplemental 
gastrostomy feeding to maintain adequate nutrition but is maintaining adequate IgG trough 
levels on standard therapy.  In contrast to the first patient undergoing HSCT, this second 
patient is able to maintain IgG trough levels on standard therapy, and his IgG dose has not had 
to be increased after the development of the norovirus infection.  The failure to clear 
norovirus in this patient by conventional and other novel therapies has been described 
previously (185).  
One patient has confirmed Crohn’s disease, which is currently well controlled, and he is the 
maternal uncle to patient 24.  Patient 24 has chronic, non-infectious diarrhoea and has been 
described as IBD (inflammatory bowel disease) like disease, but with normal histology, 
although it should be noted no biopsies were taken from the terminal ileum.  A further one 
patient has been described as having IBD like disease.  
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Table 5-18 GI disease in XLA cohort 
Patient ID Details Histology Resolved or Current 
4 Non-infectious colitis Normal Resolved 
17 Chronic norovirus infection, 
chronic enteropathy, poor 
weight gain, NG feeding.   
Chronic enteropathy with duodenal villous 
blunting, marked increased intraepithelial 
lymphocytes and lymphocytosis in lamina 
propria. Colonic biopsies showed increased 
epithelial lymphocytes 
Current.  Has undergone HSCT 
22 Chronic non-infectious 
diarrhoea 
Normal  Current 
23 Poor growth.  “IBD like 
disease” – improvement with 
infliximab.  Treatment for 
confirmed Giardia   
Duodenal villous blunting Current – Infliximab and Giardia 
treatment has resulted in the 
beginning of good growth and 
improvement of symptoms 
24 Chronic non-infectious 
diarrhoea.  Related to Patient 
ID 26 
Normal (no terminal ileum samples) Current 
25 Persistent Nausea, previous 
diarrhoea 
Upper OGD Normal Current 





Patient ID Details Histology Resolved or Current 
30 Stool urgency and diarrhoea – 
Irritable bowel syndrome 
2014 - normal Current 
36 Chronic Norovirus, On PEG 
supplemental feeds 
Villous Blunting, Some ulcers in the small 
bowel 
Current.  Considering HSCT. 
37 Chronic abdominal pain and 
non-infectious diarrhoea 
Normal Current 
38 Previous Giardia Infection None done Resolved 
50 Deranged liver function tests.  
Thought to be non-alcoholic 
fatty liver disease (NAFLD) 




Further analysis was carried out on ten of the patients with GI disease.  No further analyses 
were carried out for the patient with deranged liver function tests (patient 50) or the patient 
with a previous Giardia infection (patient 38).  For patient 50, it was felt the deranged liver 
function was most likely due to non-alcoholic fatty liver disease (NAFLD), unrelated to the 
XLA. 
There were no significant differences in the demographics, current immunology values or 
clinical therapy between those currently with and without GI disease. 
Table 5-19 Characteristics of those with and without current GI disease (median (IQR)) 
Variable No GI disease GI disease p-value 
Age (years) 28.34 (10.65 – 36.41) 21.38 (11.33 – 41.15) 0.717 
Age group  
Paediatrics 14 4 (22%) 1.000 
Adult 26 6 (19%) 
Age at diagnosis 
(years) 
2.85 (1.09 – 5.66) 0.77 (0.17 – 3.58) 0.099 
Follow up (years) 20.81 (5.28 – 30.31) 20.88 (9.53 – 27.63) 0.645 
Lifetime IgG Trough 
(g/dL) 
9.07 (7.83 – 10.50) 10.5 (9.89 – 11.40) 0.066 
Latest IgG trough 
(g/dL) 
9.56 (8.54 – 11.25) 11.32 (8.18 – 13.60) 0.190 
Latest IgA level 
(g/dL) 
0 (0 – 0) 0 (0 – 0) 0.137 
Latest IgM level 
(g/dL) 
0 (0 – 0) 0 (0 – 0) 0.620 
Latest CD19/20 
(cells/µL) 
0 (0 – 0) 0 (0 – 0) 0.382 
Current IGRT  
SCIg 20 5 0.264 
IVIg 19 4 
SCIg/IVIg 0 1  
Previous IM therapy 8 1 0.665 
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Variable No GI disease GI disease p-value 
BTK expression 
Normal 6 0 1.000 
Absent 18 1 
Reduced 2 0 
Genetic Defect 
Yes 33 10 1.000 
No 2 0 
BMI  
Grade 2 Thinness 2 0 1.000 
Grade 1 Thinness 4 1 
Normal Weight 13 5 
Overweight 14 4 
Obese 2 0 
 
Twenty of the forty-five patients for whom BMI data were available were overweight (44%) 
(Table 5-20).  Eighteen (40%) were a healthy weight and seven (16%) were underweight.  
Only one of the 13 paediatric patients were overweight versus 19 (59%) of the adult patients 
(p = 0.002).   There was no statistically significant association with BMI category and the 
presence of XLA related GI disease (p = 1.000).  The median BMI for adults was 23.63 (IQR 
21.00 – 27.12).  The median BMI Z-score for children was -0.14 (IQR -0.73 – 0.71). 
Table 5-20 BMI status for the cohort 
 Paediatrics Adults Total 
Grade 2 Thinness 2 0 2 
Grade 1 Thinness 1 4 5 
Normal Weight 9 9 18 
Overweight 1 17 18 
Obese 0 22 2 
   
5.9.3 Musculoskeletal disease 
 Seven patients had chronic muscle and joint pains, arthritis or muscle and joint-related 
fatigue.  Four of these patients have a formal diagnosis of arthritis.  All of these four patients 
had previously confirmed mycoplasma infection of the affected joints. 
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A further three patients with significant muscle aches and/or fatigue had also been diagnosed 
with fibromyalgia.  There were no reported previous joint or bone infections in these three 
patients.   
5.9.4 Malignancy 
Only one patient had a reported history of malignancy.  This patient developed acute 
lymphoblastic leukaemia (ALL) at the age of seven years.  During his treatment and recovery, 
he demonstrated a persistent agammaglobulinaemia, which was later proven to be XLA.  He 
has an older brother with XLA, recruited to this study, who has no history of malignancy. 
5.9.5 Memory disturbances 
Three (6%) patients had reported problems with their memory, warranting specialist referral 
with a neurologist.  Their current median age was 38.63 years (IQR 31.11 – 48.76).  One of 
these patients had depression and a further one has anxiety.  The third patient had a history of 
recurrent echovirus encephalitis.  The supervising medical team presumed that the memory 
problems were related to the echovirus infection 
5.9.6 Deafness 
Five (10%) patients have at least unilateral deafness, all of whom it is presumed this is 
secondary to infection.  Three of the five had meningitis prior to the diagnosis of XLA, and 
the remaining two had recurrent ear infections.  No patient with deafness or within the whole 
cohort has mutations at the 3’ end of BTK and the closely linked TIMM8A gene associated 
with both XLA and deafness (337). 
5.9.7 Other complications 
Two patients have epilepsy, one of whom is a patient with recurrent echovirus encephalitis.  
In this case, it is highly suspected that the epilepsy is due to the underlying infection. 
5.10 Disease Severity 
There was sufficient clinical detail for 50 patients to ascertain a disease severity as per the 
process described in the methods chapter.  Fifty – four per cent of patients have moderate or 
severe disease severity.  After Bonferroni (Holm) correction, patients with moderate disease 
are significantly older than those patients with mild disease (p = 0.006).  There were no 
statistically significant differences in age at diagnosis across the disease severity groups. 
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Table 5-21 Disease severity by current age and age at diagnosis (years, median (IQR)) 
Disease severity Number of patients Current age  Age at diagnosis 
Asymptomatic 3 (6%) 21.30 (2.40 – 30.06) 3.28 (0.94 – 12.14) 
Mild 19 (38%) 12.83 (6.34 – 32.03) 1.28 (0.75 – 3.58) 
Moderate 19 (38%) 34.35 (24.66 – 41.15) 2.80 (1.04 - 7.00) 
Severe 9 (18%) 31.11 (19.88 – 48.11) 2.60 (1.25 – 14.92) 
p value 0.031 0.622 
 
5.11 Immunoglobulin Therapy 
Immunoglobulin replacement therapy data were available for 49 patients.  One patient, with a 
proven BTK genetic defect, recurrent infections and mild hypogammaglobulinaemia had not 
yet been started on IGRT at the time of the study. 
5.11.1 Route of IGRT 
Fifty-one per cent of patients (n = 25) were receiving their IGRT intravenously, and 47 per 
cent (n = 24) via the subcutaneous route.  There is one child on both IV and SC 
immunoglobulin therapy.  This patient has persistent norovirus infection and is undergoing 
HSCT.  His enteropathy was severe enough that he required high doses of combined SCIg and 
IVIg to maintain adequate IgG trough levels. 
A significantly larger proportion of children received SCIg versus IVIg compared to adults (p 
= 0.001).  82% of paediatric patients received their therapy via the SC route versus 29% of 
adults.  Despite this, there was no significant difference between the age groups as to how 
many receive their therapy at home (p = 0.330).  This lack of significant difference was likely 
since 55% of adults who do receive their IGRT intravenously still being able to administer 
this at home, under their own or a relative’s cannulation.  None of the four children who 
received IVIg were able to do this at home, due to patient and family preference. 
As expected, significantly more patients on SCIg received their therapy at home compared to 
IVIg (p < 0.001).  All patients on SCIg received their therapy at home versus 48% of IVIg.   
Nine (18%) patients have received intramuscular IGRT previously.  These patients are 
significantly older than patients who have never received IM IGRT (median age 40.34 years 
versus 20.08 years, p = 0.0002).  Having IM IGRT previously was not associated with a 
significant difference in lifetime median infection annual incidence (0.81 infections/year with 
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previous IM therapy versus 1.25 infection per year, p = 0.134).  It was not associated with 
disease severity, p = 0.100. 
Figure 5-11 Site and route of IGRT 
 
Privigen is the commonest IV preparation, accounting for 36% of all products (Table 5-22 IV 
immunoglobulin products).  Hizentra accounts for the commonest SC immunoglobulin 
products accounting for 50% of all SC products (Table 5-23). 
Table 5-22 IV immunoglobulin products 
Product Number (n) Percent (%) 
Privigen 9 36 
Flebogamma 8 32 
Kiovig 5 20 
Gamunex 3 12 












Table 5-23 SC immunoglobulin products 
Product Number (n) Percent (%) 
Hizentra 11 50 
Subcuvia 6 27 
Subgam 4 18 
Cuvitru 1 5 
Total 22 100 
 
5.11.2 Dosing of IGRT 
The median IGRT dose for the entire cohort was 568mg/Kg/month (IQR 488 – 678, n = 44).  
For IVIg, the median dose was 533mg/Kg/month (IQR 489 – 644).  For SCIg, the median 
dose was 593mg/Kg/month (IQR 447 – 678).  These were not significantly different (p = 
1.000).  The median interval between doses was seven days (IQR 7 - 21, n = 46) (Figure 
5-12).  For IVIg, the median interval was 21 days (IQR 21-21) and for SCIg 7 days (IQR 7-
14).  This was significantly different (p = 0.000). 
Figure 5-12 Frequency of IGRT  
 
The median last recorded IGRT dose for the entire cohort was 568mg/Kg/month (IQR 490 – 
656, n = 44).  This is does not significantly correlate with the last recorded median IgG trough 
levels (10.0 g/L, IQR 8.70 = 12.17) (Spearman’s rho = 0.269, p = 0.085) (Figure 5-13).  This 













potential different in pharmacokinetics and IgG metabolism between patients.  This lack of 
correlation adds further argument to the individual of IgG doses based on clinical symptoms 
rather than a blanket target as supported by others (207).  
Figure 5-13 Current IGRT dose and IgG trough level 





























  The lifetime median IGRT dose was 568mg/Kg/month (IQR 490 – 656).  This did not 
correlate with lifetime median IgG trough levels (9.37 g/L, IQR 8.05 – 10.82) (rho = 0.083, p 
= 0.600) or median lifetime infection incidence (rho = 0.206, p = 0.181).  Lifetime median 
IgG trough levels were not significantly associated with median lifetime annual infection 
incidence (rho = 0.174, p = 0.242) (Figure 5-14).   
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Figure 5-14 Median lifetime IgG trough levels and median lifetime median annual 
infection incidence 

































The last recorded IGRT dose for current paediatric patients is significantly higher than adults 
(median 640 mg/Kg/month, IQR 585 – 741 versus 522 mg/Kg/month, IQR 449 – 600, p = 
0.012).  Their last recorded IgG trough levels were not significantly different (p = 0.857). 
Last recorded IgG trough levels did not significantly differ by current administration route (p 
= 0.078). 
After Bonferroni (Holm) correction, patients with moderate disease (as defined by my 
classification) have significantly lower last recorded IgG trough levels than those with mild 
disease (p = 0.006).  There was no significant difference for median lifetime IgG trough levels 
across disease severity (p = 0.340) (Table 5-24). 
Table 5-24 Disease severity and IgG trough levels (g/L, median (IQR)) 
Disease severity Number of patients Last recorded IgG 
trough level  
Median lifetime IgG 
trough level  
Asymptomatic 3 (6%) 9.40 (6.93 – 11.20) 7.78 (6.12 – 9.31) 
Mild 19 (38%) 11.15 (10.27 – 12.80) 9.84 (8.34 – 11.40) 
Moderate 19 (38%) 9.40 (8.40 – 10.10) 9.75 (8.18  - 10.50) 
Severe 9 (18%) 10.00 (8.00 – 14.80) 8.28 (7.61 – 11.40) 




There was no correlation with the standard deviation of the yearly mean IgG trough levels 
with annual infection incidence or annual respiratory infection incidence.  Having spent a 
longer time on IGRT also did not correlate with the standard deviation.  There was no 
significant difference in the lifetime IgG trough SD based on current IGRT route, therapy 
compliance or disease severity (Table 5-25).  This suggests that therapy compliance and route 
do not significantly affect variation in IgG trough levels.  In turn, any variations in IgG trough 
levels do not appear to affect clinical phenotype or disease severity. 
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Table 5-25 Association of the standard deviation of median annual IgG trough levels on 
outcomes 
 Correlation of SD of the 
median annual IgG trough 
levels 
p-value 
Lifetime yearly infection 
incidence 
Rho = 0.186 0.217 
Life time yearly respiratory 
tract infection incidence 
Rho = 0.084 0.581 
Time on IGRT Rho = 0.100 0.509 
 SD (Median, IQR)  
Current IGRT route 
Subcutaneous 1.31 (0.92 – 1.74) 0.215 
Intravenous 1.47 (0.90 – 2.14) 
Mixed 6.73 (NA)  
Therapy Compliance Issues 
None 1.44 (0.97 – 2.14) 0.210 
Mild 0.92 (0.90 – 1.21) 
Moderate 1.77 (1.74 – 2.51) 
Disease Severity 
Asymptomatic 0.92 (0.79 – 1.66) 0.513 
Mild 1.40 (1.12 – 2.36) 
Moderate 1.39 (0.88 – 2.09) 
Severe 1.51 (0.97 – 2.51) 
5.12 Prophylactic antibiotics 
Twenty-one patients (42%) are on prophylactic antibiotics.  Nine (32%) patients without 
bronchiectasis are on prophylactic antibiotics.    Twelve (55%) patients with bronchiectasis 
are on prophylactic antibiotics.  There was no significant association with the use of 
prophylactic antibiotics and the presence or absence of bronchiectasis (p = 0.111).  
Azithromycin accounts for the most commonly prescribed antibiotics for prophylaxis, 
accounting for 62% of all prophylactic antibiotics.  There were no significant differences in 




Table 5-26 Prophylactic antibiotic use in cohort (n, %) 




Amoxicillin 2 (10%) 0 (0%) 2 (22%) 
Azithromycin 13 (62%) 8 (67%) 5 (56%) 
Co-Trimoxazole 4 (19%) 2 (17%) 2 (22%) 
Doxycycline 2 (10%) 2 (17%) 0 (0%) 
 
Accurate dosing data were available for 18 patients.  The majority of patients took a daily 
regimen (61%) versus a three-time a week dosing regimen (usually Monday, Wednesday and 
Friday).  The majority of patients (80%) took their prophylactic antibiotics all year round as 
opposed to just over the winter period.  The choice of antibiotics did not significantly affect 
dosing choices (p = 0.457), or whether it was just given over winter (p = 1.000) (Table 5-27). 
Table 5-27 Dosing of prophylactic antibiotics (n, %) 
 All Amoxicillin Azithromycin  Co-
Trimoxazole 
Doxycycline 
Daily 11 (61%) 2 (100%) 5 (45%) 2 (66%) 2 (100%) 
Three time 
as week 
7 (39%) 0 (0%) 6 (55%) 1 (34%) 0 (0%) 
Winter only 4 (20%) 0 (%) 3 (25%) 1 (34%) 0 (0%) 
 
There are no significant differences in the median lifetime annual infection incidence for 
patients who are currently on prophylactic antibiotics versus those who are not (p = 0.558), 
and this remains true when only analysing respiratory tract infections (p = 0.467) (Table 
5-28).  There continue to be no significant differences when comparing those with and 
without bronchiectasis (Table 5-28).  
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Table 5-28 Median lifetime annual infection incidence and the use of prophylactic 
antibiotics (median (IQR)) 






Whole Cohort 1.09 (0.81 – 1.87) 1.15 (0.62 – 1.91) 0.558 
Bronchiectasis 1.00 (0.80 – 1.41) 1.05 (0.63 – 1.85) 1.000 
No Bronchiectasis 1.38 (0.86 – 1.89) 1.19 (0.35 – 1.97) 0.440 
Respiratory Tract infections 
Whole Cohort 0.91 (0.54 – 1.87) 0.73 (0.45 – 1.76) 0.467 
Bronchiectasis 0.86 (0.52 – 1.18) 0.78 (0.55 – 1.65) 0.895 
No Bronchiectasis 1.38 (0.76 – 1.89) 0.69 (0.18 – 1.88) 0.280 
 
The data on the use of prophylactic antibiotics only pertains to the patient’s current clinical 
status.  It was not possible to accurately determine when prophylactic antibiotics were started 
and how long patients have been prescribed them.  This, therefore, introduces some 
limitations and confounding in the analysis above to determine the effectiveness of 
prophylactic antibiotics in XLA.  
To address some of these limitations, I also analysed only the last single year of available data 
for annual infection incidence, where I was able to accurately determine if prophylactic 
antibiotics were used that year. 
Table 5-29 Number of infections for last year of available data collection, comparing the 
use of prophylactic antibiotics 






All 1 (0 – 2.5) 0 (0 – 1) 0.096 
Bronchiectasis 1 (0 – 3) 0.5 (0 – 2.5) 0.653 
No Bronchiectasis 1 (1 – 1) 0 (0 – 1) 0.089 
Respiratory tract infections only 
All 1 (0 – 1.5) 0 ( 0 -1) 0.108 
Bronchiectasis 1 (0 – 2) 0.5 (0 – 2) 0.822 




Just looking at the last single year of available infection and prophylactic antibiotic data, there 
are no significant differences in the number of overall infections or respiratory tract infections 
comparing those on prophylactic antibiotics and those who are not.  There remained no 
significant differences when analysing according to the current presence of bronchiectasis or 
not. 
5.13 Treatment compliance 
Using the criteria I defined in the methodology, 19% of patients (n = 9) were defined as 
having current or previous mild and moderate issues with treatment compliance (from a total 
of 48 patients for whom data was available).  There was no association between treatment 
compliance and disease severity (p = 0.092) (Table 5-30).  There were no significant 
differences or therapy compliance comparing adults to children (p = 0.253).  Although, it 
should be noted there is a trend towards more issues with compliance and worsening disease 
severity with no patient with asymptomatic disease or mild severity reporting issues with 
treatment compliance.  Further details on compliance were not available so it is not possible 
to ascertain the time frame of these issues and its relationship to disease severity.  It is 
therefore not possible to ascertain if worsening treatment compliance is associated with 
increased disease severity or vice versa.  
Table 5-30 Treatment compliance (n) 
Compliance/Disease 
Severity 
None Mild Severity Moderate Severe 
No issues 2 18 12 7 
Mild 0 0 5 1 
Moderate 0 0 2 1 
Significant issues 0 0 0 0 
5.14 Genetics 
A genetic defect was found for 44 patients (88%).  Two patients underwent genetic testing, 
but no defect has been found.  For the remaining four patients, I could find no evidence of 
genetic testing being carried out.  Out of the 44 patients with a genetic mutation in BTK, basic 
data on the mutation was available for 37 of them, of which precise data were available for 
31.  Seven patients are recorded as having a BTK mutation but no details available.  The most 
common reason for this was being diagnosed on the basis on absent B-lymphocytes and a 
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positive history of a family member with a proven BTK mutation, but where I was unable to 
recruit the family member and ascertain the exact mutation.  There were two patients 
(brothers) who are recorded as having a BTK mutation in the clinic notes but I was unable to 
find the original genetic report.  
5.14.1 Mutations  
Null mutations accounted for 68% of mutations versus 32% missense mutation.  Premature 
stop codons were the most prevalent type of mutation, accounting for 40% of patients in 
whom data was available. 
Table 5-31 Mutations in the cohort (* denotes mutations not previously described in the 
literature) 
Codon change Protein 
change 
Position Domain Mutation 
c.238C>T* (n = 2) P80A Exon 3 PH Amino acid 
substitution at non 
conserved sites  
c.1000T>C* Y334H Exon 12 SH2 AA substitution at 
conserved sites in 
Btk family 
c.1070_1071delAGinsTCT* E357Vfs*4 Exon 12 SH2 Frameshift Mutation 
c.1275C>A Y425X Exon 14 Kinase Premature Stop 
Codon 




Splice defects at 
conserved invariant 
base pairs 




Splice defects at 
first/last intron base 
pairs 
c.1684_1685delCGinsTA* R562X Exon 17 Kinase Premature Stop 
Codon 
c.1691C>A* (n = 2) S564Y Exon 17 Kinase Amino acid 




Codon change Protein 
change 
Position Domain Mutation 
c.1733_1735dupCTG* S578_D579
insA 





Splice defects at 




Exon 16 Kinase Frameshift Mutation 
c.1889T>C M630T Exon 18 Kinase AA substitution at 
conserved sites in 
Btk family 






Splice defects at 
first/last intron base 
pairs 
c.43C>T Q15X Exon 2 PH Premature Stop 
Codon 




Exon 9 SH33 Frameshift Mutation 
c.756G>A W252X Exon 9 SH33 Premature Stop 
Codon 
c.763C>T (n = 2) R255X Exon 8  SH33 Premature Stop 
Codon 
c.778C>T Q260X Exon 9 SH33 Premature Stop 
Codon 
c.82C>T R28C Exon 2 PH AA substitution at 
conserved sites in 
Btk family 
c.863G>A R288Q Exon 10 SH2 AA substitution at 




Codon change Protein 
change 
Position Domain Mutation 
c.866G>T* S289L Exon 11 SH2 AA substitution at 
conserved sites in 
Btk family 
c.952T>C S318P Exon 11 SH2 AA substitution at 
conserved sites in 
Btk family 
Deletion of Promotor in Exon 
1* (n = 2) 
 
Exon 1 PH 
 
Duplication of exons 6 -18 
creates a frameshift mutation 







Frame Shift --> Stop Codon 





































Figure 5-16 - Age at diagnosis and lifetime annual infection incidence by mutation 
protein domain site for missense mutations 
 
For missense mutations, there were no significant differences for median lifetime annual 
infection incidence (p = 0.763) or age at diagnosis (p = 0.572) by protein domain of the 
underlying genetic mutation. 
Using the definitions from Broides et al., (368) 40% had a mild mutation versus 60% with a 
severe mutation (Figure 5-17). 








5.14.2 Correlation with age at diagnosis and disease severity 
To assess for clinical phenotype and genotype correlation, mutation severity, type and 
location were assessed against age at diagnosis and disease severity (Table 5-32).  Disease 
severity was assessed as per the methods section.  Proposing that milder disease would 
present later, age at diagnosis could be used as a proxy for disease severity, at least in the 
initial phase.  Patients who were screened asymptomatically because of their family history 
were excluded from these analyses, but the index case in the family with the same mutation 
could be used as they were diagnosed on clinical grounds and not because of family history. 
Disease severity was not significantly associated with mutation severity (p = 1.000), the 
protein domain of the mutation (p = 0.792) or the mutation type (p = 1.000).  Age at diagnosis 
was not significantly effect by mutation severity (p = 0.113), protein domain of the mutation 
(p = 0.657) or the mutation type (p =   0.827) (Table 5-32).
Table 5-32 Association between mutation and age at diagnosis and disease severity.  
(Excluding patients screened who screened asymptomatically due to family history) (years, 
median (IQR)) 
 Age at Diagnosis p-value Disease Severity 
p-value 
Broides et al., Mutation Severity (368) 
Mild  2.29 (0.51 – 5.36) 0.113 1.000 
Severe 3.82 (2.47 – 8.38) 
Protein Domain for Missense mutations 
PH Domain 7.41 (5.61 – 8.38) 0.657 0.792 
TH Domain N/A 
SH3 N/A 
SH2 2.09 (1.11 – 12.18) 
Kinase 4.12 (1.25 – 7.00) 
Mutation Type 
Missense 2.89 (1.25 – 7.00) 0.827 1.000 
Null 3.30 (2.00 – 5.96) 
 
To further assess any correlation with the genetic mutation and clinical phenotype, mutations were 
analysed as per a number of pathogenicity prediction scores as defined in the methodology.  None 
of the chose mutation pathogenicity programs demonstrated a correlation with the prediction score 
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and the age at diagnosis.  Aside from the PROVEAN program, no program demonstrated a 
correlation with the median lifetime annual infection incidence.  The PROVEAN program 
demonstrated a significant and moderate correlation with increasing severity as per their algorithm 
and the median lifetime annual infection incidence (ρ = 0.464, p = 0.011) (Table 5-33). 
Table 5-33 Correlation of mutation prediction algorithm scores and clinical phenotype (rho, 
p-value) 
Mutation prediction algorithm Correlation with Age at 
diagnoses 
Correlation with 
infection incidence  
DANN ρ = 0.001, p = 0.965 ρ = -0.236, p = 0.228 
FATHMM ρ = 0.023, p = 0.913 ρ = -0.022, p = 0.914 
Mutation Taster ρ = -0.185, p = 0.366 ρ = 0.001, p = 0.965 
PROVEAN ρ = -0.074, p = 0.705 ρ = 0.464, p = 0.011 
SIFT ρ = -0.157, p = 0.625 ρ = -0.265, p = 0.066 
ADA Score ρ = 0.632, p = 0.093 ρ = -0.069, p = 0.872 
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Figure 5-18 Disease severity and mutation prediction scores 
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There were no significant differences amongst increasing disease severity and DANN scores 
(p = 0.561), FATHMM scores (p = 0.743), Mutation Taster scores (p = 0.460), PROVEAN 
scores (p = 0.757), SIFT scores (p = 0.115) or ADA scores (p = 0.323) (Figure 5-18). 
For my final analysis of any genotype and phenotype correlation, I have analysed the genetic 
defects for associations with circulating immunoglobulin levels at diagnosis and latest clinic 
appointment to investigate any association with a genetic defect and the immunological 
phenotype.  There are no differences in immunological phenotype at either diagnosis or latest 
clinic based on mutation type, protein severity or mutation severity.  This suggests that 
residual levels of BTK function and circulating peripheral immunoglobulin levels (and 
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therefore a theoretically milder clinical phenotype) cannot be predicted by the underlying 
BTK mutation (Table 5-34). 








Current IgA Current 
IgM 
Protein Domain for missense mutations 
PH Domain 3.4 (2.9 – 
4) 
0 (0 – 0.1) 0 (0 – 0.24) 0 (0 – 0.17) 0 (0 – 0.07) 
TH Domain N/A N/A N/A N/A N/A 
SH3 N/A N/A N/A N/A N/A 
SH2 0 (0 – 0) 0 (0 – 0.02) 0 (0 – 0) 0 (0 – 0) 0 (0 – 0) 
Kinase N/A N/A N/A 0.04 (0 – 
0.05) 
0 (0 – 0.12) 
p value 0.076 1.000 0.414 0.263 0.408 
Mutation severity (Broides et al., (368)) 
Mild 2.42 (0 – 
7.5) 
0 (0 – 0.34) 0.17 (0 – 
0.38) 
0 (0 – 0) 0 (0 – 0) 
Severe 0.14 (0 -
3.4) 
0 (0 – 0) 0 (0 – 0.02) 0 (0 – 0) 0 (0 – 0) 
p value 0.623 0.659 0.122 0.417 0.914 
Mutation type 
Missense 2.9 (0 – 
3.4) 
0 (0 – 0.02) 0 (0 – 0) 0 (0 – 0.05) 0 (0 – 0.04) 
Null 0.14 (0 – 
4.4) 
0 (0 – 0) 0 (0 – 0.09) 0 (0 – 0) 0 (0 – 0) 
p value 0.859 0.552 0.474 0.101 0.459 
5.15 Cost of therapy 
The mean annual cost of the immunoglobulin products per patient is £24, 171 (SD 9270).  
Being a weight-dependent product, the mean annual cost is higher for adults compared to 
paediatrics (£18, 276 vs £26, 137, p = 0.0253) (Table 5-35).   
The mean annual cost is higher for those patients on intravenous versus subcutaneous therapy 
(£26, 085 vs £19, 280, p = 0.0161). 
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Table 5-35 Cost of immunoglobulin therapy (£, mean (SD)) 
 Mean annual cost p-value 
All £24, 171 (9270)  
Paediatrics £18, 276 (13614) 0.025 
Adults £26, 137 (6528) 
Subcutaneous £19, 280 (6503) 0.016 
Intravenous £26, 084 (8403) 
No Bronchiectasis £21, 839 (2974) 0.181 
Bronchiectasis £26, 037 (6192) 
 
5.16 Summary of Clinical Results 
• The current median age of diagnosis for XLA in England and Wales was 2.97.  
This has improved with time.  However, when excluding those patients who were 
screened because of family history (and therefore relying upon clinical judgment 
alone), this trend does not reach statistical significance. 
• Bronchiectasis is a significant complication affecting nearly half the cohort.  This 
will be discussed in detail in the next chapter. 
• Twenty per cent of patients have GI complications, requiring endoscopic 
investigations.  These are a mixture of infectious and inflammatory (IBD/IBD like) 
diseases. 
• Patients still experience recurrent infections on IGRT, the vast majority of which 
are of the respiratory tract.   
• Twenty-two per cent of patients have chronic sinusitis. 
• Infection incidence is not significantly associated with IGRT dose, methods of 
delivery or IgG trough levels. 
• There is no correlation with gene mutation and clinical phenotype using a variety 
of analysis methods. 
• Eighteen per cent of patients have severe disease. 
• The degree of disease severity is not associated with infection incidence, IgG 




Chapter 6 Respiratory Health Results 
This chapter will examine the respiratory health of XLA patients.  As discussed in the 
literature review, the primary concern for clinicians is the development of bronchiectasis as a 
result of repeated infections.  This is especially pertinent given the potential limitations of 
current therapy discussed in this thesis thus far.  Each potential risk factor for developing 
bronchiectasis will first be described within its section.  The major determining factors will 
then be included in a time to event analysis. 
Progression of disease will be analysed through lung function results, HRCT results and the 
need for any surgical interventions. 
The primary respiratory outcome in this cohort is the development, or not, of bronchiectasis.  
As such, much of the comparisons and analysis within this chapter will be between these two 
subgroups to determine what, if any, are the determining risk factors for developing 
bronchiectasis in XLA 
6.1 Data Quality 
Approximately half of all potential follow up data was available and collected for both 
patients (n = 22) with and without bronchiectasis (n = 28) (Table 6-1).  The median data 
coverage tended to be higher for patients without bronchiectasis, although this only reached 
statistical significance for IgG trough data.  These differences are because patients without 
bronchiectasis tend to be younger (35.29 years versus 13.41 years) and, as such, it was easier 
to get access to their full clinical records. 
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Follow up (patient years) 568.77 446.80  
Available clinical information 
(years, %) 
321.37 (57%) 249.81 (56%)  
Median clinical information 
coverage per patient (%, IQR) 
51% (45 – 82) 100% (54 – 
100) 
0.072 
Available IgG trough levels 
(years, %) 
264.61 (47%) 277.73 (62%)   
Median IgG trough levels 
coverage per patient (%, IQR) 
58% (31 – 78) 99 (55 – 100) 0.012 
 
6.2 Respiratory Disease 
At the time of final data analysis (August 2018), 22 patients (44%) had bronchiectasis on 
HRCT.  A further nine patients (18%) had abnormal findings on HRCT (Figure 6-1).   
Four of these nine patients have bronchial wall thickening, three have small airway disease, 
and one has atelectasis.  While these findings could demonstrate post-infection changes and 
are therefore potentially reversible; they are also important potential precursors to 
bronchiectasis.  None of these eight patients has yet demonstrated a return to normality on 
HRCT.  The remaining patient previously had scarring on his HRCT because of repeated 
infections pre-diagnosis of his XLA resulting in a pneumonectomy in later adult life.  This 
necessitated further surgery at 32, with residual abnormal findings on his HRCT, but no 
formal diagnosis of bronchiectasis.  Overall, 31 (62%) have either bronchiectasis or abnormal 
findings on HRCT.  
Eight out of the fifty-one patients (16%) have never had an HRCT performed.  At last follow 
up, five of these were children under the age of five, where performing an HRCT would likely 
require a general anaesthetic or sedation.  It would, therefore, not be clinically justified to 
perform an HRCT in these patients unless there was a clear clinical indication.  The median 
age of the remaining three patients at last follow up was 21.30 years.    
Twenty out of thirty-two (63%) adults have bronchiectasis, and two out of 18 paediatric 
patients (11%) have bronchiectasis (p = 0.001). 
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Figure 6-1 Prevalence of abnormal HRCT findings on latest HRCT 
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6.3 Prevalence of Bronchiectasis 
The prevalence in 2018 of bronchiectasis within the XLA cohort in England and Wales was 
44%.  By looking back over time and diagnosis of bronchiectasis, it is possible to estimate the 
prevalence of bronchiectasis each year over time (Figure 6-2).  It would be expected that the 
prevalence of bronchiectasis would increase over this time, with an increasing number of 
patients now living long enough to develop the complication.  However, it may also be 
expected that if more recent improvements in care were decreasing the risk of bronchiectasis 
and overall survival continues to improve, then the prevalence would, at some moment in 
time, begin to plateau and decrease.  As of 2018, demonstrated in Figure 6-2, there is no 
plateau in the annual prevalence of bronchiectasis within the XLA cohort. 
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Figure 6-2 Annual prevalence of bronchiectasis within the XLA cohort 
 
The main risk factor for non-CF bronchiectasis (irrespective of the underlying diagnosis) is 
the burden of repeated infections (275).  Age, therefore, is a useful proxy for infection burden 
as a measure of risk for developing bronchiectasis over time.  This may overcome some of the 
limitations in trying to record and ascertain true infection incidence and take into account the 
burden of subclinical infections.  Figure 6-3 demonstrates an apparent increasing 
bronchiectasis prevalence within the cohort with increasing age groups with 62% of patients 
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Figure 6-3 Prevalence of bronchiectasis by age group 
































Kaplan-Meir analysis demonstrates a 50% risk of developing bronchiectasis by 32.50 years 
(95% CI 22.37 – 36.44) (Figure 6-4). 
Figure 6-4 Kaplan-Meir cumulative risk plot over time (age) 






















Prevalence of bronchiectasis is not significantly different amongst the centres according to 
where the patient is currently being treated (Table 6-2) (p = 0.130).  Data on previous centres, 
the patient may have been treated at was not available. 
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Table 6-2 Prevalence of bronchiectasis amongst the recruiting centres 
Centre Number and proportion of XLA patients 
with bronchiectasis 
Birmingham Heartlands 4, 66% 
Epsom & St Helier 3, 100% 
Great Ormond Street 1, 13% 
Manchester Royal 0, 0% 
Newcastle 9, 53% 
Royal Free Hospital 1, 33% 
Salford Royal Hospital 3, 50% 
Sheffield Hospital 1, 33% 
University Hospital Wales 0, 0% 
 
6.4 Current Demographics 
Patients with bronchiectasis were significantly older than patients without bronchiectasis and 
had a significantly longer follow up period (Table 6-3) 
XLA patients who were smokers or ex-smokers were significantly more likely to have 
bronchiectasis.  All current and ex-smokers had bronchiectasis.  
Patients with bronchiectasis were not more likely to have received previous intramuscular 
immunoglobulin therapy (IMIg), report a history of serious disease pre-diagnosis of XLA or 




Table 6-3 Baseline characteristics of those patients with and without bronchiectasis 
(median (IQR)) 
 Bronchiectasis No Bronchiectasis p-value 
Age (years) 35.29 (26.12 – 41.15) 13.41 (5.55 – 31.05) 0.001 
Follow Up (years) 25.59 (20.60 – 35.18) 10.43 (4.40 – 26.60) 0.012 
Smoking (n) 
Smoker 2 0 0.006 
Ex-smoker 4 0 
Non-Smoker 16 26 
Ever IM therapy (Yes, %) 23% 14% 0.481 
Screened (Yes, %) 9% 25% 0.266 
Serious disease pre XLA 
diagnosis (Yes, %) 
47% 33% 0.505 
 
Patients with bronchiectasis were diagnosed with their XLA significantly later than those 
without (3.71 years versus 1.09 years p = 0.002) (Figure 6-5).  However, due to improvements 
in reducing the age of diagnosis over time (demonstrated in Chapter 5), patients without 
bronchiectasis were also significantly younger at last follow up.  It is, therefore, possible that 
patients who currently do not have bronchiectasis have not yet had enough time (and 
therefore, exposure to risk) to develop bronchiectasis. 
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6.5 Age of onset 
The gold standard for diagnosis of bronchiectasis is by HRCT.  Age of onset is defined as the 
time of the first HRCT to detect bronchiectasis. 
Seventeen patients had bronchiectasis diagnosed on their first HRCT (77% of all patients with 
bronchiectasis).  There will be a lag from the actual clinical onset of bronchiectasis to 
diagnosis, due to delays in recognising symptoms and arranging an HRCT to diagnose 
bronchiectasis.  Therefore, as described in the methods, to compensate for some of this lag, 
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patients who had bronchiectasis demonstrated on their first HRCT and within 12 months of 
their XLA diagnosis, it was assumed their bronchiectasis onset was present at the time of their 
XLA diagnosis.  In this cohort, three patients fulfilled these criteria.  As such, for all future 
analyses, the onset of bronchiectasis for these patients was equal to their XLA diagnosis. 
For the 14 patients who were diagnosed with bronchiectasis on their first HRCT, but more 
than 12 months after their XLA diagnosis, the median age of bronchiectasis onset was 24.58 
years (IQR 15.67 – 34.63).  The median follow up time from their XLA diagnosis to 
bronchiectasis onset for these 14 patients was 13.77 years (IQR 4.70 – 21.00).  No patient was 
diagnosed with bronchiectasis before the diagnosis of his XLA. 
The median age of onset of bronchiectasis was 21.97 years (Table 6-4).  The median time 
from XLA diagnosis to the onset of bronchiectasis was 13.15 years.  Patients with 
bronchiectasis are significantly older and have a significantly longer follow up (Table 6-4).  
Table 6-4 Age at and time to diagnosis and onset of bronchiectasis (years, median (IQR)) 
Variable Bronchiectasis No Bronchiectasis p-value 
Age of onset 21.97 (14.55 – 32.51)   
Follow up period until 
bronchiectasis 
13.15 (3.00 – 21.00)   
Bronchiectasis on first 
HRCT (n) 
8   
Current Age 35.29 (26.12 – 41.15) 13.41 (5.55 – 31.05) 0.001 
Current Follow up 25.59 (20.60 – 35.18) 10.43 (4.40 – 26.60) 0.012 
Age at diagnosis 3.71 (2.00 – 8.38) 1.09 (0.55 – 3.30) 0.002 
Time from XLA to first 
HRCT 
18.44 (9.90 – 26.73) 7.52 (2.78 – 17.27) 0.055 
 
Age at diagnosis of bronchiectasis has significantly decreased over time (Spearman’s rho = -
0.758, p <0.001) (Figure 6-6).  Rather than the actual onset of bronchiectasis decreasing over 
time, this most likely represents a greater awareness for bronchiectasis and easier access to 
HRCT.  This supported by decreasing time to first HRCT after diagnosis of XLA over time 
(Spearman’s rho = -8.05, p < 0.001) (Figure 6-6). 
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Figure 6-6 Age of onset of bronchiectasis and time to first HRCT over time 































































6.6 Infections on IGRT 
Similar to the previous chapter, aside from infections of the respiratory tract, the overall raw 
number of infections recorded is displayed for illustration purposes due to the rarity of these 
infections.  Where comparing for statistically analyses, it is the annual infection incidence 
being compared unless stated otherwise 
There were no significant differences in the lifetime median annual infection incidence 
comparing patients with and without bronchiectasis (1.03 versus 1.24) (p = 0.856) (Table 6-5) 
(Figure 6-7).   
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As bronchiectasis itself will increase the susceptibility to infections, infections were separated 
before and after the development of bronchiectasis.  The median annual infection incidence 
for current healthy patients was first compared to patients with bronchiectasis, but only in 
their pre-bronchiectasis period (1.24 versus 0.85, p = 0.206).  For patients with bronchiectasis, 
their pre bronchiectasis period was then compared to their post bronchiectasis period and 
found no significant differences in annual infection incidence (0.85 versus 0.99, p = 0.346) 
(Figure 6-7) (Table 6-5). 































































With respiratory tract infections being the main infection risk, these had a further analysis.  
No significant differences were found in median annual respiratory tract infection rates for 
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patients currently with or without bronchiectasis (0.80 versus 0.88, p = 0.856) (Table 6-5).  
There were no differences in current healthy patients compared to patients with bronchiectasis 
in their pre-bronchiectasis period values (0.88 versus 0.74, p = 0.201).  There were no 
significant differences when comparing median annual respiratory tract infection rates in 
patients’ pre-bronchiectasis periods compared to their post bronchiectasis periods (0.74 versus 
0.85, p = 0.347) (Table 6-5) (Figure 6-8). 
As discussed within the methodology, the diagnosis of bronchiectasis is made on HRCT.  It 
is, therefore, possible that due to the interval between HRCT scans, that there is a lag from 
true clinical onset of bronchiectasis to the HRCT diagnosis.  The analysis of infection 
incidence data was therefore done with adjustments made to the age of bronchiectasis 




Figure 6-8 Annual respiratory tract infection incidence.  (Vertical scatterplot, median 
and IQR) 




















































































Table 6-5 Annual infection incidence (median (IQR)).  ($Bronchiectasis versus none #pre versus post bronchiectasis ^no bronchiectasis 
versus pre-bronchiectasis) 
 
No Bronchiectasis Ever Bronchiectasis   
Total p 
value$ 
Pre-Bronchiectasis Bronchiectasis p 
value# 
p value^ 
All infections 1.24 (0.68-1.97) 1.03 (0.80-1.48) 0.856 0.85 (0.66-1.06) 0.99 (0.80-1.84) 0.347 0.206 
Respiratory tract infections 0.88 (0.45 - 1.89) 0.80 (0.53 - 1.27) 0.856 0.74 (0.35 - 1.01) 0.85 (0.48 - 1.85) 0.347 0.201 
Lower respiratory infections 0.76 (0.34-1.87) 0.79 (0.53-1.27) 0.904 0.74 (0.35-1.01) 0.80 (0.48-1.84) 0.410 0.377 
Sinus infections 0.00 (0.00-0.03) 0.00 (0.00-0.04) 0.836 0.00 (0.00-0.00) 0.00 (0.00-0.04) 0.084 0.056 
Otitis infections 0.00 (0.00-0.00) 0.00 (0.00-0.06) 0.123 0.00 (0.00-0.11) 0.00 (0.00-0.00) 0.047 0.102 
Totals 
Skin infections 8 9 0.474 3 6 0.791 0.518 
Eye infections 9 16 0.278 0 16 0.158 0.166 
GI infections 5 2 0.549 2 0 0.158 0.884 
CNS infections 0 0 NA 0 0 NA NA 
Bone and Joint infections 0 0 NA 0 0 NA NA 
Sepsis 1 0 0.367 0 0 NA 0.505 
GU infections 6 5 0.620 4 1 0.256 0.357 
Other infections 3 1 0.397 0 1 0.317 0.236 
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6.7 Time to event analysis 
A Kaplan-Meir failure plot demonstrates a 50% risk of bronchiectasis by 32.51 years.  The 
analysis above demonstrates that patients without bronchiectasis were diagnosed with XLA 
significantly younger than patients with bronchiectasis.  However, they were also 
significantly younger and may not have had enough time (and therefore, exposure to 
infection) to develop bronchiectasis at last follow up.  Also, the previous analysis has 
demonstrated that there were no significant differences in infection rates for patients with and 
without bronchiectasis.  Data are now presented from a time to event analysis to analyse 
further the potential risk factors leading to the development of bronchiectasis.  Individual 
factors were first assessed by univariate analyses (log-rank test of equality for categorical 
variables and Cox proportional hazard model with a single predictor for continuous variables) 
before integrating to a final time to event analysis   
6.7.1 Asymptomatic screening 
First, patients were analysed based on whether they were screened asymptomatically due to 
family history (a proxy for newborn screening).  This did not show any significant 
differences in the development of bronchiectasis (p = 0.621). 
Figure 6-9 Kaplan-Meir failure plot for bronchiectasis by asymptomatic screening 
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6.7.2 Age of diagnosis 
Age of diagnosis was analysed in two ways.  It was modelled as a continuous variable (Table 
6-6).  Due to the small sample size, it was also analysed a categorical variable, representing 
early or late diagnosis.  The current median age of diagnosis in this study was 2.60 years 
which is tending to improve with time, as shown in Chapter 5.  After discussion with 
immunology specialist and general paediatricians regarding what would be considered an 
early diagnosis, a cut off of 2 years was chosen.  This was felt to be an ambitious but realistic 
target.  Targeting an earlier diagnosis based on clinical diagnosis was felt to be unrealistic 
given the difficulties facing clinicians in identifying the child with antibody deficiency 
against the backdrop of the healthy background population and the normal pattern of 
childhood infections.  Being diagnosed before the age of two was associated with a decreased 
risk of developing bronchiectasis but did not reach statistical significance (p = 0.071) (Figure 
6-10). 
Figure 6-10 Kaplan-Meir failure plot for bronchiectasis by early or late diagnosis 
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6.7.3 Continuous variables 
The following were analysed by Cox proportional hazard model. 
Table 6-6 Univariate analyses for continuous variables on the risk of bronchiectasis 
Variable Hazard 
ratio 
p-value 95% Confidence 
Interval 
Age 0.952 0.047 0.910, 0.999 
Lifetime median IgG trough level  0.938 0.563 0.754, 1.167 
Lifetime median annual respiratory 
tract infection incidence 
1.604 0.064 0.973, 2.645 
Age at Diagnosis 1.01 0.745 0.966, 1.05 
First recorded FEV Z Score  0.684 0.037 0.478, 0.978 
 
6.7.4 Time to event model 
The variables were then included into a final time to event analysis.  Due to the small sample 
size, as described previously, age at diagnosis was not included.  Instead, age at diagnosis 
was coded as a categorical variable based on a cut-off of 2 years. 







Age 0.940 0.066 0.881, 1.00 
Diagnosed before 2 years of age 0.588 0.514 0.120, 2.895 
Lifetime median annual respiratory tract 
infection incidence 
1.197 0.691 0.493, 2.903 
Lifetime median IgG trough level 0.837 0.310 0.593, 1.180 
First recorded FEV Z Score 0.716 0.249 0.406, 1.262 
 
As demonstrated in Table 6-7, in the multivariate analysis, there was no significant 
association between the variables and the risk of bronchiectasis.  Unexpectedly, increasing 
age was close to being significantly associated with a decreasing risk of bronchiectasis.  
However, due to better access to HRCT, the formal age of diagnosis of bronchiectasis has 
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decreased in recent years.  This likely means it is difficult to analyse the risk of 
bronchiectasis with age thoroughly.   
Patients diagnosed at under two years of age were also found to have a significantly lower 
risk of developing bronchiectasis in the univariate but not multivariate analysis.  As described 
early, patients with an earlier diagnosis are also more likely to be diagnosed more recently.  
Therefore, they will also benefit from overall improvements in clinical care for PID (459).  
6.8 Immunology 
There were no statistically significant differences in latest IgA, IgM or CD19/20 B-
lymphocyte numbers investigations between patients with and without bronchiectasis (Table 
6-8).  However, patients with bronchiectasis had lower current IgG trough level than those 
without bronchiectasis (p = 0.040). 
Table 6-8 Latest immunology investigations (median (IQR)) 
 Bronchiectasis No bronchiectasis p-value 
IgA (g/L) 0 (0 - 0) 0 (0 – 0) 0.948 
IgM (g/L) 0 (0 – 0) 0 (0 – 0) 0.134 
Trough IgG (g/L) 9.40 (8.40 – 10.10) 10.80 (9.40 – 12.50) 0.040 
CD19/20 
(cells/mcL) 
0 (0 – 0) 0 (0 – 0.5) 0.356 
 
There was no statistically significant difference in the initial diagnostic immunology 
investigations between patients with and without bronchiectasis.  These data were available 
for 19 patients (Table 6-9). 
Table 6-9 Initial diagnostic immunology investigations (median (IQR)) 
 Bronchiectasis No bronchiectasis p-value 
IgA (g/L) 0 (0 – 0.1) 0 (0 – 0) 0.389 
IgM (g/L) 0 (0 – 0.17) 0 (0 – 0.08) 0.919 
Trough IgG (g/L) 1.21 (0 – 2.90) 0.17 (0 – 5.87) 0.524 
CD19/20 
(cells/mcL) 




6.8.1 BTK expression 
Patients with bronchiectasis were not more likely to have absent BTK expression compared 
to patients without bronchiectasis (p = 0.565). 
Table 6-10 BTK expression in the two groups 
 Bronchiectasis (n) No bronchiectasis (n) p-value 
Absent 10 9 0.565 
Reduced 0 2 
Normal 3 3 
6.8.2 Genetic mutations 
There were no significant differences in the number of patients with bronchiectasis amongst 
difference classifications of mutation severity/type (Table 6-11). 
Table 6-11 Rates of bronchiectasis amongst different mutation severity classifications 
 Bronchiectasis (n) No bronchiectasis 
(n) 
p value 
Broides et al., Mutation Severity (368) 
Mild  4 8 0.504 
Severe 12 14 
Protein Domain for Missense mutations 
PH Domain 3 5 1.000 
TH Domain 0 0 
SH3 3 3 
SH2 2 3 
Kinase 4 5 
Mutation Type 
Missense 6 6 0.725 
Null 10 16 
6.9 Microbiology 
Sputum microbiology within the last 12 months was available for 34 patients (24 with 
bronchiectasis and ten without).  There were no significant differences in the growth cultures 
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between those with and those without bronchiectasis (p = 0.330).  The overall majority of 
cultures grew H. influenzae. (76%) (Table 6-12). 
Table 6-12 Latest sputum microbiology 
Organism All (n) Bronchiectasis (n) No bronchiectasis (n) 
H. Influenzae 26 20 6 
Moraxella 2 0 2 
Regional flora 2 2 2 
No growth 2 2 0 
 
Focusing on H. influenzae, 66% of the sputum samples taken above were during a presumed 
acute infective episode.  The remaining 34% were taken because of ongoing monitoring or 
investigation of chronic symptoms.  Twenty-three percent of H. influenzae cultures were 
resistant to either amoxicillin or co-amoxiclav, although no H. influenzae was resistant to 
both (Table 6-13).   H. influenzae resistance to doxycycline was low at 8% with 85% 
reporting as being sensitive to doxycycline.   
Table 6-13 Sputum samples antibiotic sensitivities 
Antibiotic Sensitive (n, %) Resistant (n, %) 
Amoxicillin 12 (46%) 6 (23%) 
Co-amoxiclav 6 (23%) 6 (23%) 
Doxycycline 22 (85%) 2 (8%) 
 
6.10 High-Resolution Computerised Topography 
6.10.1 Monitoring of lung disease 
The median time from XLA diagnosis to first HRCT was 6.45 years at a median age of 11.57 
years (Table 6-14).  For patients who currently had bronchiectasis their median time to first 
HRCT after diagnosis was 8.34 years and for those without 6.08 (p = 0.756).  The age at first 
HRCT was 18.21 years and 7.53, respectively (p = 0.031).  Again, patients without 
bronchiectasis were younger and therefore may have benefited from easier access to HRCT 
in recent years. 
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Table 6-14 Timing and intervals for HRCT (years, median (IQR)) 
 All No bronchiectasis Bronchiectasis p value 
Age of first HRCT 11.57 (5.74 – 
27.64). 
7.53 (4.17 – 18.51) 18.21 (8.60 – 
35.84) 
0.031 
Time to first HRCT 
from XLA diagnosis 
6.45 (2.06 – 
19.16) 





8.05 (5.69 – 
14.70) 
14.70 (6.41 – 
19.20) 
7.75 (4.16 – 8.82) 0.063 
 
Excluding those patients who have never had an HRCT, the median number of HRCT scans 
per patient over the available data period was one. For patients, without bronchiectasis, this 
was also one and with bronchiectasis, three (p = 0.017).  The median interval between HRCT 
for those who have more than one HRCT was 8.05 years.  This was not significantly different 
comparing those with and without bronchiectasis, but patients with bronchiectasis tended to 
have more frequent HRCT than those patients without bronchiectasis (Table 6-14).  
6.10.2 Progression of bronchiectasis on HRCT 
Excluding those patients whose bronchiectasis progressed to such a degree of severity, they 
required cardiothoracic surgery; three patients demonstrated a progression of their 
bronchiectasis on HRCT.  This is over a median time of 11.38 years from diagnosis of 
bronchiectasis to the time of data collection.  A further three patients required surgery 
because of the degree of progression of their bronchiectasis.  These patients will be discussed 
in further detail in 6.14.3.  Therefore, 16 patients (73% of those with bronchiectasis) 
demonstrated no progression of their lung disease on HRCT. 
6.11 Lung Function 
For lung function analysis, data were first presented regarding monitoring in XLA.  To assess 
disease severity and progression of lung disease based on lung function, the first recorded and 
latest lung function test results were compared.  Changes in lung function over time are then 
analysed using a multilevel mixed model analysis. 




The median time from XLA diagnosis to first lung function testing did not differ significantly 
for patients with and without bronchiectasis (10.88 versus 8.76 years, p = 0.637) (Table 
6-15).  The age of first lung function testing, however, was significantly younger for those 
patients without bronchiectasis (10.30 versus 19.48 years old, p = 0.02).  As described 
previously, patients without bronchiectasis are more likely to have been diagnosed more 
recently and therefore benefiting from improved clinical care to perform lung function testing 
at earlier ages (460).  The median time between lung function testing was 5.40 years between 
the two groups and was not significantly different.      
Table 6-15 Frequency and timing of pulmonary function testing (years, median (IQR)) 
 
All patients Patients with 
bronchiectasis  





4 (2 – 6.5) 5 (3 – 8) 3 (1 – 5) 0.0382 
Time to First 
LFT 
9.14 (5.08 – 
20.34) 
10.88 (4.12 – 
20.55) 
8.76 (6.01 – 16.68) 0.637 
Age of first 
LFT 
16.67 (9.48 – 
22.55) 
19.48 (12.87 – 
34.03) 
10.30 (6.75 – 17.52) 0.020 
Frequency of 
LFT  
5.40 (2.61-8.97) 6.65 (2.61-12.08) 5.51 (3.00-9.25) 0.493 
 
Patients with bronchiectasis had significantly lower first recorded FEV1, FVC and FEV: 
FVC Z-scores compared to patients without bronchiectasis (Table 6-16).  In keeping with 
their diagnosis, the latest FEV1, FVC and FEV: FVC Z-scores are also significantly lower for 
patients with bronchiectasis compared to those without.
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Table 6-16 First and latest pulmonary function.  (median (IQR)) 
 
All Patients Bronchiectasis No bronchiectasis p-value 
FEV1 
Starting FEV1 % predicted 82.08 (70.67 - 97.15) 71.66 (53.05 - 79.92) 97.15 (88.31 - 102.75) 0.000 
Latest FEV1 % predicted 85.87 (67.25 - 101.54) 74.43 (44.69 - 89.15) 94.43 (82.08 - 102.75) 0.003 
Starting FEV1 Z-score -1.47 (-2.50 - -0.25) -2.41 (-3.82 - -1.63) -0.25 (-1.02 - 0.21) 0.000 
Latest FEV1 Z-score -1.23 (-2.73 - 0.13) -2.26 (-3.97 - -0.93) -0.45 (-1.37 - 0.21) 0.004 
FVC 
Starting FVC % predicted 90.80 (75.38 - 99.45) 76.70 (68.91 - 88.04) 99.18 (91.42 - 104.56) 0.002 
Latest FVC % predicted 89.68 (76.37 - 104.56) 79.02 (61.11 - 89.68) 96.77 (91.21 - 104.73) 0.007 
Starting FVC Z-score -0.80 (-2.10 - -0.04) -2.00 (-2.65 - -1.02) -0.07 (-0.73 - 0.37) 0.002 
Latest FVC Z-score -0.87 (-1.95 - 0.37) -1.64 (-3.08 - -0.87) -0.26 (-0.68 - 0.39) 0.001 
FEV: FVC Ratio 
Starting FEV:FVC Z-score -0.81 (-2.24 - 0.72) -1.41 (-2.73 - -0.33) -0.32 (-1.48 - 1.01) 0.028 







Patients with bronchiectasis have significantly worse lung function compared to patients 
without bronchiectasis for FEV1, FVC and FEV: FVC ratio.  Also, the first recorded lung 
function scores are significantly worse for patients with bronchiectasis (Table 6-16).  Due to 
limitations in data collection, some of these first recorded results may have been at a time 
when the patient already had bronchiectasis.  Therefore, analyses were then carried out only 
using starting lung function results in the documented absence of bronchiectasis (Table 6-17). 
Table 6-17 First recorded lung function Z-score results in the absence of bronchiectasis 
(median (IQR)) 
 No Bronchiectasis Bronchiectasis p-value 
ZFEV1 -0.25 (-1.02 – 0.21) -2.38 (-3.26 - -1.47) 0.002 
ZFVC -0.07 (-0.73 – 0.37) -1.92 (-2.88 - -0.66) 0.013 
ZFEV: FVC -0.32 (-1.48 – 1.01) -0.97 (-2.70 – 0.11) 0.137 
 
Initial ZFEV1 and ZFVC scores were still significantly lower for patients who would later go 
on to develop bronchiectasis compared to those who are currently healthy, even when strictly 
only including those who did not have bronchiectasis and presumed, clinically, to have 
normal lung health. 
There were no significant differences between the first and latest FEV1 Z-scores (Figure 
6-11), FVC Z-scores (Figure 6-12) or FEV: FVC Z-scores (Figure 6-13) indicating an 
element of stability in lung disease in patients both with and without bronchiectasis.  This 




Figure 6-11 First and last recorded FEV1 Z-scores.  (Scatterplot, median and IQR).  
Dotted line represents the lower limit of normal 
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Figure 6-12 First and last recorded FVC Z-scores.  (Scatterplot, median and IQR).  
Dotted line represents the lower limit of normal 
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Figure 6-13 First and last recorded FEV1: FVC Z-scores.  (Scatterplot, median and 
IQR).  Dotted line represents the lower limit of normal 
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6.11.1 Longitudinal Data 
A multilevel mixed model analysis was used to analyse the longitudinal changes in lung 
function over time (age) (Table 6-18).  The model below was based on the hypothesis that 
increasing age and an increasing number of infections would be associated with a declining 
lung function.  An additional hypothesis proposed that delayed diagnosis may result in 
increasing lung damage due to repeated infections while not being not on IGRT.  Therefore, 
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age at diagnosis was also included in the model.  Proposing that any decline in lung function 
may not be linear, a quadratic function of age was also added to give a second-degree 
polynomial.  The model below converges after two iterations.  On average, the presence of 
bronchiectasis was associated with an FEV1 Z score 1.11 lower than those patients without 
bronchiectasis.  An increasing lifetime median annual respiratory tract infection incidence 
was also associated with lower FEV1 Z scores.  Neither age nor the quadratic function of age 
had a significant coefficient.  This would be in keeping with the simpler analysis above, 
suggesting a degree of stability in lung function over time in this cohort.  Increasing age at 
diagnosis was not associated with decreasing FEV1 Z-scores. 
Table 6-18 Multilevel mixed model analysis of FEV1 Z-scores 
 Coefficient p value 95% CI 
Age 0.00 0.875 -0.08, 0.09 
Age (Quadratic) 0.00 0.353 0.00, 0.00 
Bronchiectasis -1.11 0.009 -1.96, -0.28 
Median respiratory tract 
infection incidence 
-0.73 0.001 -1.18, -0.28 
Age at diagnosis -0.04 0.630 -0.90, 1.49 
Random effects 
 Estimate  95% CI 
SD (Age) 0.09  0.06, 0.12 
SD (_cons) 1.76  1.25, 2.47 
  
6.12 IGRT therapy 
6.12.1 Place and site of therapy 
There were no significant differences in route of IGRT (p = 0.442) or place of IGRT (p = 
0.650) based on the presence of bronchiectasis or not. 
6.12.2 Doses and IgG trough levels 
There were no significant differences between current IGRT doses or lifetime IgG trough 
levels for patients with and without bronchiectasis (Table 6-19).  However, patients with 
bronchiectasis currently have significantly lower IgG trough levels compared to patients 
without bronchiectasis (9.40 g/L versus 10.80 g/L, p = 0.040). 
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As discussed in Chapter 5, the standard deviation of the annual mean IgG trough levels was 
also analysed for any association with the development of bronchiectasis as a proxy for 
treatment compliance/stability.  There were no significant differences in the standard 
deviation of yearly median IgG trough levels for patients with and without bronchiectasis. 
Table 6-19 Latest IGRT doses (mg/Kg/month), median lifetime and latest IgG trough 
levels (g/L) and SD of annual median IgG trough levels (median (IQR)) 
 Bronchiectasis No bronchiectasis  p-value 
Current IGRT dose 532 (469 – 644) 596 (490 – 696) 0.572 
Latest IgG trough 
levels 
9.40 (8.40 – 10.10) 10.80 (9.40 – 12.50) 0.040 
Lifetime median IgG 
trough level 
9.30 (8.05 – 10.60) 9.37 (8.34 – 10.82) 0.662 
SD of yearly median 
IgG trough levels 
1.44 (1.04 – 2.14) 1.44 (0.92 – 2.09) 0.939 
 
While analysing patients who currently have bronchiectasis, but in their ‘pre-bronchiectasis 
period, their IgG trough levels are not significantly different from patients who currently have 
no bronchiectasis (p = 0.125) (Figure 6-14).  After patients develop bronchiectasis, their IgG 
trough levels tended to be higher (8.01 g/L versus 9.88g/L), but these did not reach statistical 
significance (p = 0.086).  
As for the infection incidence data, the analysis of IgG trough data was done with 
adjustments made to the age of bronchiectasis diagnosis of minus 1, 3 and 5 years.  In each 
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6.13 Other therapies 
Twenty percent of patients with bronchiectasis were receiving physiotherapy as part of their 
current therapy, either directed or self-administered.  Seven percent of patients without 
bronchiectasis also received some form of physiotherapy. 
Twelve patients (55%) of those with bronchiectasis are currently prescribed prophylactic 
antibiotics.  Prophylactic antibiotics were discussed in Chapter 5 (5.12). 
6.14 Bronchiectasis severity  
6.14.1 Bronchiectasis severity index (BSI) 
Figure 6-15 BSI for the cohort 
BSI Score Number (n) Per cent 
0-4 19 86% 
5-8 3 14% 
 
Eighty-six percent of patients with bronchiectasis had a BSI score of 0-4, and 14% had a 
score 5-8.  A BSI score of 0-4 is predicted to have a 4-year mortality of 0 -5.3% and a score 
of 5-8 is predicted to have a 4-year mortality of 4 – 11.3% (309,417).  As expected, an 
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increased BSI score correlate strongly with worsening lung function (ρ = -0.690, p = 0.002).  
BSI scores did tend to increase with age, although this correlation was not statistically 
significant (ρ = 0.400, p = 0.067). 
6.14.2 FACED scoring of bronchiectasis severity 
Table 6-20 FACED bronchiectasis severity scores 
Bronchiectasis Severity Number Percentage 
Mild 17 77% 
Moderate 4 18% 
Severe 1 5% 
 
Seventy-seven percent of patients with bronchiectasis had mild bronchiectasis as scored by 
the FACED bronchiectasis severity score (Table 6-20). Twenty-three percent had moderate or 
severe bronchiectasis.  Similar to the BSI, an increasing FACED score was associated with 
worsening lung function (ρ = -0.734, p = 0.001).  However, FACED scores were not 
correlated with age (ρ = 0.147, p = 0.515).  BSI scores and FACED scores strongly correlated 
(ρ = 0.538, p = 0.010). 
6.14.3 Surgical intervention 
Three patients have required surgical intervention for their bronchiectasis.  Two patients have 
had pneumonectomies at ages 8 and 18 years.  One further patient has required a bilateral 
lung transplant at the age of 32.  These patients are defined as having severe disease as per 
the definitions in Chapter 4.  As analysed in Chapter 5, patients with severe disease have no 
significant difference in clinical or immune phenotype. 
6.15 Conclusions 
• Bronchiectasis remains the major complication for XLA patients, affecting approximately 
half the cohort 
• There have been significant improvements in monitoring for bronchiectasis, demonstrated 
by a significant decline in the age of bronchiectasis onset 
• There were no significant associations with IgG trough levels or infection incidence and 
the risk of developing bronchiectasis. 
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• Being diagnosed before the age of 2 years may be associated with a significantly lower 
risk of developing bronchiectasis. 
• The prevalence of bronchiectasis within the XLA cohort has not yet begun to reduce 
• Initial lung function testing for patients who would later go on to develop bronchiectasis 
was significantly lower than patients who have no current evidence of bronchiectasis.  
This may suggest a significant amount of lung damage has occurred before the diagnosis 
of XLA or shortly after that.  It may be that, for these patients, the development of 
bronchiectasis is almost inevitable. 
• For a small number of patients, their bronchiectasis severity progresses to such a degree 
that radical intervention is needed. 
o However, for the majority of patients, lung function remains stable over time, 
albeit remaining abnormal in those patients with bronchiectasis. 
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Chapter 7 Results – Psychological Health 
This chapter will present the data pertaining to the psychological health and its related quality 
of life in the XLA cohort. 
7.1   Diagnosis 
Twelve patients (24%) have a history of a formally diagnosed mental health condition, of 
which six have resolved.  At last follow up, five patients reported a history of anxiety, five 
reported depression and two reported anxiety and depression.  Although direct access to 
mental health records was not possible, three of these patients report their mental health 
issues are as a direct result of concerns regarding their prognosis and current clinical status. 
7.2 SF36v2 MCS scores 
SF36v2 contains domains scoring the quality of life-related to psychological health and 
mental health wellbeing (441).  These scores were compared against UK norms (431) and 
UK patients with CF (432).  Comparisons were also made between XLA patients with and 
without bronchiectasis.  There are four subdomains; energy/vitality, social functioning, role 
(mental), mental health.  These domains are common across both version 1 and version 2 of 
the SF36.  Version 2 of the SF36 combines these domains to produce an overall MCS.  The 
UK CF data derives from version 1 of the SF36, and there is, therefore, no MCS available for 
this dataset. 
The SF36v2 was filled by 30 adults (91% of the adult study participants). 
7.2.1 SF36v2 MCS scores versus UK norms and CF patients 
Scores for the SF36v2 subdomains and overall MCS for the cohort versus UK norms and 
patients with cystic fibrosis are shown in Table 7-1.  Only mean and standard deviation (SD) 
values were available for the UK and CF data.  However, presuming these data were 
normally distributed, the corresponding median value would be similar to the mean and 
therefore could be compared against the median values for the XLA patients.  The mean and 
SD for the XLA data is also presented for comparison. There were no significant differences 
in any domain comparing XLA patients against UK norms.  There were no significant 
differences comparing XLA patients against UK CF patients, except for the mental role 
subdomain scores, which were significantly higher for XLA patients. 
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7.2.2 SF36v2 scores for patients with bronchiectasis 
There was no difference between XLA patients with bronchiectasis and those without aside 
from social functioning scores, which were significantly lower for XLA patients with 
bronchiectasis (Table 7-2).  There were no significant differences in the SF36v2 
psychological health-related QoL scores comparing XLA patients with bronchiectasis against 
healthy UK male norms and UK male CF patients.  Scores for the mental health subdomain 
did tend to be lower for XLA patients with bronchiectasis compared against UK male CF 
patients, but this did not reach statistical significance.
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Table 7-1 SF36v2 MCS scores for the cohort (median (IQR)) compared to UK norms and UK patients with cystic fibrosis (mean (SD)). $ 
Data not available 































47.50 (10.03) 51.16 (9.34) 0.307 $ N/A 
Table 7-2 SF36v2 MCS scores for the cohort (median (IQR)), comparing bronchiectasis versus no bronchiectasis, UK norms and UK CF 
patients.  $ Data not available 
Component Bronchiectasis No bronchiectasis p-value Versus male UK 
norms 
Versus male UK CF 
patients 
Energy/Vitality 50.00 (43.75- 62.50) 62.50 (46.88 - 71.88) 0.394 0.277 0.277 
Social Functioning 75.00 (62.50- 100.00) 100.00 (93.75 - 100.00) 0.045 0.275 0.275 
Role-Mental 91.67 (83.33- 100.00) 91.67 (79.17 - 100.00) 0.910 0.972 0.273 
Mental Health 65.00 (55.00- 80.00) 72.50 (65.00 - 85.00) 0.342 0.151 0.054 
MCS 46.59 (44.29 - 54.72) 52.47 (42.58 - 54.30) 0.612 0.173 $ 
168 
 
7.2.3 Association of SF36v2 mental health scores and disease severity 
There were no significant differences in SF36v2 psychological health scores across disease severity groups.  Patients with severe disease tended 
to report lower scores in all domains, particularly mental health, but these differences did not reach statistical significance (Table 7-3). 
Table 7-3 Short Form 36 version 2 scores and disease severity (median (IQR)) 
 Asymptomatic Mild Moderate Severe p-value 
Energy/Vitality 81.25 (62.5 – 100.00) 62.50 (31.25 – 62.50) 56.25 (50.00 – 75.50) 40.63 (18.75 - 
62.50) 
0.377 
Social Functioning 93.75 (87.50 – 100.00) 100.00 (100.00 – 
100.00) 
87.50 (75.00 – 100.00) 31.25 (23.00 – 
68.75) 
0.132 
Role-Mental 95.84 (91.67 - 100.00) 83.33 (75.00 – 91.67) 100.00 (83.3 – 100.00) 83.33 (50 – 91.67) 0.443 
Mental Health 95.00 (90.00 – 100.00) 65.00 (65.00 – 70.00) 72.50 (65.00 – 85.00) 57.50 (40.00 – 
67.50) 
0.057 







7.2.4 Correlation of SF36v2 psychological health scores and clinical status 
There was no correlation between the patient’s current overall mental component score and 
their clinical status or phenotype (Table 7-4). 
Table 7-4 Correlation of short-form 36 version 2 MCS and clinical outcomes and 
phenotype.  Spearman’s rho and p values shown. 
 Spearman’s ρ p-value 
Age  0.239 0.297 
Age at diagnosis 0.003 0.991 
Annual infection incidence -0.188 0.414 
Latest FEV1 Z-Score 0.191 0.513 
 
7.3 SDQ Scores 
The SDQ was filled in by nine children and seventeen parents (81% of paediatric patients).  
SDQ scores were compared against healthy UK male normative data (449).  SDQ scores 
were not compared for those children with and without bronchiectasis due to the small 
numbers with bronchiectasis who completed the SDQ (n = 1).   Excluding this one patient did 
not make any differences to the results. 
7.3.1 SDQ scores versus UK norms 
There were no significant differences in the SDQ subdomains or the total SDQ score 
compared to healthy UK male norms.  This applied to both self-reported and parent-reported 
scores (Table 7-5) 
For the UK norm data, only mean and standard deviation (SD) values were available.  
However, presuming these data were normally distributed; it has been assumed the median 
value is similar to the mean and therefore can be compared against the median for the XLA 
data.  The mean and SD values for the XLA data is included for comparison. 
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Table 7-5 SDQ scores for the cohort (median (IQR)) versus UK norms (mean (SD)) (449) 
Component Cohort (median, IQR) Cohort (mean, SD) UK norms p-value 
Self-Scores 
Emotional Score 2.00 (1.00 - 4.00) 2.43 (2.07) 2.6 (1.9) 0.513 
Conduct Score 1.00 (1.00 - 3.00) 1.43 (1.72) 2.4 (1.7) 0.513 
Hyperactivity Score 4.00 (3.00 - 5.00) 3.71 (1.38) 3.9 (2.2) 0.439 
Peer Score 0.00 (0.00 - 3.00) 1.14 (2.04) 1.6 (1.4) 0.582 
Prosocial Score 8.00 (7.00 - 9.00) 8.43 (0.98) 7.5 (1.7) 0.509 
Impact Score 0.00 (0.00 – 0.00) 0.29 (0.76) 0.3 (0.8) 0.492 
Total Score 9.00 (5.00 – 14.00) 8.71 (4.46) 10.5 (5.1) 0.634 
Parent Scores 
Emotional Score 2.00 (1.00 - 4.00) 2.58 (1.93) 1.8 (2.0) 0.329 
Conduct Score 1.00 (1.00 - 4.00) 2.33 (2.50) 1.7 (1.8) 0.924 
Hyperactivity Score 4.50 (4.00 - 7.00) 4.75 (2.18) 4.0 (2.7) 0.924 
Peer Score 1.00 (0.00 - 2.00) 1.25 (1.60) 1.5 (1.7) 0.288 
Prosocial Score 9.00 (7.00 - 9.00) 8.5 (1.51) 8.3 (1.6) 0.505 
Impact Score 0.00 (0.00 – 1.00) 0.58 (1.00) 0.5 (1.2) 0.397 
Total Score 10.00 (7.00 - 15.00) 10.92 (5.71) 9.1 (6.0) 0.396 
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7.3.2 SDQ prediction of disorders 
Using the SDQ score results, 24% of patients are likely to have a hyperactivity disorder.  
Thirty per cent are predicted to possibly or probably have a conduct disorder and 18% to 
possibly or probably have an emotional disorder (Table 7-6). 
Table 7-6 Likelihood of emotional, conduct and hyperactivity disorders on the SDQ 
 Unlikely Possible Probable 
Hyperactivity 
Disorder 
13 (76%) 4 (24%) 0 (0%) 
Conduct Disorder 12 (71%) 4 (24%) 1 (6%) 
Emotional Disorder 14 (82%) 2 (12%) 1 (6%) 
7.3.3 Comparing SDQ scores between children and parents 
The total SDQ score was highly correlated between parent proxy and child self-reported 
scores (ρ = 0.654, p = 0.021) (Table 7-7 Correlation between child and parent SDQ Score.).  
However, correlations for the subdomains were inconsistent.  There was a strong correlation 
for the emotional and peer scores (although the peer score did not reach statistical 
significance).   
Table 7-7 Correlation between child and parent SDQ Score. 
SDQ Component Correlation (Spearman's rho) p-value 
Emotional Score 0.955 0.003 
Conduct Score -0.440 0.383 
Hyperactivity Score 0.647 0.165 
Peer Score 0.801 0.056 
Prosocial Score -0.426 0.399 
Impact Score 0.633 0.178 
Total Score 0.654 0.021 
7.3.4 Correlation of SDQ score and clinical status 
There were, largely, no significant correlations between self or parent-reported total SDQ 
score and clinical status.  However, FEV1 scores were negatively associated with a 
worsening total SDQ score.  This did not reach statistical significance for self-reported scores 
but did so for parent proxy scores (Table 7-8). 
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Table 7-8 Correlation of SDQ score and clinical outcomes and phenotype.  Spearman’s 
rho and p values shown. 
 Spearman’s ρ p-value 
Self-scores 
Age  0.281 0.378 
Age at diagnosis 0.512 0.676 
Annual infection incidence 0.133 0.732 
Latest FEV1 Z-Score -0.800 0.104 
Parent scores 
Age  0.068 0.842 
Age at diagnosis -0.117 0.765 
Annual infection incidence 0.333 0.381 
Latest FEV1 Z-Score -0.900 0.037 
 
7.4 Anxiety 
Twenty-six patients filled out of the HADS screening tool for anxiety (79% of eligible 
patients) (451).  These results were compared against healthy UK norms (437) and UK male 
CF patients (438). 
Table 7-9 HADS-anxiety outcomes for the cohort 
HADS-anxiety outcome Number of patients (n, %) 
Normal 18, 69% 
Borderline 3, 12% 
Abnormal 5, 19% 
 
Nineteen percent screened positive for anxiety on the HADS-A questionnaire with a further 
three patients reporting a borderline score (Table 7-9).  This compares against 12.5% of 
healthy UK male norms who screen positive on the HADS-A and 13.9% who screen as 
borderline (437).  11.5% of UK male CF patients screen positive on the HADS-A and 18.6% 
screen borderline (438).  There were no significant differences in the raw HADS-A scores 
versus UK male norms or UK male CF patients (Table 7-10).  
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Table 7-10 Raw HADS-A Scores versus UK male norms (median (IQR)) (437) and UK 










5 (4 – 9) 5 (2 – 8) 0.316 5.7 (3.9) 0.809 
 
There were no differences in the HADS-A screening outcomes between those with and 
without bronchiectasis, p = 1.000 (Table 7-11).  There were no significant differences in the 
raw HADS-A scores between the two groups; median score 4 versus 5, p = 0.142. 
Table 7-11 HADS-anxiety outcomes comparing those with and without bronchiectasis 
(n, %) 
HADS-anxiety outcome Bronchiectasis No bronchiectasis 
Normal 9. 64% 8, 73% 
Borderline 2, 14% 1, 9% 
Abnormal 3, 22% 2, 18% 
 
There is a strong and significant correlation between a worsening HADS-A raw score and a 
worsening overall mental component score from the SF36v2, ρ = -0.610, p = 0.003. 
There was no correlation between HADS-A raw scores and clinical status or phenotype 
(Table 7-12).  
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Table 7-12 Correlation of HADS anxiety score and clinical outcomes and phenotype.  
Spearman’s rho and p values shown 
 Spearman’s ρ p-value 
Age  0.147 0.483 
Age at diagnosis 0.037 0.862 
Annual infection incidence 0.123 0.566 
Latest FEV1 Z-Score 0.260 0.350 
7.5 Depression 
Twenty-six patients filled out of the HADS screening tool for depression (79% of eligible 
patients) (451).  These results were compared against healthy UK norms (437) and UK male 
CF patients (438). 
7.5.1 HADS depression scores  
Only one patient (4%) screened positive for depression on the HADS-D questionnaire with a 
further two patients scoring borderline (Table 7-13).  This compares against 6.9% of UK 
male norms who screen positive on the HADS-D and 8.5% who screen as borderline (437).   
Table 7-13 HADS-D outcomes for the cohort 
HADS-depression outcome Number of patients (n, %) 
Normal 23, 88% 
Borderline 2, 8% 
Abnormal 1, 4% 
 
3.1% of UK male CF patients screen positive on the HADS-A and 10% screen borderline 
(438).  There were no significant differences in the raw HADS-D scores versus UK male 
norms or UK male CF patients (Table 7-14).
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Table 7-14 Raw HADS-D Scores versus UK male norms (median (IQR)) (437) and UK 










2 (0 – 5) 3 (1 – 6) 0.664 3.4 (3.3) 0.422 
 
There was no difference in the HADS-D outcomes between those with and without 
bronchiectasis, p = 0.487 (Table 7-15).  However, no patient without bronchiectasis screened 
a positive or borderline for depression.  In addition, patients with bronchiectasis had a 
significantly higher HADS-D raw scores compared to those without; 4 versus 0, p = 0.017. 
Table 7-15 HADS-depression outcomes comparing those with and without 
bronchiectasis (n, %) 
HADS-depression outcome Bronchiectasis No bronchiectasis 
Normal 11, 79% 11, 100% 
Borderline 2, 14% 0, 0% 
Abnormal 1, 7% 0, 0% 
 
Similar to the HADS-A scores, a worsening HADS-D score was strongly and significantly 
associated with a worsening overall mental component score form the SF36v2, ρ = -0.728, p 
< 0.001. 
There was no correlation between HADS-D raw scores and clinical status or phenotype 
(Table 7-16).   
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Table 7-16 Correlation of HADS depression score and clinical outcomes and phenotype.  
Spearman’s rho and p values shown 
 Spearman’s ρ p-value 
Age  0.270 0.192 
Age at diagnosis 0.265 0.201 
Annual infection incidence 0.361 0.083 
Latest FEV1 Z-Score 0.324 0.239 
7.6 Rosenberg Self Esteem Scale 
Thirty participants filled in the RSES (452).  Six patients were aged 12-18 and twenty – four 
were over eighteen years of age.  Fifty-six percent had bronchiectasis (compared to forty-four 
percent of the entire cohort).  Eighty-three percent of the cohort reported normal or high self-
esteem on the RSES (Table 7-17). 
Table 7-17 RSES outcomes for the cohort 
RSES outcome Number of patients (n, %) 
Low self-esteem 5, 17% 
Normal self-esteem 16, 53% 
High self-esteem 9, 30% 
 
7.6.1 RSES scores for the cohort versus UK norms and CF patients 
While rates of low esteem were low, and most patients recorded high self-esteem, raw RSES 
scores for XLA patients were significantly lower than UK healthy male norms (439) and UK 
male CF patients (440) (Table 7-18). 
Table 7-18 RSES Scores (median (IQR)) versus UK male norms (439) and UK male CF 
patients (440) (mean (SD)) 
XLA UK Norms p value CF patients p value 
26.50 (18 – 29) 31.68 (5.67) <0.001 33.94 (5.1) <0.001 
7.6.2 RSES scores for patients with bronchiectasis 
There were no significant differences in the rates of levels of self-esteem between patients 
with and without bronchiectasis (p = 0.163, Table 7-19).  There were no differences in their 
raw RSES scores (27 versus 26, p = 0.158).  However, no patient without bronchiectasis 
reported low self-esteem versus 29% of patients with bronchiectasis doing so on the RSES. 
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Table 7-19 RSES outcomes for bronchiectasis and no bronchiectasis 
RSES outcome Bronchiectasis No bronchiectasis 
Low self-esteem 5, 29% 0, 0% 
Normal self-esteem 4, 24% 5, 38% 
High self-esteem 8, 47% 8, 62% 
 
7.6.3 Correlation of RSES score and clinical status 
There was no correlation between RSES scores and clinical status or phenotype (Table 7-20).  
There was strong positive correlation between RSES scores and SF36v2 MCS scores 
(Spearman's rho = 0.670, p = 0.001). 
Table 7-20 Correlation of RSES score and clinical outcomes and phenotype.  
Spearman’s rho and p values shown 
 Spearman’s ρ p-value 
Age  0.077 0.716 
Age at diagnosis 0.009 0.966 
Annual infection incidence -0.246 0.246 
Latest FEV1 Z-Score 0.262 0.345 
7.7 Summary 
• Quality of life related to mental health for adult XLA patients, as measured by the 
SF36v2, were broadly comparable to both UK healthy norms and patients with cystic 
fibrosis.  For patients with bronchiectasis, these scores tended to be lower than those 
patients without bronchiectasis, with the social functioning subdomain being significantly 
lower. 
• SDQ scores for paediatric XLA patients were comparable to UK healthy norms. 
• A higher proportion of XLA patients screened positive for anxiety disorders on the 
HADS-A questionnaire (19%) compared to UK male norms (12.5%) and UK male CF 
patients (11.5%). 
• There is a strong correlation between a worsening score on the HADS anxiety screening 
questionnaire and quality of life-related to psychological health as measured by the 
SF36v2. 
• There were no differences in the proportion of XLA patients who scored positive on the 
HADS-D questionnaire (4%) compared to UK male norms (6.9%) and UK male CF 
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patients (3.1%).  However, all XLA patients who score borderline or positive on the 
HADS-D had bronchiectasis. 
• There is a strong correlation between a worsening score on the HADS depression 
screening questionnaire and quality of life-related to psychological health as measured by 
the SF36v2. 
• Seventeen percent of the cohort reported low self-esteem on the RSES.  Raw RSES 
scores for XLA patients were significantly lower than UK norms and CF patients. 
• Aside from parental proxy total SDQ scores and latest FEV1 Z-Score, there were no 







Chapter 8 Results – Quality of Life 
This chapter will present the data pertaining to the quality of life-related to physical health.  
In addition, it will focus on the impact of respiratory healthy specifically on patients’ quality 
of life. 
8.1 Paediatric Quality of Life Scores (PedsQl 4.0) 
A total of 17 parents and 13 children filled out the PedsQl 4.0 (81% of enrolled patients) 
(442).  Results were compared against healthy UK norms (433) and UK cystic fibrosis 
patients (434).  It was not possible to separate the group based on the presence of 
bronchiectasis or not due to the small numbers of paediatric patients with bronchiectasis (n = 
1).  Excluding this one patient made no significant difference to the results.      
8.1.1 Parent and child correlation of the PedsQl 4.0 scores 
The overall total score correlated strongly and significantly for parent and child reports 
(Table 8-1).  In addition, the social score subdomain also strongly correlated between the 
child and parent reports.  The remaining subdomains did tend to correlate, but not reaching 
statistical significance. 
Table 8-1 Correlation between Parent and Child PedsQl 4.0 Score.  Shown as 
coefficient, p-value 
Peds QL4.0 Component Spearman’s rho p-value 
Psychosocial Score 0.463 0.130 
Physical Score 0.510 0.090 
Emotional Score 0.215 0.502 
Social Score 0.835 0.001 
School Score 0.397 0.201 
Total Score 0.654 0.021 
8.1.2 Paediatric quality of life scores versus UK norms and CF patients 
There were no significant differences in any of the subdomains nor the total PedsQl 4.0 score 
for XLA patients compared to healthy UK norms or UK CF patients (Table 8-2).   This 
applied to both self-reported scores and parent proxy scores.    Only mean values were 
available for the UK and CF data.  However, presuming these data were normally distributed, 
the corresponding median value would be similar to the mean and therefore could be 
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compared against the median values for the XLA patients.  The mean and SD for the XLA 
data is also presented for comparison.
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Table 8-2 PedsQl 4.0 Scores (median (IQR)) versus UK norms (mean (SD)) (433) and CF patients (434) (mean (SE)) 
 UK Cohort (median, IQR) UK cohort 
(mean, SD) 
UK Norms p value CF Patients p value 
Self-Scores 
Psychosocial Score 78.33 (63.33-85.00) 71.67 (20.58) 80.50 (14.06) 0.249 72.3 (1.47) 0.552 
Physical Score 87.50 (82.14-87.50) 80.63 (16.39) 86.08 (14.06) 0.551 79.2 (1.64) 0.194 
Emotional Score 70.00 (60.00-80.00) 67.50 (20.03) 76.99 (18.43) 0.173 70.7 (1.92) 0.649 
Social Score 95.00 (70.00-100.00) 86.5 (23.34) 86.85 (16.86) 0.972 78.8 (1.73) 0.216 
School Score 70.00 (50.00-80.00) 61.00 (23.55) 77.29 (16.92) 0.194 65.6 (1.86) 0.551 
Total Score 80.43 (71.74-88.04) 74.78 (18.22) 82.25 (13.09) 0.311 74.7 (1.42) 0.345 
Parent Scores 
Psychosocial Score 81.67 (67.50-87.50) 79.44 (15.25) 79.00 (14.70) 0.875 73.3 (1.23) 0.346 
Physical Score 85.94 (73.44-90.63) 77.08 (18.62) 84.99 (16.08) 0.753 79.3 (1.52) 0.530 
Emotional Score 75.00 (65.00-85.00) 76.11 (19.49) 74.67 (17.67) 1.000 68.0 (1.55) 0.387 
Social Score 95.00 (80.00-100.00) 92.78 (12.53) 84.62 (17.24) 0.080 81.7 (1.53) 0.131 
School Score 70.00 (55.00-82.50) 69.44 (19.44) 77.72 (18.50) 0.084 68.8 (1.65) 0.937 




8.1.3 Correlation of paediatric quality of life scores and clinical outcomes 
There were no differences in the total PedsQl 4.0 score for both self and total scores across 
disease severity groups (p = 0.635 and 0.300 respectively). 
There was no significant correlation with the paediatric QoL scores and current age, age at 
diagnosis or annual infection incidence for self or parent reports (Table 8-3).  There was a 
strong negative correlation with the patient’s current respiratory health as measured by their 
latest FEV1 Z-score for both parent and self-score.  This did not reach statistical significance 
for self-score but did so for parent score (Table 8-3). 
Table 8-3 Correlation of PedsQl 4.0 scores and clinical outcomes and phenotype.  
Spearman’s rho and p values shown 
 Spearman’s ρ p-value 
Self PedsQl 4.0 total score 
Age  0.280 0.378 
Age at diagnosis 0.152 0.676 
Annual infection incidence -0.133 0.732 
Latest FEV1 Z-Score -0.800 0.104 
Parent PedsQl 4.0 total score 
Age  0.068 0.842 
Age at diagnosis -0.117 0.765 
Annual infection incidence 0.333 0.381 
Latest FEV1 Z-Score -0.900 0.037 
8.1.4 Paediatric quality of life scores by site and route of IGRT 
Children’s self-reported PedsQl 4.0 tended to lower in all domains for those on IVIG 
compared to SCIG, although the numbers receiving IVIG was very small (n = 2), and these 
differences did not reach statistical significance (Table 8-4).  There were no differences noted 
in the parent proxy scores for the two groups.  One child was receiving both IVIG and SCIG 
and omitted from this initial analysis 
Similarly, children’s self-reported scores for hospital therapy tended to be lower than those 
receiving home therapy, again with small numbers (3 patients receiving hospital therapy) and 
did not reach statistical significance.  All three patients receiving their therapy in hospital 
were receiving IV therapy (including the two from the above analysis and the one patient 
183 
 
receiving both IVIG and SCIG).  There were no differences notes in the parent proxy scores 




Table 8-4 PedsQl 4.0 score by route and site of IGRT (median (IQR)) 
 Intravenous (n =2) Subcutaneous (n=14) p value Hospital (n = 3) Home (n = 13) p value 
Self Scores 
Psychosocial  50.83 (25.00 – 76.70) 80.00 (71.67 – 88.33) 0.142 63.33 (25.00 – 76.67) 80.00 (71.67 – 88.33) 0.086 
Physical 73.44 (59.38 – 87.50) 87.50 (71.88 – 93.75) 0.552 87.50 (59.38 – 87.50) 87.50 (71.88 – 93.75) 0.724 
Emotional  50.00 (40.00 – 60.00) 70.00 (65.00 – 90.00) 0.142 60.00 (40.00 – 70.00) 70.00 (65.00 – 90.00) 0.649 
Social  65.00 (30.00 – 100.00) 100.00 (95.00 – 100.00) 0.385 70.00 (30.00 – 100.00) 100.00 (95.00 – 100.00) 0.156 
School  37.50 (5.00 – 70.00) 75.00 (50.00 – 80.00) 0.182 50.00 (5.00 – 70.00) 75.00 (50.00 – 80.00) 0.104 
Total Score 58.70 (36.96 – 80.43) 81.52 (76.09 – 90.22) 0.242 71.74 (36.96 – 80.43) 81.52 (76.09 – 90.22) 0.139 
Parent Scores 
Psychosocial  87.50 (83.33 – 91.67) 81.67 (73.33 – 91.67) 0.500 83.33 (68.33 – 91.67) 81.67 (73.33 – 91.67) 1.000 
Physical  76.56 (65.63 – 87.50) 85.94 (81.25 – 90.63) 0.615 65.63 (46.88 – 87.50) 85.94 (81.25 – 90.63) 0.243 
Emotional  92.50 (90.00 – 92.50) 75.00 (65.00 – 80.00) 0.180 90.00 (70.00 – 95.00) 75.00 (65.00 – 80.00) 0.362 
Social  90.00 (80.00 – 100.00) 100.00 (100.00 – 100.00) 0.513 90.00 (80.00 – 100.00) 100.00 (100.00 – 100.00) 0.283 
School  80.00 (75.00 – 85.00) 70.00 (55.00 – 90.00) 0.502 75.00 (45.00 – 85.00) 70.00 (55.00 – 90.00) 1.000 
Total Score 83.70 (77.17 – 90.22) 82.61 (79.35 – 89.13) 1.000 77.17 (60.87 – 90.22) 82.61 (79.35 – 89.13) 0.606 
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8.2 Adult quality of life scores – Short form 36 version 2 
HRQoL for adults was measured using the SF36v2 (441).  This was filled by 30 adult 
participants (91% of enrolled adults).  Their results were compared against healthy UK males 
norms (431) and UK male patients with CF (432).  There are four subdomains; physical 
function, role (physical), general health and pain.  These domains are shared across both 
version 1 and version 2 of the SF36.  Version 2 of the SF36 combines these domains to 
produce an PCS.  The UK CF data derives from version 1 of the SF36 and there is, therefore, 
no PCS available for this dataset. 
8.2.1 Adult XLA quality of life scores versus UK norms and CF patients 
The XLA patients had significantly lower scores for the pain and general health subdomains 
of the SF36v2 compared to UK healthy male norms (Table 8-5).  There were no significant 
differences in the physical function, pain role or the overall PCS compared to UK norms. 
XLA patients had significantly better scores in the physical role component compared to CF 
patients.  They also tended to have higher physical function scores, but this did not reach 
statistical significance.  There was no other significant difference in the QoL scores compared 
to CF patients. 
Only mean values were available for the UK and CF data.  However, presuming these data 
were normally distributed, the corresponding median value would be similar to the mean and 
therefore could be compared against the median values for the XLA patients.  The mean and 
SD for the XLA data is also presented for comparison. 
8.2.2 Adult XLA quality of life scores in bronchiectasis 
Patients with bronchiectasis scored statistically significant lower scores for all domains of the 
SF36v2 apart from the physical role domain, compared to patients without bronchiectasis 
(Table 8-6).  Patients with bronchiectasis had statistically significantly lower scores in the 
general health subdomain compared to UK norms.    Their scores were broadly comparable to 
UK CF patients aside from the pain subdomain.  This tended to be lower for XLA patients 
with bronchiectasis compared to CF patients but did not reach statistical significance.  
8.2.3 Adult quality of life scores by route and site of IGRT 
There were no statistical differences in SF36v2 scores when comparing either route or site of 
IGRT (Table 8-7). 
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8.2.4 Correlation of adult quality of life scores and clinical outcomes 
Patients with severe disease had significantly worse overall SF36v2 physical component 
scores compared to patients with moderate or mild disease (Figure 8-1). 
























































Table 8-5 SF36v2 physical health scores for the cohort (median (IQR)) compared to male UK norms (431) and UK patients with cystic 
fibrosis (432) (mean (SD)). $(Data not available) 
 UK XLA patients 
(median, IQR) 
UK XLA patients 
(mean, SD) 
UK Norms p-value CF patients p-value 
Physical Function 100.00 (85.00-100.00) 88.57 (19.63) 89.76 (18.78) 0.253 82.4 (20.7) 0.061 
Role-Physical 93.75 (87.50-100.00) 86.90 (18.53) 89.01 (21.09) 0.351 75.00 (22.5) 0.028 
Pain 74.00 (62.00-100.00) 75.76 (24.63) 81.25 (22.21) 0.197 84.2 (19.6) 0.165 
General Health 42.00 (27.00-62.00) 47.24 (26.39) 70.86 (20.29) 0.002 46.8 (24.0) 0.935 
PCS 52.65 (47.88-56.71) 51.24 (8.77) 50.63 (9.41) 0.322 $ $ 
 
Table 8-6 SF36v2 physical health scores for patients with bronchiectasis compared against the rest of the cohort (median (IQR)), UK 
norms and cystic fibrosis patients (p values shown).  $ Data not available 
 Bronchiectasis No Bronchiectasis Versus XLA patients 
with No Bronchiectasis 




90.00 (85.00- 90.00) 100.00 (100.00 - 100.00) 0.049 0.699 0.504 
Role-Physical 87.50 (81.25- 93.75) 93.75 (87.50 - 100.00) 0.066 0.599 0.460 
Pain 74.00 (72.00- 100.00) 73.00 (62.00 - 84.00) 0.021 0.054 0.054 
General Health 42.00 (22.00- 52.00) 71.00 (42.00 - 100.00) 0.035 0.002 0.196 




Table 8-7 SF36v2 physical health scores by route and site of IGRT (median (IQR)) 
 Intravenous (n = 21) Subcutaneous (n = 9) p value Hospital (n = 10) Home (n = 20) p value 
Physical 
Function 
100.00 (85.00 – 100.00) 100.00 (90.00 - 100.00) 1.000 95.00 (85.00 – 100.00) 100.00 (90.00 - 100.00) 0.479 
Role-
Physical 
100.00 (87.50 – 100.00) 87.50 (81.25 – 93.75) 0.087 100.00 (93.75 – 100.00) 90.63 (84.38 – 96.88) 0.231 
Pain 84.00 (62.00 – 100.00) 72.00 (61.00 – 100.00) 0.617 84.00 (84.00 – 100.00) 72.00 (61.50 – 100.00) 0.450 
General 
Health 
42.00 (22.00 – 67.00) 42.00 (22.00 – 52.00) 0.768 67.00 (37.00 – 82.00) 42.00 (22.00 – 47.00) 0.265 
PCS 55.62 – 47.88 – 58.64) 49.57 (48.08 – 53.25) 0.696 54.95 (47.89 – 58.95) 50.81 (47.98 – 56.50) 0.598 
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The overall SF36v2 physical component score had a significant negative correlation with the 
patient’s annual infection incidence and a significant correlation with their current respiratory 
health as measured by their current FEV1 Z-score (Table 8-8). 
Table 8-8 Correlation of short-form 36 version 2 physical component scores and clinical 
outcomes and phenotype.  Spearman’s rho and p values shown 
 Spearman’s ρ p-value 
Age  -0.113 0.626 
Age at diagnosis -0.282 0.216 
Annual infection incidence -0.473 0.030 
Latest FEV1 Z-Score 0.697 0.006 
 
8.3 St George’s Respiratory Questionnaire 
Quality of life directly related to patient’s respiratory health was measured using the SGRQ 
(435).  A higher score depicts a higher impact on a patient’s QoL in that domain.  This was 
filled in by 30 adult participants (91% of enrolled adults).  Their results were compared 
against healthy UK male norms (435) and patients with CF (436). 
Only mean values were available for the UK and CF data.  However, presuming these data 
were normally distributed, the corresponding median value would be similar to the mean and 
therefore could be compared against the median values for the XLA patients.  The mean and 
SD for the XLA data is also presented for comparison. 
8.3.1 SGRQ scores versus UK norms and CF patients 
XLA patients had significantly worse QoL scores related to respiratory health in all domains 
of the SGRQ compared to UK healthy norms (Table 8-9).  There were no differences in their 
scores compared to cystic fibrosis patients. 
8.3.2 SGRQ scores in bronchiectasis 
XLA patients with bronchiectasis had significantly worse SGRQ scores in all domains 
compared to XLA patients without bronchiectasis and healthy UK norms (Table 8-10).  Their 
scores were not significantly different compared to CF patients except for the symptom score 
domain, which was significantly worse in XLA patients with bronchiectasis.
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Table 8-9 XLA SGRQ scores (median (IQR)) compared against UK healthy norms (mean, 95% CI) and cystic fibrosis patients (mean 
(SD)) 
 
UK XLA patients 
(median, IQR) 
UK XLA patients 
(mean, SD) 
UK Norms p-value CF patients p-value 
Symptom Score 39.43 (19.67 – 66.54) 44.48 (31.17) 12 (9-15) 0.001 35.29 (19.3) 0.274 
Activity Score 18.47 (12.17 – 35.60) 28.53 (27.17) 9 (7 -12) 0.005 28.90 (25.2) 0.394 
Impact Score 14.42 (3.89 – 25.13) 19.21 (18.00) 2 (1 -3) 0.001 18.60 (14.6) 0.689 
Total Score 21.06 (11.44 – 33.30) 26.16 (20.90) 6 (5-7) 0.011 24.50 (16.8) 0.484 
 
Table 8-10 St George's respiratory health questionnaire scores for patients with bronchiectasis compared against the rest of the cohort 
(median (IQR)), UK norms and cystic fibrosis patients (p values shown) 
 Bronchiectasis No Bronchiectasis Versus XLA patients 
with No Bronchiectasis 
Versus UK Norms Versus CF 
Patients 
Symptom Score 58.58 (32.33- 77.57) 12.37 (0.00 - 34.29) 0.004 0.002 0.023 
Activity Score 35.60 (18.47- 54.43) 5.96 (0.00 - 12.17) 0.011 0.003 0.345 
Impact Score 22.29 (14.42- 41.44) 0.00 (0.00 - 5.52) 0.001 0.002 0.173 
Total Score 32.58 (21.06- 49.44) 6.37 (1.52 - 14.00) 0.002 0.002 0.446 
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8.3.3 Correlation of SGRQ with clinical outcome 
SGRQ total scores worsened significantly with worsening disease severity (Figure 8-2).  
There were only two patients in the asymptomatic group who returned an SGRQ 
questionnaire, and their total scores were therefore not statistically significant than other 
groups. 
Figure 8-2 St George’s respiratory questionnaire total scores by disease severity. * = p 












































The total SGRQ score did not correlate with the patient's current age nor their age at 
diagnosis.  It did correlate significantly and strongly with their annual infection incidence 
and, as expected, their current lung function results (Table 8-11).  It also correlates strongly 
with patient’s overall HRQoL as measured by the physical component score of the SF36v2. 
Table 8-11 St George’s respiratory questionnaire total scores and clinical outcomes and 
phenotype.  Spearman’s rho and p values shown 
 Spearman’s ρ p-value 
Age  0.152 0.523 
Age at diagnosis 0.206 0.384 
Annual infection incidence 0.640 0.002 
Latest FEV1 Z-Score -0.666 0.009 




• HRQoL scores for paediatric XLA patients are comparable to UK healthy norms and 
CF patients. 
• HRQoL scores for paediatric XLA patients largely correlate well for self-reported and 
parent-reported scores. 
• Respiratory health, as measured by lung function, correlates strongly with HRQoL in 
paediatric patients 
• HRQoL in adult patients was broadly comparable to UK healthy norms apart from the 
general health domain, which was worse in XLA patients. 
• HRQoL in adult patients with bronchiectasis was significantly worse than patients 
without bronchiectasis 
• HRQoL directly related to respiratory health was significantly worse in XLA patients 
compared to healthy norms and comparable to CF patients.   
• Having bronchiectasis results in a significantly worse respiratory-related HRQoL and 
for the symptom score domain was significantly worse than CF patients. 
• HRQoL related to respiratory health, worsened with disease severity, increasing 
annual infection incidence and was strongly correlated with lung function. 
• The respiratory health QoL scores correlated strongly with the overall HRQoL scores 
measured by the SF36v2, implying respiratory health plays a significant factor in 
determining the patients overall HRQoL. 
193 
 
Chapter 9  Discussion 
9.1 Summary 
This analysis of 53 patients with a definite diagnosis of XLA, demonstrates that the vast 
majority of patients suffer at least one chronic complication as a result of their XLA.  The 
majority of these are bronchiectasis with 44% developing bronchiectasis at the time of data 
collection. 
9.2 Diagnosis 
9.2.1 Genetic testing 
This study only included those patients with a definite diagnosis of XLA as per the ESID and 
PGAIID guidelines, i.e. absent BTK expression or a proven BTK mutation  (4).  The number 
of XLA patients is significantly lower than the number of patients with 
agammaglobulinaemia in the UKPID registry (n = 204 ) (247).  Not all of these are male, and 
many of these patients most likely have only a probable or possible diagnosis, i.e. lacking a 
genetic mutation.   A recent survey of antibody patients in the UK found 109 patients with a 
BTK mutation from a total of 130 male patients with agammaglobulinaemia (286).  From 
personal correspondence with PIs across the UK, I am aware of a further 15 patients in 
Northern Ireland and 14 patients in Scotland with a proven BTK mutation who are not in this 
data set.   
Several patients had been initially diagnosed as other PADs, usually CVID based on a 
negative genetic mutation testing in BTK.  These tests were often done shortly after the 
discovery of the BTK gene and improvements have been made in genetic testing since (461).  
These patients then went onto to have BTK mutation testing redone more recently and were 
found to have disease-causing mutations in their BTK gene and their diagnosis reclassified as 
XLA.  This reclassification is essential, giving patients a definitive diagnosis and offering a 
significantly different prognosis (CVID vs XLA) and is vital for them and family members 
regarding family planning.  These few examples therefore also raise the possibility of other 
PAD patients in the UK (most likely CVID), being misdiagnosed based on previous negative 
testing for BTK mutations.  Studies using whole genome and whole exome sequencing in 
patients initially diagnosed with CVID have discovered patients with BTK mutations who 
had previously had normal results using historical Sanger sequencing techniques (462).  It is 
therefore vital that as new genetic techniques become available or improvements are made in 
currently available techniques that patients without a genetic diagnosis, who may have had 
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previously had BTK mutations ruled out and fit phenotypically with XLA should have their 
DNA retested for BTK mutations. 
21% of those patients tested had apparent BTK expression on monocytes despite BTK 
mutations and phenotype consistent with XLA.  There may be some patients with a label of 
antibody deficiency in the UK who have not had genetic testing for XLA because they have 
normal BTK expression and the (incorrect) belief this rules out XLA.  This may be especially 
pertinent in more historic cohorts where access to genetic testing was limited.  These data 
demonstrate that normal BTK expression does not rule out XLA and all patients with a 
phenotype consistent with XLA should undergo genetic testing for XLA. 
9.2.2 Age 
Reducing the age of diagnosis is a major driver for many clinicians working in primary 
immune deficiency, meaning that supportive or curative therapy can be instigated as soon as 
possible before complications develop.  This theory may hold true for XLA patients, with 
starting IGRT as soon as possible, before patients either succumb to life-threatening 
infections or by reducing the number of severe respiratory tract infections and thereby 
reducing the risk of bronchiectasis. 
The median age of diagnosis in this XLA cohort was 2.59 years and had been improving with 
time.  This age of diagnosis is nearly one year younger than the Italian cohort by Plebani et 
al., analysed in 2000 (186).  Similar to the Plebani et al., data it would appear that these 
improvements in age at diagnosis are reaching a plateau.  The median age of diagnosis since 
1990 is very young at 1.28 years, but with no significant trend in reduction over time 
(Spearman’s rho = -0.270, p = 0.191).  Much of this reduction in time to diagnosis may be, in 
part, due to this cohort having much higher survival rates and therefore being able to pass the 
BTK mutations on.  Offspring would, therefore, be able to be diagnosed at birth.  This is 
partially supported by the result that after 1990 the median age of diagnosis for those who 
were not screened was 2.60 years.  
Clinicians are likely reaching their limit in being able to clinically recognise and diagnose 
XLA in the absence of a positive family history.  Infants often only become symptomatic 
after the age of 6 months once maternally transferred antibody levels have fallen, and they 
have presented with recurrent infections and an astute clinician has considered the possibility 
of a primary immune deficiency.  However, it can be challenging to identify the child with a 
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PID against a backdrop of the healthy background population experience typical childhood 
infections.  It may be that a general paediatrician may only encounter a new presentation of 
PID once or twice in their career. 
It is therefore likely that, if clinicians wish to reduce the age of diagnosis even further, 
newborn screening would be the only feasible way of attaining this. 
9.2.3 Clinical Presentation 
Nine patients were screened while asymptomatic due to family positive family history of 
XLA.  However, two patients, where a family history of XLA was known, were not screened 
and only diagnosed once they had become symptomatic.  It is vital that, during booking of 
pregnant women, an accurate family history is taken.  Hopefully, as awareness of PID grows 
through initiatives such as the Jeffrey Modell Foundation, diseases like XLA will be more 
readily remembered and appropriate action, such as screening, taken at the birth of newborns 
(253). 
Several patients (15 out 43) presented with repeated serious or invasive infections defined as 
either meningitis, osteomyelitis or ITU stay.  Five of these patients required ITU admissions 
due to life-threating infections.  These data highlight that not only do patients present with 
repeated mild infections but approximately a third of patients present with potentially life-
changing or even life-threatening disease.  While all these patients have ultimately survived 
these infections, I did not have access to death record data, and it is likely a number of XLA 
patients have died due to infections before the diagnosis of their XLA was made.  It is also 
possible there are some patients who died due to infections, in whom a diagnosis of XLA has 
never been made. 
Again, due to increased awareness if PID, many UK ITU departments do readily investigate 
children presenting with severe and invasive infections for PID especially those who have 
succumbed to infections they have been vaccinated to (with XLA patients being unable to 
mount appropriate responses to the vaccine programme).  However, this will not change the 
course of the initial severe infection(s).  Only newborn screening and early instigation of 
IGRT could potentially prevent these severe infections.  As will be discussed later, the fact 
that the number of serious infections was vanishingly rare once IGRT once started, 
instigation of IGRT while asymptomatic would likely prevent nearly all serious and life-
threatening infections in this cohort. 
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The remaining patients presented with milder, but repeated infections, the majority being 
lower respiratory tract infections as expected (40%).  There was also a significantly higher 
number than expected of patients (14%) presenting with repeated skin infections.  The 
majority of causative organisms were encapsulated bacteria, again as expected for this 
disease.  The number of Pseudomonas aeruginosa infections at presentation was surprisingly 
high (n = 5) and is not typically thought of as an organism XLA patients would be 
particularly susceptible to.  One explanation may be due to the neutropenia seen in 10- 25% 
of XLA patients before IGRT is started (141).  Four patients in this cohort had neutropenia at 
diagnosis; however I was unable to find neutrophil counts at diagnosis for the patients who 
had Pseudomonas infections at diagnosis, but I theorise these patients did indeed have 
neutropenia before diagnosis rendering them susceptible to Pseudomonas infections. 
The exact cause of neutropenia in XLA patients is currently unknown and is rarely seen once 
IGRT is started (63).  In this cohort, no patient developed neutropenia once IGRT had started.   
The exact reason is unknown, but neutrophil maturation in XLA patients has shown to be 
arrested at the myelocyte/promyelocyte stage (140–142).  One potential theory is that, before 
IGRT is started, the stress on the bone marrow caused by severe or repeated infections leads 
to a degree of bone marrow suppression and neutropenia, which is then relived once IGRT is 
started and the number of serious infections is reduced (189).  However, this is only 
conjecture and would need to be studied accurately to fully ascertain the reasons for 
neutropenia in XLA patients before IGRT is started. 
9.3 Infections on Immunoglobulin replacement therapy 
Overall, the data in this cohort demonstrates that XLA patients receive one course of 
antibiotics for infection once every 18 months.  The vast majority of these (85%) are 
respiratory tract infections.  Otitis and sinus infections account for the small number of 
remaining infections.  There are a handful of occasional infections of other sites, most 
notably of the GI tract. 
Respiratory tract infection comprising the majority of infections while on IGRT does not 
come as a great surprise given the limitations of IGRT as described throughout this thesis.  
The lack of replacement IgA and IgM appears to still make XLA patients susceptible to 
respiratory treat infections. 
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What is perhaps more concerning, is the lack of a difference in infection rates before and 
after treatment is instigated (1.11 versus 1.12 infections per year).  While the number of 
severe and invasive infections become vanishingly rare after IGRT is started, the annual 
incidence of respiratory tract infections remains largely the same, 0.90 versus 0.86 infections 
per year.  Caution must be taken with these results as data before IGRT was limited, with 
data only available for 18 patients, and limitations relating to the recording of infection data 
discussed further in this chapter.  Nevertheless, these data strongly suggest that while IGRT 
makes significant impacts on serious and life threatening infections, its impact on milder, 
more indolent infections, particularly of the respiratory tract, appear limited.  Again, this 
supports the theoretical concerns regarding the lack of IgA and IgM in current products and 
the limited ability of current IGRT to protect mucosal surfaces against infections. 
Paediatric patients had significantly higher respiratory tract infection rate than adults while on 
IGRT.  There are likely to be several reasons for this.  The threshold to treat infections may 
be less in children compared to adults, amid worry of missing actual bacterial infections.  
This may be further exacerbated by recent attempts to improve the diagnosis and treatment of 
sepsis across the UK (463).  Even healthy children experience more respiratory tract 
infections than adults, with normal healthy children reporting between 6-10 viral colds per 
year (464).  While XLA patients will be perfectly capable of combating viral infections, it 
can be challenging to differentiate between viral and bacterial infections in children, and it is 
understandable for clinicians to overtreat in this age group so as to not miss significant 
bacterial chest infections.  This apparent difference in respiratory tract infections between 
adult and paediatric XLA patients is most likely a bias due to these natural differences in the 
number of viral infections the two age groups experience per year and not a reflection of a 
different XLA phenotype between children and adults.   
However, it should be highlighted that the retrospective nature of this data collection, in 
addition to relying on patient’s recognition of their symptoms and seeking medical attention, 
is likely to have resulted in an underestimation of the infection burden in these patients.  Two 
prospective studies calculated a much higher respiratory infection burden, with Ponsford et 
al., reporting a mean respiratory exacerbation of once every 6 days in PAD patients versus 
once every 6 weeks in controls (269,465).  These two studies also highlight the significant 
burden of viral infections in respiratory infections for PAD patients, potentially accounting 
for up to 56% of exacerbations (269,465).  Viral infections have perhaps not been thought of 
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as major drivers of respiratory infections in XLA patients, but it is likely they are and, in 
addition, potentially increasing the risk bronchiectasis.   
9.4 Bronchiectasis 
9.4.1 Rates and onset 
The rate of bronchiectasis of 44% in this cohort tallies well with a recent survey of UK 
primary antibody patient (107 of whom with presumed XLA), which reported 56% of 
patients had bronchiectasis (286).  This rate increases to 62% for patients over 30.  These data 
correlate well with the large study from Plebani et al., (186).  Interestingly, although the 
Italian data is 18 years older than this UK study, the rates of bronchiectasis are remarkably 
similar, although there were fewer patients with bronchiectasis detected before their XLA 
diagnosis in these UK data.  
Three patients had bronchiectasis diagnosed on their first HRCT after their XLA diagnosis 
and within 12 months of their XLA diagnosis. As discussed within this thesis, as 
bronchiectasis is a radiological diagnosis, the exact lag from the actual onset of 
bronchiectasis to its detection on HRCT is unknown and dependent on many factors 
including clinical preference and access to perform HRCTs.  However, a pragmatic decision 
to classify any patient who had bronchiectasis detected on their first HRCT, and within 12 
months of their XLA diagnosis, as having bronchiectasis at the time of their XLA diagnosis 
was felt to be reasonable.  It is possible, even probable, that their bronchiectasis disease 
predates the clinical diagnosis of their XLA by some time, although no one in this cohort had 
a formal diagnosis of any chronic lung disease before the diagnosis of their XLA.  However, 
even in worse case scenarios, presuming these three patients did have bronchiectasis before 
their XLA was diagnosed, these numbers are still better than the cohort data from Plebani et 
al. where 15 out of 71 had a diagnosis of chronic lung disease before their XLA (186).  This 
England and Wales cohort is significantly more recent than the Italian cohort, and awareness 
of PID and PAD has significantly improved since then resulting in quicker routes to 
diagnosis.  It may also be possible that improvements and increase uptake in vaccination 
programmes since then has resulted in less carriage by the population of pathogens XLA 
patients are susceptible to (e.g. Streptococcus pneumoniae).   
A further nine patients (18%) have abnormal changes on their HRCT, the majority of which 




Figure 9-1 attempts to estimate the prevalence of bronchiectasis within the XLA cohort over 
time.  While there will be increasing numbers simply as the cohort becomes older, so too will 
new younger patients (presumably without bronchiectasis) be entering the cohort.  This figure 
demonstrates that over the past decade, the prevalence of bronchiectasis has remained stable 
at approximately 50-55%.  This study suggests that the risk of developing bronchiectasis has 
not decreased over this, and I, therefore, do not expect this number to decrease.  It is possible 
that the prevalence of bronchiectasis increases as the current cohort becomes older.  This 
effect will not have been seen before as, before the availability of IVIg in the 1980s, the poor 
survival rate of XLA did not allow a long enough survival to see these effects (168). 
Figure 9-1 Annual prevalence of bronchiectasis within the XLA cohort 
 
These data along with others strongly suggests that a significant proportion, possibility even 
the majority of XLA patients should expect to develop bronchiectasis as some point in their 
adult life and likely in early adulthood rather than later.  No previous study has attempted to 
document the longitudinal progression of bronchiectasis in this cohort or other cohorts of 
PAD patients, given the difficulties of setting up a large enough longitudinal study with such 
rare diseases.  Although this study was limited by using retrospective data, it does give some 
insight into the patterns of onset of bronchiectasis in this cohort and its progression. 
Diagnosis of bronchiectasis is made by HRCT, and due to increased availability and access to 
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bronchiectasis.  The current age of onset of bronchiectasis was 21.97 years, which would be 
considered extremely young for developing for such a complication.  However, as Figure 6-7 
demonstrates, the age of onset of bronchiectasis has decreased over time.  This demonstrates 
easier and quicker access to HRCT over time.  If we take a pragmatic cut-off of 1990 to 
represent when HRCT became more readily available, the age of onset of bronchiectasis was 
10.87 years which is particularly concerning and strongly suggests that disease phenotype 
and infection incidence early in life needs to be aggressively monitored and treated.  It may 
also demonstrate that much lung damage has occurred even before diagnosis, and it may be 
inevitable for some patients to develop bronchiectasis. 
Figure 9-2 Age of onset of bronchiectasis and time to first HRCT over time 

































































9.4.2 Risk factors 
While on initial analyses age at diagnosis does appear to be younger for patients without 
bronchiectasis, as discussed previously, due to reductions in age at diagnosis over time, 
patients without bronchiectasis are also younger and therefore may not have enough time (as 
a proxy for exposure to infections) to develop bronchiectasis. 
Although the overall numbers are small, the time to event model attempts to overcome some 
of these confounding factors.  Interestingly, this model showed that increasing infection 
incidence did not increase the risk of bronchiectasis.  This tallies with the simple analysis of 
comparing infection incidence for those without and with bronchiectasis, which found no 
significant difference (1.24 versus 0.84 infections per year).  Again, these findings suggest a 
somewhat inevitability of bronchiectasis. 
Being diagnosed before the age of two was associated with a decreased risk of developing 
bronchiectasis on univariate analysis but did not reach statistical significance (log-rank p = 
0.071).  There was no significant decreased risk of developing bronchiectasis for early 
diagnosis on the multivariate analysis.  Being diagnosed asymptomatically due to screening 
was not associated with a significantly decreased risk, but it should be noted that the numbers 
who were screened were small (n = 9).  However, these findings suggest that early diagnosis 
and early instigation of IGRT can reduce the risk of bronchiectasis, and it is possible that 
newborn screening could make even further reductions.  This may also suggest that much of 
the risk for developing bronchiectasis occurs in the pre-diagnosis period.  Infections in this 
pre-IGRT period may be more severe due to the lack of any immunoglobulin and are a 
significant driver in developing further bronchiectasis.  These could cause an element of sub-
clinical lung damage which increases the risk of later developing bronchiectasis.  
Furthermore, there may be some patients who have developed significant enough damage 
before their XLA diagnosis, and that the development bronchiectasis is inevitable.  This 
theory is further supported by the data demonstrating that patients who later went to develop 
bronchiectasis had significantly lower lung function scores at diagnosis than patients who 
have not developed bronchiectasis. 
In summary, this study is too small fully ascertain if younger age at diagnosis, while 
asymptomatic, significantly reduces the risk of bronchiectasis.  However, the early onset of 
bronchiectasis within this cohort, strongly suggests a high burden of infection within early 
childhood is a significant contributor to the development of bronchiectasis.  Furthermore, the 
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time to event analysis suggest a reduced risk for those patients diagnosed at less than two 
years.  Taking these two findings together suggests that the infection load and path to 
bronchiectasis occurs early on life and diagnosis.  It may be, for patients diagnosed after the 
age of 2 years, the path to bronchiectasis has already begun and potentially inevitable.  If this 
were correct, future practice should aggressively target high IgG trough levels in children and 
lends strength to the argument for prophylactic antibiotics for all XLA patients, including 
those without apparent bronchiectasis.  However, it may still be the likely outcome for 
patients diagnosed early to still develop bronchiectasis, all be it at a later time onset than the 
current cohort, as these data demonstrate that patients continue to report respiratory tract 
infections throughout their life. 
9.4.3 Progression 
There were a small number of patients whose bronchiectasis became very severe, very 
quickly necessitating pneumonectomy and, in one case, a bilateral lung transplant.  There is a 
case report of another patient with XLA in whose bronchiectasis severity necessitated a lung 
transplant (273).  The long-term outcome for this patient is difficult to predict with his 
underlying PID now exacerbated by the need to take immunosuppression for their transplant.  
Presumably, their risk of re-developing bronchiectasis is still quite high as their risk factors 
(having XLA, the limitations of IGRT) remain. 
For the remainder of patients, however, the HRCT and pulmonary function data suggest the 
severity of their lung disease is relatively stable.  73% of patients demonstrated no 
progression of bronchiectasis on HRCT, and the multilevel mixed model analysis 
demonstrated that lung function is not significantly declining over time.  This model did note 
that increasing respiratory infection incidence did result in a declining lung function over 
time, which makes logical sense.  This finding emphasises the need to carefully monitor and 
quickly and aggressively treat chest infections.  
While the progression for many appears stable, it should be noted that severity for a 
significant proportion remains high even in those who have not required surgery.  The 
median last recorded FEV1 Z-score was -2.26, and 14% have a bronchiectasis severity index 




9.5 Monitoring of Respiratory Disease 
As discussed above, while the onset of bronchiectasis is potentially inevitable and perhaps 
only modifiable by very early diagnosis, the progression of bronchiectasis can be kept at bay, 
most importantly by reducing the number of respiratory tract infections.  It is therefore vital 
that patients have regular and accurate monitoring of their lung health and respiratory tract 
infections treated early and aggressively.  Both lung function and HRCT play a significant 
role in the ongoing monitoring of lung disease. 
Monitoring for the development and progression of bronchiectasis should be paramount in 
the management of XLA.  Early detection will allow more judicious use of prophylactic 
antibiotics, use of physiotherapy and stricter control of IgG trough levels.  These data also 
show that the onset the bronchiectasis may be very young, and this will pose some challenges 
in the diagnosis of bronchiectasis as it requires HRCT.  As well as balancing the risk of 
radiation exposure, in children, there is the added challenge of getting children to lie still.     
This will often need oral sedation, and may often need general anaesthetic, and these factors 
will need to be taken into account in the balancing the risk ratio of deciding when to perform 
an HRCT.   
The underlying pathological process underpinning bronchiectasis probably starts long before 
any clinically significant declines in lung function can be detected.  Biomarkers, such as 
sputum neutrophil elastase, catalase activity or lipid peroxidation offer the promise of safe, 
minimally invasive techniques to detect the onset of bronchiectasis earlier, but the clinical 
implementation of these seems far away (304,305).  MRI would offer a safe alternative to 
HRCT (295,296).  However, even if this reached clinical practice, it is doubtful there would 
be enough availability within the NHS (or indeed any health care system) to offer regular 
MRI as the primary means of diagnosing bronchiectasis. 
The lung function data in this study demonstrates that PFT can play a role in the detection of 
significant lung disease.  Lung function can be reliably performed in children as young as 
five years of age (298).  To both aid the early diagnosis of bronchiectasis and to reduce the 
burden of HRCT, I would recommend that all patients have annual lung function if 
asymptomatic.  This is significantly more frequent than current practice with these data 
demonstrating a median interval of 5.4 years between lung function testing.  While most 
patients do not demonstrate a progression of their bronchiectasis, up to 25%, do, with a small 
but significant number progressing to such a degree to require radical surgery or lung 
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transplantation.  I would therefore recommend that patients with severe bronchiectasis or 
bronchiectasis, which demonstrates progression either clinically or on HRCT have lung 
function performed every six months. 
A prosed framework for the timing of HRCT scans in adults could be; five-yearly in patients 
with no lung disease or clinical concerns, 2-3 yearly in patients with stable and mild 
bronchiectasis and 1-2 yearly in patients with severe or progressing bronchiectasis.  There 
should also be proactive efforts to perform HRCT at any points in between these intervals if 
there any clinical concerns.  These proposals are consistent with a recent European survey, in 
which most experts reported they recommend HRCT be performed every 2-4 years in 
patients with lung disease and less frequently in those without (299). 
Access to HRCT has dramatically improved over recent years.  Figure 9-3 clearly 
demonstrates that the age at which first HRCT is performed has significantly decreased in 
recent years.  Allowing for that age at diagnosis has also decreased over time; the time from 
diagnosis to HRCT has also decreased over time. 
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Figure 9-3 Age of onset of bronchiectasis and time to first HRCT over time 
 
9.6 Immunoglobulin Therapy 
Immunoglobulin replacement therapy can be administered via the subcutaneous or 
intravenous routes.  Both options are available to be administered at home or hospital with 
advantages and disadvantages to each.   
These data demonstrated there were no significant differences in quality of life scores when 
comparing IV or SC IGRT or when comparing home against hospital therapy.  QoL scores 
did tend to be lower for children who received their therapy via the IV route, but these 
numbers were small and did not reach statistical significance.  There will be several factors 


























































influencing the decisions as to where and how IGRT is administered.  These will be 
individual to each patient and their family, for example; clinical indications, venous access 
and compliance.  Furthermore, as the patient’s social and clinical circumstances alter over 
time, likely, the route and site of IGRT may also have to be flexible and change and adapt as 
per the patient’s needs.  Appropriate training, support and flexibility of immunoglobulin 
services must be therefore be maintained to meet patient’s needs. 
However, as these data demonstrate, infection-related complications still represent a 
significant burden for this cohort.  Although there are no data available to assess the impact 
of increasing IGRT doses on the chronic infection/colonisation suggested in this discussion, a 
more tightly controlled and aggressive targeting of IGRT dosing may be enough to 
significantly reduce the significance breakthrough infection which may, in turn, help delay 
the onset of end-organ damage or even reduce its prevalence.  Stubbs et al., have 
demonstrated that with current IGRT practices in the UK, lung damage still occurs 
demonstrated by deteriorating lung function (286).  One potential adjunct to treatment may be 
the targeted use of regular hospital admissions and administration of IV antibiotics, similar to 
the practice for CF patients (466). 
Immunoglobin products are expensive.  The annual cost of immunoglobulin for PID in 
England in 2015/16 was £40 million with an average annual cost of £12, 614 (467).  By 
recording the individual preparations used by patients this study was able to more accurately 
calculate the current costs of IGRT for XLA patients.  The current annual mean cost in this 
cohort for 2018 is £24, 171.  Ignoring the effects of inflation, this would equate to a cost of 
£1, 205, 550 over a 50-year period.  These costs do not include those attributed to staff costs, 
training, time or consumables associated with IGRT.  
Increasing demand and variable supply place continuous pressures on the immunoglobulin 
service for the UK (467).  This is further confounded by the fact that no immunoglobulin 
products are sourced from UK donors due to the theoretical risk of transmitted prion disease 
following the mad cow disease outbreak in the UK (467).  Furthermore, the Brexit process 
may place even further pressures on this service with the potential need for new agreements 
and regulatory approvals (467).  The secure availability of IGRT of XLA patients and all PID 




9.6.1 IgA and IgM enriched products 
As discussed throughout this thesis, that fact that current IGRT only replaces IgG potentially 
places patients at significant risk of still developing infections and their subsequent 
complications, something that this project strongly suggests is occurring.  In addition, IgA 
and IgM play major roles in immune modulation and regulation.  Their loss may lead to 
defects in these areas, as potentially suggested by these data.  Again, these defects would not 
be compensated for with current immunoglobulin products.  One option, therefore, maybe the 
introduction of IGRT products which contain IgA or IgM. 
Fresh frozen plasma has historically been suggested as a replacement for IGRT, starting in 
1975, when the currently available option of IM-IGRT also had the added limitation of 
limited volumes (468).  Infused FFP can result in significant levels of IgG, IgA and IgM in 
patients (469).  However, to be used a long-term replacement therapy and achieve 
satisfactory trough levels, it has been to given twice weekly, which is not feasible or 
convenient enough for patients.  Interestingly there is, however, reported use of FFP as an 
adjunct therapy in 2 patients with PID and relapsing Campylobacter jejuni infection (470).  
This was given for between 2 and 4 weeks and resulted in complete remission for the two 
patients (470). 
There are some IgA/IgM enriched IGRT products available most notably Pentaglobin, 
Trimodulin and IgAbulin. 
Pentaglobin contains 72% IgG, 12% IgM and 16% IgA respectively and is given as an IV 
preparation (471).  There are some data available to suggest that Pentaglobin has better 
opsonic activity against Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia 
Coli compared against IVIG (472,473).  There is no reported use of Pentaglobin as the 
standard IGRT in patients in PID.  However, there are again case reports of using Pentaglobin 
as an adjunct therapy in successfully treating patients with hypogammaglobinaemia and 
chronic Campylobacter jejuni  GI infections (470). 
Trimodulin contains 21% IgA and 23% IgM and 56% IgG (474).  A recent phase II trial 
examining patients with severe community-acquired pneumonia demonstrated that the use of 
Trimodulin resulted in less infection-related adverse events when compared to placebo (474).  
It also demonstrated improved outcomes in patients with higher CRPs and lower initial IgM 
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levels (474).  However, there is no work demonstrating the effectiveness of Trimodulin in 
PID patients. 
IgAbulin is an oral preparation of an IgA.  It has shown to be effective in preventing 
necrotising enterocolitis in neonates and has been used in treatment for children with chronic 
diarrhoea (475,476).  There are no data for the use of IgAbulin in patients with PID. 
It should be noted that all the above preparations derive their IgA from plasma.  As discussed 
in the introduction, serum IgA is predominately monomeric (477), in contrast to locally 
produced IgA from mucosal surfaces which is mainly dimeric (54).  It is feasible, however, 
that the administration of serum-derived monomeric IgA may still be of benefit for patients 
with PAD or PID.  There is some work demonstrating that serum-derived monomeric IgA 
and IgM can bind recombinant secretory component and form secretory IgA (sIgA) and 
secretory IgM (sIgM) (478).  There is no human work to establish its effectiveness published 
yet. 
There are some early data describing the feasibility of nebulised IgG, IgM and IgA allowing 
direct topical therapy to the lung tissue (479).  This has been shown to be feasible in primates 
and, in mice, that the administration of nebulised IgG appeared to offer protection against 
pneumococcal pneumonia (479).  However, as described above, the derived IgA is likely to 
be monomeric rather dimeric.  It is unclear if this therapy could replace the 
immunomodulatory functions of IgA and IgM lost in XLA.  There are no clinical data 
available to determine if this modality is feasible or effective for XLA patients. 
IgA and IgM enriched products being used as the standard IGRT product for patient with 
XLA may be worth serious consideration.  In the meantime, however, for those patients with 
chronic, potentially serious infections (for example to two patients with chronic norovirus 
infection, once of which is undergoing HSCT), using adjunct IgA/IgM enriched products 
should be thought as a potential treatment modality before consideration of more radical 
options, most notably HSCT. 
9.7 Adjunct therapies 
9.7.1 Prophylactic antibiotics 
The use of prophylactic antibiotics was variable, either in the presence of bronchiectasis or 
not.  This study was not designed nor powerful enough to evaluate the effectiveness of 
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prophylactic antibiotics in bronchiectasis.  However, there is a large body of work clearly 
demonstrating their effectiveness in non-CF bronchiectasis (466).  While there needs to be a 
balance against increasing the risk of resistant organisms (as demonstrated by the 
microbiology data in this study), all efforts should be made to reduce the risk of progression 
of bronchiectasis, and it should be standard practice that all XLA patients with bronchiectasis 
should be on prophylactic antibiotics.  Relying on reported infection rates to decide on 
whether prophylactic antibiotics should be used is unreliable.  As discussed earlier, it is 
possible that these patients are chronically infected and chronically damaging their airways.  
The fact they have developed enough infections to develop bronchiectasis should be enough 
to warrant prophylactic antibiotics.  It is unclear if prophylactic antibiotics play a role in the 
management of XLA in the absence of bronchiectasis. 
There is surprisingly little evidence on the use of prophylactic antibiotics in PID patients with 
bronchiectasis.  There is one recent RCT of 89 patients with PAD which demonstrated a 
significant reduction in the number of exacerbations and hospitalisation for those patients on 
prophylactic azithromycin versus placebo (319).  Aside from unknown effectiveness, a 
significant argument against the widespread use of prophylactic antibiotic use is the potential 
risk of antibiotic resistance, although little data are examining this.  In the UK, there is 
currently an RCT assessing the effects of prophylactic flucloxacillin in newly diagnosed 
patients with cystic fibrosis (ISRCTN 18130649).   This study should present some necessary 
data on the impact of prophylactic antibiotic use on antimicrobial resistance.  
These data have shown that bronchiectasis remains a major burden for XLA patients and that 
respiratory tract infections are still common.  The role of prophylactic antibiotics for all XLA 
patients should be explored further to determine if this has a place in the management of 
XLA, including in the absence of bronchiectasis. 
9.8 Other complications 
Whilst the risk of bronchiectasis has been known for some time, this study highlights the 
prevalence and severity of other complications such as gastrointestinal disease.  It is 
especially important to note that these complications may be due to immune dysregulation 
rather than from an infectious component (e.g. the IBD like phenotype seen in XLA patients).  
It is likely that the XLA phenotype includes a degree of immune dysregulation given the 
phenotype described in these data and the wide-ranging role of B-lymphocytes and BTK as 
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described in the introduction.  It is vital to note these complications. as they are unlikely to be 
amenable to current therapy, consisting of IgG replacement.  
IgA and IgM play vital roles as anti-inflammatories and in maintaining immune system 
homoeostasis between commensal microorganisms and pathogens at mucosal surfaces 
(480,481).  The loss of these immune regulators at mucosal surfaces may go some way to 
explain the IBD like phenotype seen in XLA patients.  It may also play a role in the lungs of 
XLA patients where the burden of immune dysregulation and inflammation could be as 
important as the burden of infection in determining long term respiratory health.  Again, the 
lack of IgA and IgM replacement in current immunoglobulin products mean that these 
defects will still be present in XLA patients on current therapies. 
9.8.1 GI 
A significant proportion of patients have or still are suffering from GI 
symptoms/complications, most of whom warranted endoscopic investigation. 
There were three patients (6%) with confirmed IBD or IBD-like disease, which tallies well 
with the US data (326).  The exact pathogenesis behind the link of XLA and IBD is poorly 
understood, but the potential loss of inflammatory regulation caused by the lack of B-
lymphocytes may go some way to explain this.  Standard practice for the management of IBD 
in this XLA cohort was similar to that of general IBD patients, namely polymeric diet and the 
consideration of steroids or biologics such as Infliximab. 
Of note are the two patients with chronic norovirus infections, one of whom has been 
published as a case report prior (185).  Due to the persistent symptoms and ongoing 
nutritional compromise, both of these patients were recently referred for HSCT, one of whom 
has successfully undergone bone marrow transplant.  Persistent norovirus infection is well 
associated with CVID but, aside from the aforementioned case report, has not previously 
been reported in XLA (338).  The underpinning mechanism explaining why XLA patients 
would be unable to clear Norovirus infection is unclear, but these two cases and two other 
international cases (personal communication) further highlight the immune defects in XLA 
aside from a pure antibody deficiency.  In particular, the lost role of B-lymphocytes acting as 
antigen-presenting cells, and the lost role of BTK in cells other than B-lymphocytes may be 
important factors.  Of particular concern in Norovirus infection in PID, is its refractory nature 
to standard and novel therapies.  As shown during this PhD, the resulting enteropathy can be 
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severe and it was, for this reason, radical options such as HSCT were considered.  The patient 
in this cohort offered HSCT is now 18 months post HSCT with good immune reconstitution 
and normal vaccine responses off IGRT. 
Although controversial, this case demonstrates that carefully selected and targeted use of 
HSCT may play a role in XLA and is discussed further within this chapter. 
9.8.2 Musculoskeletal 
The proportion of patients with a formal diagnosis of arthritis or inflammatory arthritis 
symptoms is mirrored strongly by the USA registry data (13% vs 12%) (324). Interestingly, 
however, the four patients with a formal diagnosis of arthritis all reported previous confirmed 
episodes of mycoplasma infections of the affected joints.  There were no reported cases of de 
novo joint inflammation in this cohort in the absence of previously infected joints.   
There were three other patients with non-specific but significant muscle aches or fatigue who 
have been given the diagnosis of fibromyalgia but not a formal inflammatory disorder.   
Previous data have raised the concern of inflammatory joint conditions in XLA through some 
process of inflammatory deregulation as a result of a lack of B-lymphocytes (324).  These 
data find no strong evidence for an increased risk of inflammatory joint disorders in XLA, 
although as described in the GI complications section, it may well be this cohort is still at risk 
of other inflammatory conditions.  The inflammatory joint conditions reported in other 
cohorts might be due to missing data regarding previous infections of the affected joints and 
incorrect diagnosis. 
9.8.3 Malignancy 
There was only reported case of malignancy in this cohort, a case of acute lymphoblastic 
leukaemia (ALL), at the age of 7 years when he was also diagnosed with XLA. 
As discussed in Chapter 2, previous cohort data have found potentially higher rates of 
malignancy than the background population with 1.5 – 6% of patients reporting a history of 
malignancy (332).  The majority of reported malignancy is either lymphoproliferative 
(largely AML or B-cell precursor ALL) or solid tumours of the GI tract (330,332).  It is 
postulated that the risk of the latter is directly related to chronic inflammation as a result of 
recurrent infections (334). Indeed, in this cohort, no solid GI malignancies were reported, 
although I am aware through personal communications and the UKPIN registry of a UK 
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patient over the age of the 50 years old who has previously had colon cancer.  This data set 
has not included data on deceased patients, and it is possible cases of malignancy have 
therefore been missed if the patient succumbed to their illness.  Efforts are currently 
underway to try and access data relating to deceased patients. 
There has been previous discussions and concerns regarding the risk of haematological 
malignancy in XLA, possibly through impaired or absent BTK playing a role in the 
development of ALL (482).  Mary Conley has previously concluded that if there is an 
increased risk of haematological malignancies in XLA, this increased risk is likely to be 
minimal, and these UK data would agree with that conclusion (482).  However, it may take 
larger cohort than this one to ascertain this risk fully.  Again, through personal 
communications from European colleagues, there remain ongoing concerns regarding the risk 
of haematological malignancies in XLA, and further observational work in this area is 
probably warranted but would likely need European wide data to assess this fully.  
9.8.4 Neurodegeneration 
Although not included within this cohort, I am aware of two UK patients with XLA who have 
severe neurodegeneration with no apparent cause.  While enterovirus is a well-recognised, all 
be it historical, cause of CNS disease in this cohort, no pathogen has been identified in either 
of these patients (172).  Although there are no published data on the phenomena on 
unexplained neurodegeneration in XLA patients, through this PhD study, I have become 
aware of several XLA patients in the UK, Europe and USA with this phenomenon.  There are 
plans to study this group in more detail to ascertain a cause.  Potential explanations would be 
a viral infection that has not been tested for (or needs invasive brain biopsy to isolate), or a 
neurodegenerative condition associated with their BTK mutation. 
9.9 Genetic Mutations 
Although there are no formally agreed methods for assessing mutation severity nor clinical 
severity in XLA, the methods described here present some of the most detailed work seen in 
this cohort.  A variety of methods were used to assess mutation severity, including those 
suggested by Broides et al. (368).  Also, I assessed severity based on mutation type and 
position as well using a variety of mutation prediction score algorithms. 
Although the sample size is small, the level of detail allowed assessment of disease severity 
based on several variables including complications, infection incidence and age at diagnosis.  
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Age at diagnosis may be a useful proxy for disease severity with the presumption that milder 
disease presents later on.  Supporting this, are the data from this thesis that demonstrated a 
lower annual infection incidence pre-diagnosis was associated with a higher age at diagnosis.  
Whether or not these patients do indeed continue to have milder disease and fewer 
complications, is currently unknown although these data in this data suggest age at diagnosis 
bases on clinical findings may not have a significant impact on long term clinical outcomes. 
Allowing for the limitations above; however, the data here suggest there is no correlation 
between gene mutation and clinical phenotype.  Therefore, attempting to stratify disease risk 
or treatment strategies cannot be based on the patient’s BTK mutation.   
9.10 Psychological and emotional health 
Overall rates of depression and anxiety, as well as psychological related QoL scores were 
broadly comparable against the UK healthy population.  However, it should be noted, all 
patients who scored abnormal scores in the HADS depression scoring tool had 
bronchiectasis. 
One unusual symptom reported in this cohort was the difficulties with memory.  These have 
been severe enough to warrant neurological investigation although these have all been shown 
to be normal.  In one of the patients, this is having a significant impact on their work.  This is 
unreported in the current literature, and the exact mechanism and relationship to their XLA 
are unknown.  One explanation may be that these symptoms are on the milder end of the 
unexplained neurodegeneration seen in other XLA patients.  Another potential explanation is 
this symptom as a manifestation of an underlying psychological disease, although none of 
these patients had a formal diagnosis of anxiety or depression and their HADS anxiety and 
depression screening scores were normal.   
It may be prudent to regularly screen patient with XLA for depression and anxiety, and 
develop access to psychological support within clinical services. 
9.11 Quality of life 
The main pertinent finding from the HRQoL data was that, in the absence of bronchiectasis, 
HRQoL is broadly comparable to the background healthy population.  However, in the 
presence of bronchiectasis, HRQoL is significantly reduced and comparable to patients with 
CF.  Furthermore, respiratory symptoms, lung function and SGRQ all correlate strongly with 
the overall HRQoL, demonstrating that respiratory health is a significant determinant of 
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HRQoL in XLA.  These findings add further strength to the argument that prevention of lung 
disease should be a major focus of management in XLA given these data suggest in the 
absence of lung disease XLA patients can have normal physical health and a normal quality 
of life.  
9.12 Strengths 
This is the most extensive review of XLA patients in England and Wales and the first in the 
modern era.   The inclusion criteria of genetic proven or functionally proven (absent BTK 
expression) also significantly decreases the diagnostic heterogeneity of the cohort compared 
to other studies examining primary antibody deficiency.  Other XLA studies may have 
included patients with agammaglobulinaemia incorrectly diagnosed as XLA if not 
necessitating genetic diagnosis or absent BTK as inclusion criteria. 
The dedication of a 3-year PhD research project and one researcher has allowed a depth of 
retrospective data collection not seen in any previous XLA cohort study. Notably, previous 
studies examining PAD or XLA have not been able to examine separately the pre and post 
bronchiectasis periods in those patients who would later go onto develop bronchiectasis.  This 
has allowed the analysis of patients with bronchiectasis to see if their initial post-diagnosis, 
‘non-bronchiectasis’ period, was any different to patients who remain without bronchiectasis. 
Converting lung function scores to correct Z-scores is also a significant strength of this study.  
As discussed within the methodology, using percentage predicted values to compare ages and 
analyse initial longitudinal fashion is inaccurate. 
9.13 Limitations 
9.13.1 Sample size 
During this study, I was unable to recruit any patient with autosomal recessive 
agammaglobulinaemia due to a lack of definitive diagnosis.  Although I came across several 
patients have a diagnosis of ARA, I found no patient with a proven molecular or genetic 
diagnosis explaining their ARA and, as such, were not included in this study. 
XLA is a rare disease, and the resulting sample size of this study is small, although it still 
provides useful and reliable descriptive statistics on outcomes in XLA patients.   In particular, 
this limits the ability to carry out a robust statistical analysis on the factors leading to 
complications, most notably bronchiectasis. Similarly, the small differences in the HRQoL 
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scores are also limited by the small sample size, and interpretation of these must be taken 
with caution.  However, small sample sizes are a constant limitation in the study of rare 
diseases and a balance must be struck between carrying out a detailed analysis on a strictly 
selected but small group, against carrying out a larger analysis on a more heterogeneous 
cohort with potentially less detail recorded.  Despite its small size, the level of detail 
contained by these data, does not exist anywhere else for XLA.  Furthermore, with the future 
plan to extend this study to Northern Ireland and Scotland, the projected samples size will be 
80-100 and, whilst still small, will make this one of the largest and detailed XLA studies to 
date. 
9.13.2 Missing data 
The main limitation of this study is its retrospective component, small sample size and the 
problem of missing data.  The missing data mainly pertains to patients diagnosed before 
1999, with many paediatric patients having 100% data available for this study.  This is 
undoubtedly a potentially significant area of bias with older patients potentially developing  
more severe disease as a result of inadequate, historical management plans.   
However, this limitation could not be overcome with this study design.  A prospective study 
could aim to overcome these biases; however, such a study is unlikely for such a rare disease 
as XLA.  Although, if studied as part of a broader primary antibody deficiency study, this 
may be feasible in the future. 
9.13.3 Infection data 
The recording of infection incidence relied solely on the recording of infections at the 
patient’s routine clinic appointments.  This itself is subject to recall bias from the patients at 
the time, and the onus is on the clinicians to review infections and note them at clinical 
reviews, although this should be standard practice. 
With any patient with an underlying susceptibility to infection, there may always be a bias 
from clinicians to overtreat infections with antibiotics on the presumption that is bacterial in 
origin on the fear of missing these infections.  However, the low gross number of infections 
in this cohort suggests this is not the case, but it is possible even these small numbers 
represent an ‘overtreatment’ of self-limiting viral infections.  These biases are likely to be 




Due to the retrospective nature data, it was not possible to fully ascertain the onset of 
infection symptoms and the timing from any delay to start of antibiotic treatment. 
9.13.4 Lag on the actual onset of bronchiectasis to CT detection 
The onset of bronchiectasis was defined as the first detection on HRCT.  It is challenging to 
ascertain what the interval is between the exact onset of bronchiectasis and its detection on 
HRCT.  Bronchiectasis itself is an entirely radiological diagnosis; the exact clinical onset of 
the disease is yet to be established.  Non-invasive testing such as lung function may aid 
clinicians in hinting at the development of bronchiectasis and prompting HRCT.  However, 
the current diagnoses of bronchiectasis is entirely dependent on the timing of HRCT which 
may be routine or not dependent on the clinician's opinion of the patient's risk based on their 
clinical phenotype.  The periods in this study, pre and post bronchiectasis, will, therefore, be 
subject to a degree of bias due to the lag from actual disease onset to radiological diagnosis 
which itself is subject ultimately to the clinician's decision to perform the HRCT.  However, 
adjustments to the age of bronchiectasis diagnosis of minus 1, 3 and 5 years made no 
significant differences to the results. 
9.14 Recommendations for clinical practice 
9.14.1 Diagnosis 
While BTK expression is often absent/reduced and quicker than genetic testing, this is not 
always the case.  In addition, as mentioned previously, knowing about a genetic mutation can 
offer patients and families more certainty about their diagnosis and is essential for family 
planning not only for the patient but also potentially the extended family. 
Therefore, all patients with XLA should be offered genetic testing for BTK mutations.  In 
addition, as mentioned previously, Sanger sequencing technique has improved, and BTK 
mutations may have been missed on older assays, as demonstrated by a number of patients 
within this cohort who were initially labelled as CVID due to negative BTK mutation testing 
but subsequently relabelled as XLA when repeating genetic testing was performed (461,462).  
This is important both for counselling for the patient and wider family, but also to offer 
accurate prognosis and better-tailored treatment. 
As next-generation sequencing becomes more available and cheaper, we may reach a point 
soon where all patients with PID undergo next generating genetic testing. 
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9.14.2 Follow up and monitoring 
It is clear from this work and others that despite modern therapies, awareness of PID and 
access to resources, XLA is not a benign condition and needs regular monitoring to optimise 
care. 
Part of these regular reviews should include an accurate review of infections over the 
preceding 12 months, chronic respiratory and sinus problems, nutrition, pulmonary health and 
impact upon the patients and their families’ lives. 
A proposed standard approach could an “annual MOT” for all patients with XLA where 
infections over the past 12 months are recorded along with IgG trough levels, and IGRT 
dosing can be reviewed.  Patients should be asked explicitly about chronic cough and sinus 
disease that may not have been treated with antibiotics and therefore easily missed.  Height 
and weight should be recorded. In addition, if old enough, patients should have an annual 
PFT performed and reviewed at this point.  It may also be prudent to routinely record patients 
HRQoL at these reviews using the tools or similar used in this project.  Some of this could be 
done with the support of the UKPIN and ESID registries which would have the added benefit 
of providing an accurate repository of data for further follow up of these patients. 
This MOT and ongoing clinical review of XLA patients, should have involvement of the 
MDT, particularly ENT, respiratory medicine and radiology.  This intensification of current 
follow up practice will enable earlier detection of complications and optimisation of therapies 
including novel options brought by other members of the MDT. 
One of the overarching aims of these reviews would be to optimise therapy so as to prevent 
the development of complications but also to improve the detection of bronchiectasis, which 
largely relies on HRCT imaging.  Regular PFT and a low threshold to image will aid the early 
diagnosis of bronchiectasis and enable earlier intensification of therapy to help prevent 
progression.  Regular microbiological testing of respiratory samples will also help monitor 
for infection and guide antimicrobial choices to optimise respiratory health. 
Further work into biomarkers of lung disease (e.g. sputum neutrophil elastase, catalase 
activity, lipid peroxidation (283,304,305)), may enable quicker and less invasive detection for 
bronchiectasis development which currently relies heavily on the use of HRCT, which carries 
the risk of ionising radiation.  Methods to reduce the reliance on these imaging modalities 
would be of great benefit, particularly for the paediatric population. 
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For newly diagnosed patients, paediatric patients or those with more severe complications, it 
may be prudent to offer more frequent follow-up, e.g., every six months. 
It may also be prudent to measure IgG trough levels more than once a year.  Twice a year 
would likely be sufficient for most patients unless there are clinical concerns about the 
effectiveness of treatment or compliance. 
If a patient develops bronchiectasis, there should be an intense effort to optimise treatment 
early to halt the progression of their bronchiectasis.  As these patients are tending to develop 
bronchiectasis at a relatively early age, it may also be appropriate to offer all XLA patients 
with newly diagnosed bronchiectasis an initial review with a respiratory specialist, ideally 
somebody with an interest in PID.  Early optimised of bronchiectasis therapy, e.g. 
prophylactic antibiotics, physiotherapy and smoking cessation are very likely to have 
significant improvements on later outcomes.  The majority of patients may not need further 
respiratory review, but for any patients with abnormal lung function, or progressing disease, 
it would be appropriate to offer them regular review with a respiratory specialist. 
There is a potential for XLA patients to be ‘out of sight, out of mind’ with the presumption 
that once they are on their IGRT, all that is required is a quick check-up and occasional 
HRCT and lung function testing performed, with the expectation that these patients have 
good clinical and HRQoL outcomes.  These data clearly demonstrate that the perception that 
XLA is a benign disease needs to urgently change.  The dissemination of these data will 
hopefully educate clinicians that XLA is a serious condition and can have early progression 
to end organ damage despite current therapies.  These patients still require regular and 
detailed follow up until which point a cure or more definitive treatment is introduced for this 
cohort. 
9.15 Implications for patients 
This research clearly shows that XLA places a significant burden on their lives and that of 
their families.  The introduction of IVIg/SCIg and the presumption this will adequately 
manage their disease may have led to XLA being a ‘forgotten PID’ in place of new PIDs 
being discovered with the advent of next-generation sequencing and novel therapies for other 
PID such as small molecule therapy, gene therapy and improved outcomes for HSCT. 
The overarching question for clinicians, researchers and patients alike is, ‘is current therapy 
for XLA satisfactory?’.  Most health care professionals and patients would agree satisfactory 
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is defined as minimum infections, no end-organ damage, minimal impact on daily activities 
and a normal quality of life.  This study shows that XLA patients suffer from high rates of 
bronchiectasis as well as other complications and a subsequent significant impact on their 
quality of life. 
While some may argue that some of these poorer outcomes relate to older patients from older 
suboptimal therapy, this study clearly shows patients that have never been on intramuscular 
therapy and those born in more recent times (benefiting from greater awareness and improve 
age a diagnosis) still suffer from these complications.  Furthermore, this study suggests that 
there are no obvious amenable methods to current treatment strategies to improve this.  While 
improving age at diagnosis may play a role as suggested as others, this cohort suggests we 
have a reached a plateau in out improvements in reducing the age at diagnosis.  This study 
was not able to ascertain as to whether asymptomatic screening (e.g. with a family history) 
can improve outcomes, as a proxy for newborn screening.  Although, these data suggested 
that early diagnosis (<2 years) was associated with a decreased risk of developing 
bronchiectasis and therefore even earlier diagnosis, at birth, may reduce this risk even further.  
However, this question could only be answered by a large, multination prospective study.  
The time this would take would mean any changes that are suggested could take many years 
to reach fruition.   
This study argues that current outcomes are so poor; a more considerable effort should be 
made for alternative therapies now.  Realistically, this means cure with the only current 
feasible option being gene therapy.  However, there remains hesitancy to develop research 
into these areas further due to a lack of any convincing evidence that current therapy is 
significantly ineffective.  Hopefully, these data will fil this gap and demonstrate that further 
research into gene therapy for XLA is now warranted.  Gene therapy for PID is now reaching 
fruition with numerous clinical trials, and even Strimvellis being approved by NICE for the 
treatment of ADA-SCID, demonstrating both a clinical and business case success. 
Most importantly, these data, after confirming previous XLA cohort studies, give patients and 
their families a realistic and more accurate idea of prognosis.  The risk of bronchiectasis and 
other end-organ damage should hopefully provide a further emphasis for both patients and 
clinicians to make sure IGRT is closely followed and monitored, and breakthrough infections 
treated early.  These data on longer-term outcomes also provide essential information for 
220 
 
patients and their relatives regarding family planning and the implications for daughters and 
grandsons.   
With IVIG only being made available since the 1980s and long-term survival available, 
longer-term outcomes data (i.e. 50 years plus) is still a relative unknown.  However, again, 
these data would suggest tightly controlled, and monitored therapy can either delay the onset 
of bronchiectasis or at least significantly reduce its severity and onset if it does occur.  
9.15.1 Potential impact for other PID patients 
XLA is just one disease of a much wider group of primary antibody deficiency.  The largest 
group within this being CVID, which has been extensively studied before, and the difficulties 
of lung disease (both bronchiectasis and granulomatous-lymphocytic interstitial lung disease) 
are well known.  A great deal of work is underway to better define disease groups within 
CVID, especially those with proven monogenic defects.  There are groups of PAD patients 
for whom, like XLA, IGRT is the mainstay of their treatment.  Many are rarer than XLA 
making studies of them potentially unfeasible.  While not sharing the same defect, they likely 
share the same limitations in treatment, with the same risks of recurrent infections and end-
organ damage, notably bronchiectasis.  These data could prove useful for clinicians caring for 
PADs other than XLA. 
A significant number of patients who undergo HSCT for PID do not achieve B-lymphocyte 
reconstitution.  In essence, they become primary antibody deficiency patients and require 
lifelong IGRT.  This can have a significant effect on QoL compared to patients who achieve 
full reconstitution (483).  While these patients do not share the underlying BTK defect, they 
are at risk of many of the complications XLA patients are due to the demonstrated limits in 
IGRT in preventing infections and end-organ damage.  This work strengthens to the argument 
that B cell reconstitution in HSCT for PID should be a significant outcome measure. 
9.15.2 Potential impacts for patients in developing countries 
Thanks to the efforts of the Jeffrey Modell Foundation and others, there is now increased 
awareness of PID worldwide with increasing numbers of diagnosis being made in developing 
countries and the development of specialised immunology centres (253).  This is reflected by 
the vast body of research output generated by these counties (191,248,484).  As discussed in 
Chapter 2, outcomes in these countries are invariably worse than developed nations with 
significantly higher mortality rates.  A significant reason for this is likely to be the limited 
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access to regular health care review and to replacement immunoglobulin therapy these 
patients are reliant on.  This is likely to be due to several reasons; logistics of trying to reach a 
small number of immunology specialists within an extensive geographical area and an 
inability to afford regular IGRT both from a patient and healthcare provider perspective.  It 
may be possible that for these nations, novel therapies such as a single administration of gene 
therapy may be more cost-effective than current mainstays of treatments consisting of 
lifelong clinical reviews and IGRT. 
9.16 A role for adjunct and novel therapies 
9.16.1 Role of HSCT 
HSCT is not standard care for patients with XLA in developed health care systems.  Very 
occasionally, XLA patients may require HSCT for treatment of a malignancy, which co-
incidentally, cures their XLA (485), so there certainly is the possibility of cure through 
HSCT.  However, it has always been felt that whatever the limitations of current therapy, the 
benefits of potential cure through HSCT do not outweigh the risks.  This remains true even 
when considering the ongoing improvements in outcomes following HSCT for PID. 
While this study demonstrates that recurrent infections and bronchiectasis remain a major 
burden for this cohort, the severity of these complications does not warrant HSCT becoming 
a standard of care for XLA.  It should be noted that the median age of this cohort 26.87 years 
is relatively young and it would be interesting to continue to monitor disease severity in XLA 
which may swing the risk-benefit ratio in favour of HSCT. 
However, as reported in this thesis, during the course of this study, two patients were referred 
for consideration of HSCT as a result of significant nutritional compromise from chronic 
norovirus infection.  One patient is now 18 months post HSCT, with good immune 
reconstitution and has satisfactory vaccine responses off IGRT (Figure 9-4).  It should be 
noted that clearance of the Norovirus was associated with T-cell reconstitution, occurring 
some time before reconstitution of humoral immunity.  This highlights that the defects in 
XLA must have an impact on T cell function, with complications occurring due to these 
defects not being amenable to current therapies.  Currently, the main modality of curing T 
cell defects is through HSCT.   
This example clearly shows that HSCT for XLA plays a role for patients with complications 
resistant to standard therapy.  As the safety profile and outcomes for HSCT improve the 
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threshold for deciding who and when to offer HSCT may decrease with time, but unlikely to 
reach a stage where HSCT would ever be offered as standard care for XLA.  Even so, this 
example offering HSCT solely to cure XLA is a major paradigm shift for developed health 
care settings.  As far as our unit is aware, the patient in this cohort is the first XLA patient in 
Europe and America to be transplanted solely to cure their HSCT.  As described previously, 
XLA patients have been transplanted before but in the context of other diseases where HSCT 
is standard of care, most notably leukaemia.  I am aware through personal communication, of 
one other XLA patient in Europe who has successfully undergone HSCT.  In this case, the 
patient had Sickle Cell disease and several complications related to this.  In this case, the joint 
cure of XLA and Sickle Cell, it was felt the risk-benefit ratio swung in favour of HSCT.  The 
Japanese have recently reported the successful HSCT of an adult patient (233).  The decision 
here was made to progress due to recurrent infections and the ever-increasing risk of end-
organ damage (233). Still, the role HSCT in XLA is controversial, and the experience of our 
group is due to be presented at international meetings soon, and the role of HSCT in XLA 
debated. 
There have been other PIDs described where, historically, HSCT was not routinely 
performed.  However, with improving HSCT outcomes and evidence that current therapies 
are suboptimal, HSCT is now offered for these patients.  One example would be CGD where 
recent data demonstrated that outcomes were poor with supportive therapy and now HSCT is 
offered as standard of care in many centres (486).   HSCT outcomes continue to improve with 
efforts made to tailor or reduce conditioning therapy and to improve HLA-matching with new 
graft manipulation strategies such as TCR αβ depletion of haploidentical or mismatched 
donors (487,488).  A promising future therapy is the use of antibody-drug-conjugate targeting 
the CD117 (c-kit) antigen (489).  This potentially offers the promise of excellent HSC 
depletion with minimal toxicity.  As these developments progress and HSCT becomes safer, 
it is possible the risk benefit ratio swings in the favour of HSCT for XLA. 
As this study demonstrates, there are other significant complications other than 
bronchiectasis, which can affect this cohort.  Therefore, on a case by case basis, consideration 
of HSCT for XLA should be given, even in developed health care systems. 
223 
 


































T Cells (CD3+) (cells/mcL) B Cells (CD19+) (cells/mcL)
NK Cells (CD16+CD56+) (cells/mcL) CD4+ T Cells (cells/mcL)
CD8+ T Cells (cells/mcL) IgM (g/L)
224 
 
There may also be paediatric patients who develop significant lung disease or bronchiectasis 
early on life.  As demonstrated by these data, the degree of lung disease will not improve 
with time and would, if anything, likely deteriorate over time.  Therefore, there may be a 
potential argument to offer HSCT to paediatric XLA patients who have developed significant 
lung disease early on life, in a bid to offer to cure their XLA and prevent any further 
deterioration. 
Some countries, most notably India, the benefits of HSCT do outweigh the risks as cost and 
barriers to regular IGRT mean that many patients in developing healthcare systems receive 
suboptimal care with prolonged periods of no IGRT or monitoring (250). 
9.16.2 The role of gene therapy 
These data demonstrate that XLA is not a benign disease, and complication rates remain high 
despite the best current therapies.  It is possible through closer monitoring and more 
aggressive targeting of IgG trough levels and antibiotic use that outcomes for these patients 
may improve with time.  However, the existing limitations (e.g. lack of IgA/IgM and BTK 
function) will always remain.   
The only current prospect of dramatically improving clinical outcomes would be to offer cure 
via gene therapy.  As discussed above, while HSCT could offer the best outcome for a select 
number of patients, it is highly unlikely ever to become the standard of care.  Gene therapy 
has the potential to offer a better safety profile than HSCT while matching its effectiveness.  
The two major potential criticisms of gene therapy are regarding the efficacy and its safety 
profile.  As newer gene therapy products are established, it would appear efficacy is 
improving with recent ADA-SCID trials demonstrating 96% event-free survival (event-free 
defined as the need for rescue enzyme therapy or HSCT) (490).  While initial gene therapy 
trials were marred by insertions of the viral vectors near oncogenes, and the subsequent 
development of malignancy, newer designed viral vectors have a much greater safety profile 
(239).   
Gene therapy has already become established enough to warrant inclusion into NICE 
guidance where guideline recommend gene therapy should be offered for patients with ADA-
SCID where a matched sibling donor is not available (242).  Also, there are several human 
clinical trials examining the use of gene therapy for other PIDs, and these data will help 
improve techniques and establish good quality safety data.  However, there still remain no 
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plans for human clinical trials for XLA despite several murine models (212,404,405).  The 
justification for XLA remains difficult.  Currently, diseases under review for gene therapy are 
ones where HSCT would be the standard of care, e.g. ADA-SCID, Wiskott-Aldrich 
Syndrome (WAS) and CGD.  In these cases, it is clear that any other method of reducing 
complications by reducing conditioning load and negating the risk of GvHD would be 
desirable.  The problem with XLA is that current therapy (i.e., IGRT) is relatively safe.  What 
these PhD data confirm, however, is the limitations of these therapy resulting in real-life 
effects with recurrent infections and end-organ damage.  The debate now will entail whether 
these complications warrant gene therapy. 
Further work into gene therapy would necessitate significant time and investment.  While 
existing therapies could be used as a basis for XLA gene therapy, new basic science and then 
clinical trials specifically for XLA would need to be set up.  Recruiting enough patients for 
such a rare disease would require a multi-centre international trial.  These trials would likely 
require significant commercial investment, and it is only fair that these companies should 
expect a realistic time frame for their return of investment (ROI).  Again, with such a rare 
disease (approximately 2-3 new cases per year in the UK) the time to ROI may be quite 
significant.  However, the recent establishment of gene therapy for ADA-SCID with 
Strimvelis® and the ongoing commercial support for gene therapy trials strongly suggest that 
pharmaceutical companies see this area as a significant and profitable area to pursue. 
9.16.3 The role of newborn screening 
Although these data failed to show that very early or newborn diagnosis significantly 
improves outcomes, they do strongly suggest that much of the damage leading to 
bronchiectasis occurs early in life (potentially pre XLA diagnosis), and that diagnosis before 
the age of 2 may help reduce this risk.  Newborn screening for XLA, via KREC analysis, 
may, therefore, still be a promising method for improving outcomes for these patients. 
Current KREC analysis has a high false-positive rate due to a lack of consensus regarding an 
accurate cut off level for PAD patients.  However, with further studies, these cut-off values 
could likely be refined, improving the false positive rate and improving the feasibility of 
introducing a KREC screening program.  The UK is shortly due to start a pilot TREC 
screening program.  If successful and rolled out across the UK, adding a KREC screening 
program would be relatively cheap (approximately £30, 000 for the laboratory costs) and 
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providing a more accurate cut-off level could be defined to reduce the burden of false 
positives (395). 
9.16.4 Prophylactic Antibiotics 
The effectiveness of prophylactic antibiotics in non-CF bronchiectasis is well established 
(275).  All XLA patients with bronchiectasis should be prophylactic antibiotics.  This should 
be based upon their microbiology results.  With Haemophilus influenzae being the 
predominant organism found in these sputum samples appropriate prophylaxis could be co-
trimoxazole, azithromycin or amoxicillin.   
There are currently no data in the literature or guidelines examining the use of prophylactic 
antibiotics in XLA.  However, a recent RCT examining 89 patients with PAD and 
bronchiectasis randomised patients to receiving prophylactic azithromycin or placebo (319).  
These data showed those patients who received prophylactic azithromycin reported a 
significant reduction in the number of exacerbations (HR 0.5, 95% 0.3 – 0.9) and 
hospitalisations (HR 0.5 95% CI 0.2-1.1) compared to the placebo group (319).  These data, 
and those in non-CF bronchiectasis, therefore, clearly show prophylactic antibiotics can play 
a useful role for XLA patients with bronchiectasis. 
What is potentially more controversial is whether prophylactic antibiotics play a role for 
those patients who do not have bronchiectasis, as a small number of patients did so within 
this study.  The risk of antimicrobial resistance has to be borne in mind before deciding 
whether to prescribe long term antibiotics.  However, the clear burden of bronchiectasis in 
this cohort demonstrates that more must be done to reduce the risk of developing of 
bronchiectasis and therefore serious consideration just be given as to whether all patients with 
XLA should be on prophylactic antibiotics, be that all year round or just in the winter months.  
Better quantification of the risk of antimicrobial resistance may soon be available through a 
UK RCT examining the use of prophylactic flucloxacillin in newly diagnosed infants with 
cystic fibrosis (ISRCTN 18130649).   
9.16.5 Cost effectiveness 
There have been no analyses of the cost effectiveness for the above strategies in XLA, but we 
can draw some conclusions from the available data for other PIDs, most notably SCID. 
In regard to the costs of current therapy, this will consist largely of the product and staff costs 
for immunoglobulin therapy.  As noted above, the current annual mean cost in this cohort for 
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2018 is £24, 171 per patient.  The overall cost is likely to be influenced by the place of 
therapy and whether it is self-administered.  Beaute et al., calculated for the French PAD 
cohort the costs were €19, 484 for home based IVIG and €25, 583 for hospital based IVIG.  
The costs for home based SCIG were €24, 952 per year (491). 
It would also be worth noting the cost impacts of complications, particularly bronchiectasis. 
Spanish work has calculated annual costs at between €3892 and €7520 per year for patients 
with bronchiectasis (492).  Similar US data calculated annual costs for bronchiectasis 
management of $5681, increasing to as much as $56, 499 for those with P. aeruginosa 
infections and exacerbations requiring hospital (493). 
There is no work examining the clinical or cost effectiveness of newborn screening for XLA.  
The argument for newborn screening for SCID is well established, with a cost effectiveness 
of £20, 000 per QALY (494).  Further work would need to be done to accurately calculate the 
costs effectiveness of a newborn screening program for XLA but it is promising that adding a 
KREC screening program onto an existing TREC panel would only accumulate a further £30, 
000 for the laboratory costs per year for the UK (395). 
Although HSCT would offer the chance of complete cure, and little in the way of long term 
follow up costs, there are significant costs associated with the transplant and the follow up 
shortly after.  The total cost depends on a number of factors, namely age at transplant and 
clinical condition (a proxy for expected complications).  Swedish data has estimated a mean 
cost of €301, 832 for those who were less 6 months old, and €423, 642 for those who were 
older than 6 months at the time of HSCT.  These costs include the transplant itself, 
admissions and investigations pre HSCT and up to 5 years of follow up and necessary 
investigations for monitoring the transplant (495) .  UK data would estimate the costs of 
HSCT for a child diagnosed with SCID at between £128, 363 and £231, 186 depending on 
complications encountered (494).   Follow up of children with SCID post HSCT is estimated 
to between £251 and £1005 a year depending on complications (494). 
Costing for gene therapy is difficult to analyse with only one product (Strimvellis) being 
licensed for use.  However, we can use these costings to draw some preliminary conclusions 
regarding costings of any future gene therapy program for XLA.  The cost of the Strimvellis 
therapy is £509, 027 (494).  The cost of hospital admission, administration and treatment of 
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any associated complications is between £527, 829 and £585, 994 (494).  Follow up costs are 
similar to those post allogenic HSCT for SCID (494). 
Whilst novel or more intensive therapies may have a high initial upfront cost, they are likely 
to be cost effective given their potential for reducing the risk of long-term complications.  
Further work is needed to analyse the cost-effectiveness of novel therapies against the costs 
of current treatments and associated complications. 
9.17 Future research 
Studies like this one, studying rare diseases are always hampered by small numbers even on a 
national scale, which is why multi-centre, multinational studies are needed. 
The first piece of work leading on from this project will be to extended recruitment across the 
UK, which is already underway.  I have also been granted access to mortality data from the 
UKPID registry which will be included within these dataset.  This work will aim to be the 
most detail population-based study of XLA patients in the literature. 
There could also be potential to recruit across Europe, with the aid of the ESID and national 
registries.  It is necessary to help garner interest and funding to do this as part of a more 
extensive study of primary antibody patients or patients on IGRT.  This information would 
also be useful, as many of these patient group may also face the same limitations in therapy 
and complications as XLA patients do. 
Incorporating regular lung function recording in a prospective manner, e.g. the UKPID 
registry may give a more accurate picture of progression of lung disease.  In addition, it 
would be useful to know if there are any changes in HRQoL over time, including associations 
with respiratory symptoms.  The exact microbiology of the respiratory tract and of infections, 
including the impact of viruses, is poorly understood in this group.  Potential future work 
could include the regular collection of samples from the upper respiratory tract to describe the 
organisms isolated in XLA patients and those associated with infections.  This work could 
also analyse the impact of viruses for these patients. These samples would be easy to collect 
and could be timed with patient’s regular visits to hospital appointments for clinics and 
immunoglobulin infusions.  
It would be hoped that this work and the planned UK wide work will prompt further research 
into gene therapy, be it viral vector or gene-editing techniques. 
229 
 
The setup of a newborn screening programme of SCID is still underway in the UK.  
Potentially, when this is established, this work could form the basis for initial thoughts about 
adding KRECs to the newborn screening. 
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Chapter 10 Conclusion 
This study has demonstrated that the majority of XLA patients suffer at least one chronic 
complication of their XLA.  The most common co-morbidity is bronchiectasis, with 44% 
developing bronchiectasis.  The development of bronchiectasis is not affected by IgG trough 
levels, IGRT dose or infection incidence.  Furthermore, these data suggest that significant 
lung damage has already occurred before the start of IGRT, and the path to bronchiectasis has 
already begun by the time the patient is diagnosed with XLA.  While it may be that an early 
diagnosis can mitigate these risks, any further improvements in age at diagnosis would only 
likely be achievable via newborn screening. 
There is potential for improvement with stricter monitoring of lung disease and with more 
aggressive increases in IgG doses to eliminate all infections and symptoms of chronic 
sinusitis and infection.  There may be a role for prophylactic antibiotics for all XLA patients, 
even without bronchiectasis, and this should be looked into further.  
The limitations of current therapy remain, namely the lack of IgA and IgM and the 
development of bronchiectasis may be inevitable to many patients with XLA.  These data 
demonstrated that, in the absence of bronchiectasis, XLA patients could expect a normal 
quality of life and therefore, future work should concentrate on improvements in current 
therapy or novel therapies to reduce or eliminate the risk of bronchiectasis.  These data and 
findings provide a strong argument that further research into gene therapy for XLA is now 
warranted.  Furthermore, these data have demonstrated that, in select cases, attempting cure 
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Strength and Difficulties STATA do file for scoring responses 
recode pobeys (0=2) (1=1) (2=0) (else=.), gen(qobeys) 
recode preflect (0=2) (1=1) (2=0) (else=.) , gen(qreflect) 
recode pattends (0=2) (1=1) (2=0) (else=.), gen(qattends) 
recode pfriend (0=2) (1=1) (2=0) (else=.), gen(qfriend) 
recode ppopular (0=2) (1=1) (2=0) (else=.), gen(qpopular) 
 
recode pdistres (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqdistres) 
recode pimphome (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqimphome) 
recode pimpfrie (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqimpfrie) 
recode pimpclas (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqimpclas) 
recode pimpleis (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqimpleis) 
 
egen nemotion=robs(psomatic pworries punhappy pclingy pafraid) 
egen pemotion=rmean(psomatic pworries punhappy pclingy pafraid) if nemotion>2 
replace pemotion=round(pemotion*5) 
 
egen nconduct=robs(ptantrum qobeys pfights plies psteals) 
egen pconduct=rmean(ptantrum qobeys pfights plies psteals) if nconduct>2 
replace pconduct=round(pconduct*5) 
 
egen nhyper=robs(prestles pfidgety pdistrac qreflect qattends) 
egen phyper=rmean(prestles pfidgety pdistrac qreflect qattends) if nhyper>2 
replace phyper=round(phyper*5) 
 
egen npeer=robs(ploner qfriend qpopular pbullied poldbest) 
egen ppeer=rmean(ploner qfriend qpopular pbullied poldbest) if npeer>2 
replace ppeer=round(ppeer*5) 
 
egen nprosoc=robs(pconsid pshares pcaring pkind phelpout) 
egen pprosoc=rmean(pconsid pshares pcaring pkind phelpout) if nprosoc>2 
replace pprosoc=round(pprosoc*5) 
 
egen nimpact=robs(pdistres pimphome pimpfrie pimpclas pimpleis) 
gen pimpact=qqdistres+qqimphome+qqimpfrie+qqimpclas+qqimpleis if (nimpact!=0) 
replace pimpact=0 if pebddiff==0 
 
drop qobeys qreflect qattends qfriend qpopular qqdistres qqimphome qqimpfrie qqimpclas 
qqimpleis nemotion nconduct nhyper npeer nprosoc nimpact 
 
gen pebdtot=pemotion+pconduct+phyper+ppeer 
label variable pemotion "Parent SDQ Emotion Score" 
label variable pconduct "Parent SDQ Conduct Score" 
label variable phyper "Parent SDQ Hyperactivity Score" 
label variable ppeer "Parent SDQ Peer Score" 
label variable pprosoc "Parent SDQ ProScoial Score" 
label variable pimpact "Parent SDQ Impact Score" 
label variable pebdtot "Parent SDQ Total Score" 
 
*** Recoding variables and then scoring the parent SDQ scores 2-4 year olds 
recode pobeys (0=2) (1=1) (2=0) (else=.), gen(qobeys) 
316 
 
recode preflect (0=2) (1=1) (2=0) (else=.) , gen(qreflect) 
recode pattends (0=2) (1=1) (2=0) (else=.), gen(qattends) 
recode pfriend (0=2) (1=1) (2=0) (else=.), gen(qfriend) 
recode ppopular (0=2) (1=1) (2=0) (else=.), gen(qpopular) 
 
recode pdistres (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqdistres) 
recode pimphome (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqimphome) 
recode pimpfrie (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqimpfrie) 
recode pimpclas (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqimpclas) 
recode pimpleis (0=0) (1=0) (2=1) (3=2) (.=0), gen(qqimpleis) 
 
egen nemotion=robs(psomatic pworries punhappy pclingy pafraid) 
egen pemotion=rmean(psomatic pworries punhappy pclingy pafraid) if nemotion>2 
replace pemotion=round(pemotion*5) 
 
egen nconduct=robs(ptantrum qobeys pfights pargues pspite) 
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